Clinics Review Articles

Hematology/Oncology Clinics

New Developments in Myeloma

骨髓瘤临床新进展

参 考 文 献

原著主审 [美] George P. Canellos
[美] Edward J. Benz Jr

主　　编 [美] Peter Leif Bergsagel

主　　审 侯　健

主　　译 陈君敏　郭冬梅　吴晓勇

上海科学技术出版社

目　录

献　辞

[1] Kuehl WM, Kaplan BA, Scharff MD. Characterization of light chain and light chain constant region fragment mRNAs in MPC 11 mouse myeloma cells and variants. Cell 1975;5(2):139–47.

[2] Margulies DH, Kuehl WM, Scharff MD. Somatic cell hybridization of mouse myeloma cells. Cell 1976;8(3):405–15.

[3] Riley SC, Brock EJ, Kuehl WM. Induction of light chain expression in a pre-B cell line by fusion to myeloma cells. Nature 1981;289(5800):804–6.

[4] Emorine L, Kuehl M, Weir L, et al. A conserved sequence in the immunoglobulin J kappa-C kappa intron: possible enhancer element. Nature 1983;304(5925): 447–9.

[5] Bender TP, Kuehl WM. Murine myb protooncogene mRNA: cDNA sequence and evidence for 5' heterogeneity. Proc Natl Acad Sci U S A 1986;83(10):3204–8.

[6] Timblin C, Bergsagel PL, Kuehl WM. Identification of consensus genes expressed in plasmacytomas but not B lymphomas. Curr Top Microbiol Immunol 1990;166:141–7.

[7] Bergsagel PL, Victor-Kobrin C, Brents LA, et al. Genes expressed selectively in plasmacytomas: markers of differentiation and transformation. Curr Top Microbiol Immunol 1992;182:223–8.

[8] Bergsagel PL, Brents LA, Trepel JB, et al. Genes expressed selectively in murine and human plasma cell neoplasms. Curr Top Microbiol Immunol 1995;194:57–61.

[9] Bergsagel PL, Chesi M, Nardini E, et al. Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma. Proc Natl Acad Sci U S A 1996;93(24):13931–6.

[10] Kuehl WM, Brents LA, Chesi M, et al. Selective expression of one c-myc allele in two human myeloma cell lines. Cancer Res 1996;56(19):4370–3.

[11] Misund K, Keane N, Stein CK, et al. MYC dysregulation in the progression of multiple myeloma. Leukemia 2020;34(1):322–6.

1　多发性骨髓瘤的分子发病机制及临床意义

[1] Kuehl WM, Bergsagel PL. Molecular pathogenesis of multiple myeloma and its premalignant precursor. J Clin Invest 2012;122(10):3456–63.

[2] Bergsagel PL, Chesi M, Nardini E, et al. Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma. Proc Natl Acad Sci U S A 1996;93(24):13931–6.

[3] Fonseca R, Barlogie B, Bataille R, et al. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res 2004;64(4):1546–58.

[4] Keats JJ, Chesi M, Egan JB, et al. Clonal competition with alternating dominance in multiple myeloma. Blood 2012;120(5):1067–76.

[5] Kyle RA, Larson DR, Therneau TM, et al. Long-Term Follow-up of Monoclonal GammopathyofUndetermined Significance. N Engl J Med 2018;378(3):241–9.

[6] Kyle RA, Remstein ED, Therneau TM, et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med 2007;356(25):2582–90.

[7] ACS. Cancer Statistics Center. 2023; Available at: https://cancerstatisticscenter.cancer.org/#!/cancer-site/Myeloma. Accessed June 19, 2023.

[8] Greenberg AJ, Vachon CM, Rajkumar SV. Disparities in the prevalence, pathogen- esis and progression of monoclonal gammopathy of undetermined significance and multiple myeloma between blacks and whites. Leukemia 2012;26(4):609–14.

[9] Landgren O, Graubard BI, Katzmann JA, et al. Racial disparities in the preva- lence of monoclonal gammopathies: a population-based study of 12,482 persons from the National Health and Nutritional Examination Survey. Leukemia 2014; 28(7):1537–42.

[10] Landgren O, Kyle RA, Pfeiffer RM, et al. Monoclonal gammopathy of undeter- mined significance (MGUS) consistently precedes multiple myeloma: a prospec- tive study. Blood 2009;113(22):5412–7.

[11] Weiss BM, Abadie J, Verma P, et al. A monoclonal gammopathy precedes multiple myeloma in most patients. Blood 2009;113(22):5418–22.

[12] Murray DL, Puig N, Kristinsson S, et al. Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report. Blood Cancer J 2021;11(2):24.

[13] Rustad EH, Yellapantula V, Leongamornlert D, et al. Timing the initiation of multi- ple myeloma. Nat Commun 2020;11(1):1917.

[14] Chesi M, Bergsagel PL, Brents LA, et al. Dysregulation of cyclin D1 by translocation into an IgH gamma switch region in two multiple myeloma cell lines. Blood 1996;88(2):674–81.

[15] Shaughnessy J Jr, Gabrea A, Qi Y, et al. Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to

immunoglobulin loci in multiple myeloma. Blood 2001;98(1):217–23.

[16] de Leval L, Alizadeh AA, Bergsagel PL, et al. Genomic profiling for clinical decision making in lymphoid neoplasms. Blood 2022;140(21):2193–227.

[17] Baughn LB, Li Z, Pearce K, et al. The CCND1 c.870G risk allele is enriched in individuals of African ancestry with plasma cell dyscrasias. Blood Cancer J 2020; 10(3):39.

[18] Chesi M, Stein CK, Garbitt VM, et al. Monosomic loss of MIR15A/MIR16-1 is a driver of multiple myeloma proliferation and disease progression. Blood Cancer Discov 2020;1(1):68–81.

[19] Bryce AH, Ketterling RP, Gertz MA, et al. Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis. Haematologica 2009;94(3):380–6.

[20] Fonseca R, Blood EA, Oken MM, et al. Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients. Blood 2002;99(10): 3735–41.

[21] Zhan F, Huang Y, Colla S, et al. The molecular classification of multiple myeloma. Blood 2006;108(6):2020–8.

[22] Nair B, van Rhee F, Shaughnessy JD Jr, et al. Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance. Blood 2010; 115(21):4168–73.

[23] van Rhee F, Zangari M, Schinke CD, et al. Long-term outcome of total therapy regimens: impact of molecular subgroups. Blood 2019;134:3309.

[24] Touzeau C, Dousset C, Le Gouill S, et al. The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma. Leukemia 2014;28(1):210–2.

[25] Kumar S, Kaufman JL, Gasparetto C, et al. Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma. Blood 2017;130(22): 2401–9.

[26] Chesi M, Bergsagel PL, Shonukan OO, et al. Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma. Blood 1998;91(12):4457–63.

[27] Avet-Loiseau H, Malard F, Campion L, et al. Translocation t(14;16) and multiple myeloma:is it really an independent prognostic factor? Blood 2011;117(6): 2009–11.

[28] Walker BA, Wardell CP, Murison A, et al. APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma. Nat Com- mun 2015;6:6997.

[29] Maura F, Petljak M, Lionetti M, et al. Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and mul- tiple myeloma cell lines. Leukemia 2018;32(4):1044–8.

[30] Weinhold N, Heuck CJ, Rosenthal A, et al. Clinical value of molecular subtyping multiple myeloma using gene expression profiling. Leukemia 2016;30(2):423–30.

[31] Qiang YW, Ye S, Chen Y, et al. MAF protein mediates innate resistance to protea- some inhibition therapy in multiple myeloma. Blood 2016;128(25):2919–30.

[32] Hurt EM, Wiestner A, Rosenwald A, et al. Overexpression of c-maf is a frequent

oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma. Cancer Cell 2004;5(2):191–9.

[33] Chesi M, Nardini E, Brents LA, et al. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat Genet 1997;16(3):260–4.

[34] Chesi M, Nardini E, Lim RS, et al. The t(4;14) translocation in myeloma dysregu- lates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid tran- scripts. Blood 1998;92(9):3025–34.

[35] Kuo AJ, Cheung P, Chen K, et al. NSD2 links dimethylation of histone H3 at lysine 36 to oncogenic programming. Mol Cell 2011;44(4):609–20.

[36] Martinez-Garcia E, Popovic R, Min DJ, et al. The MMSET histone methyl trans- ferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells. Blood 2011;117(1):211–20.

[37] Li F, Zhai YP, Lai T, et al. MB4-2/MB4-3 transcripts of IGH-MMSET fusion gene in t(4;14)(pos) multiple myeloma indicate poor prognosis. Oncotarget 2017;8(31): 51608–20.

[38] Stong N, Ortiz-Estevez M, Towfic F, et al. The location of the t(4;14) translocation breakpoint within the NSD2 gene identifies a subset of patients with high-risk NDMM. Blood 2023;141(13):1574–83.

[39] Benard B, Christofferson A, Legendre C, et al. FGFR3 mutations are an adverse prognostic factor in patients with t (4; 14) (p16; q32) multiple myeloma: an Mmrf commpass analysis. Blood 2017;130:3027.

[40] Scheid C, Reece D, Beksac M, et al. Phase 2 study of dovitinib in patients with relapsed or refractory multiple myeloma with or without t(4;14) translocation. Eur J Haematol 2015;95(4):316–24.

[41] Croucher DC, Devasia AJ, Abelman DD, et al. Single-cell profiling of multiple myeloma reveals molecular response to FGFR3 inhibitor despite clinical progres- sion. Cold Spring Harb Mol Case Stud 2023;9(2).

[42] Fonseca R, Bergsagel PL, Drach J, et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia 2009; 23(12):2210–21.

[43] Misund K, Keane N, Stein CK, et al. MYC dysregulation in the progression of mul- tiple myeloma. Leukemia 2020;34(1):322–6.

[44] Barwick BG, Neri P, Bahlis NJ, et al. Multiple myeloma immunoglobulin lambda translocations portend poor prognosis. Nat Commun 2019;10(1):1911.

[45] Kalkat M, De Melo J, Hickman KA, et al. MYC Deregulation in Primary Human Cancers. Genes 2017;8(6).

[46] Boyle EM, Deshpande S, Tytarenko R, et al. The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma. Nat Commun 2021;12(1):293.

[47] Subbiah V, Kreitman RJ, Wainberg ZA, et al. Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial. Nat Med 2023; 29(5):1103–12.

[48] Le Calvez B, Le Bris Y, Herbreteau G, et al. RAS mutation leading to acquired resistance to dabrafenib and trametinib therapy in a multiple myeloma patient harboring BRAF mutation. EJHaem 2020;1(1):318–22.

[49] Yang Y, Bolomsky A, Oellerich T, et al. Oncogenic RAS commandeers amino acid sensing machinery to aberrantly activate mTORC1 in multiple myeloma. Nat Commun 2022;13(1):5469.

[50] Keats JJ, Fonseca R, Chesi M, et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 2007;12(2): 131–44.

[51] De Bosscher K, Vanden Berghe W, Vermeulen L, et al. Glucocorticoids repress NF-kappaB-driven genes by disturbing the interaction of p65 with the basal tran- scription machinery, irrespective of coactivator levels in the cell. Proc Natl Acad Sci U S A 2000;97(8):3919–24.

[52] Uhlenhaut NH, Barish GD, Yu RT, et al. Insights into negative regulation by the glucocorticoid receptor from genome-wide profiling of inflammatory cistromes. Mol Cell 2013;49(1):158–71.

[53] Palombella VJ, Conner EM, Fuseler JW, et al. Role of the proteasome and NF-kappaB in streptococcal cell wall-induced polyarthritis. Proc Natl Acad Sci U S A 1998;95(26):15671–6.

[54] Richardson PG, Kumar SK, Masszi T, et al. Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. J Clin Oncol 2021;39(22):2430–42.

[55] Dash AB, Zhang J, Shen L, et al. Clinical benefit of ixazomib plus lenalidomide-dexamethasone in myeloma patients with non-canonical NF-kappaB pathway activation. Eur J Haematol 2020;105(3):274–85.

[56] Morgan D, Garg M, Tergaonkar V, et al. Pharmacological significance of the non- canonical NF-kappaB pathway in tumorigenesis. Biochim Biophys Acta Rev Can- cer 2020;1874(2):188449.

[57] Lee H, Ahn S, Maity R, et al. Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma. Nat Med 2023;29(9): 2295–306.

[58] Dib A, Peterson TR, Raducha-Grace L, et al. Paradoxical expression of INK4c in proliferative multiple myeloma tumors: bi-allelic deletion vs increased expression. Cell Div 2006;1:23.

[59] Walker BA, Leone PE, Chiecchio L, et al. A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value. Blood 2010;116(15):e56–65.

[60] Chesi M, Robbiani DF, Sebag M, et al. AID-dependent activation of a MYC trans- gene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies. Cancer Cell 2008;13(2):167–80.

[61] Linden M, Kirchhof N, Carlson C, et al. Targeted overexpression of Bcl-XL in B-lymphoid cells results in lymphoproliferative disease and plasma cell malig- nancies. Blood 2004;103(7):2779–86.

[62] Zhan F, Colla S, Wu X, et al. CKS1B, overexpressed in aggressive disease, regulates multiple myeloma growth and survival through SKP2- and p27Kip1- dependent and -independent mechanisms. Blood 2007;109(11):4995–5001.

[63] Wu D, Dean J. RNA exosome ribonuclease DIS3 degrades Pou6f1 to promote mouse pre-implantation cell differentiation. Cell

Rep 2023;42(2):112047.
[64] Corre J, Perrot A, Caillot D, et al. del(17p) without TP53 mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myeloma. Blood 2021;137(9):1192–5.

2 骨髓瘤的免疫发生机制

[1] Kumar SK, Rajkumar V, Kyle RA, et al. Multiple myeloma. Nat Rev Dis Primers2017;3:17046.

[2] Landgren O, Kyle RA, Pfeiffer RM, et al. Monoclonal gammopathy of undeter- mined significance (MGUS) consistently precedes multiple myeloma: a prospec- tive study. Blood 2009;113(22):5412–7.

[3] Dhodapkar MV. MGUS to myeloma: a mysterious gammopathy of underexplored significance. Blood 2016;128(23):2599–606.

[4] El-Khoury H, Lee DJ, Alberge JB, et al. Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrom- etry: a multicentre cohort study. Lancet Haematol 2022;9(5):e340–9.

[5] Rognvaldsson S, Love TJ, Thorsteinsdottir S, et al. Iceland screens, treats, or pre- vents multiple myeloma (iStopMM): a population-based screening study formonoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies. Blood Cancer J 2021;11(5):94.

[6] Vesely MD, Kershaw MH, Schreiber RD, et al. Natural innate and adaptive immu- nity to cancer. Annu Rev Immunol 2011;29:235–71.

[7] Dhodapkar MV. The immune system in multiple myeloma and precursor states: lessons and implications for immunotherapy and interception. Am J Hematol 2023;98 Suppl 2(Suppl 2):S4–12.

[8] Cohen AD, Raje N, Fowler JA, et al. How to Train Your T Cells: Overcoming Im- mune Dysfunction in Multiple Myeloma. Clin Cancer Res 2020;26(7):1541–54.

[9] Shah N, Aiello J, Avigan DE, et al. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma. Journal for immunotherapy of cancer 2020;8(2):e000734.

[10] Dhodapkar MV, Krasovsky J, Osman K, et al. Vigorous premalignancy specific effector Tcell response in the bone marrow of patients with preneoplastic gamm- opathy. J Exp Med 2003;198:1753–7.

[11] Finn OJ. Premalignant lesions as targets for cancer vaccines. J Exp Med 2003; 198(11):1623–6.

[12] Smyth MJ, Dunn GP, Schreiber RD. Cancer immunosurveillance and immunoedit- ing: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol 2006;90:1–50.

[13] DhodapkarMV,KrasovskyJ,Osman K, et al. Vigorous premalignancy-specific effector Tcell response in the bone marrow of patients with monoclonal gammop- athy. J Exp Med 2003;198(11):1753–7.

[14] Spisek R, Kukreja A, Chen LC, et al. Frequent and specific immunity to the embryonal stem cell-associated antigen SOX2 in patients with monoclonal gammopathy. J Exp Med 2007;204(4):831–40.

[15] Maura F, Landgren O, Morgan GJ. Designing

Evolutionary Based Interception Strategies to Block the Transition from Precursor Phases to Multiple Myeloma. Clin Cancer Res 2021;27(1):15–23.

[16] Kini Bailur J, Mehta S, Zhang L, et al. Changes in bone marrow innate lymphoid cell subsets in monoclonal gammopathy: target for IMiD therapy. Blood Adv 2017;1(25):2343–7.

[17] Bailur JK, McCachren SS, Doxie DB, et al. Early alterations in stem-like/resident T cells, innate and myeloid cells in the bone marrow in preneoplastic gammop- athy. JCI Insight 2019;5(11):e127807.

[18] Boiarsky R, Haradhvala NJ, Alberge JB,et al. Single cell characterization of myeloma and its precursor conditions reveals transcriptional signatures of early tumorigenesis. Nat Commun 2022;13(1):7040.

[19] Zavidij O, Haradhvala NJ, Mouhieddine TH, et al. Single-cell RNA sequencing re- veals compromised immune microenvironment in precursor stages of multiple myeloma. Nature Cancer 2020;1(5):493–506.

[20] De Jong MME, Kellermayer Z, Papazian N, et al. The multiple myeloma microenvironment is defined by an inflammatory stromal cell landscape. Nat Immunol 2021;22(6):769–80.

[21] Dhodapkar MV, Sexton R, Das R, et al. Prospective analysis of antigen-specific immunity, stem-cell antigens, and immune checkpoints in monoclonal gammop- athy. Blood 2015;126(22):2475–8.

[22] Guillerey C, Ferrari de Andrade L, Vuckovic S, et al. Immunosurveillance and ther- apy of multiple myeloma are CD226 dependent. J Clin Invest 2015;125(7):2904.

[23] Guillerey C, Ferrari de Andrade L, Vuckovic S, et al. Immunosurveillance and ther- apy of multiple myeloma are CD226 dependent. J Clin Invest 2015;125(5): 2077–89.

[24] Nakamura K, Kassem S, Cleynen A, et al. Dysregulated IL-18 Is a Key Driver of Immunosuppression and a Possible Therapeutic Target in the Multiple Myeloma Microenvironment. Cancer Cell 2018;33(4):634–648 e5.

[25] Larrayoz M, Garcia-Barchino MJ, Celay J, et al. Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma. Nat Med 2023;29(3):632–45.

[26] Das R, Strowig T, Verma R, et al. Microenvironment-dependent growth of preneo- plastic and malignant plasma cells in humanized mice. Nat Med 2016;22(11): 1351–7.

[27] Khoo WH, Ledergor G, Weiner A, et al. A niche-dependent myeloid transcriptome signature defines dormant myeloma cells. Blood 2019;134(1):30–43.

[28] Mateos MV, Hernandez MT, Giraldo P, et al. Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up a randomised, controlled, phase 3 trial. Lancet Oncol 2016;17(8):1127–36.

[29] Lonial S, Jacobus S, Fonseca R, et al. Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma. J Clin Oncol 2020;38(11):1126–37.

[30] Sklavenitis-Pistofidis R, Aranha MP, Redd RA, et al. Immune biomarkers of response

to immunotherapy in patients with high-risk smoldering myeloma. Can- cer Cell 2022;40(11):1358–13573 e8.

[31] Paiva B, Mateos MV, Sanchez-Abarca LI, et al. Immune status of high-risk smol- dering multiple myeloma patients and its therapeutic modulation under LenDex: a longitudinal analysis. Blood 2016;127(9):1151–62.

[32] Sehgal K, Das R, Zhang L, et al. Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cer- eblon targets. Blood 2015;125(26):4042–51.

[33] Dhodapkar MV, Dhodapkar KM. Moving Immunoprevention Beyond Virally Mediated Malignancies: Do We Need to Link It to Early Detection? Front Immunol 2019;10:2385.

[34] Robinson M, Villa NY, Jaye D, et al. Regulation of antigen-specific T-cell infiltration and spatial architecture in myeloma and premalignancy. J Clin Invest 2023; 133(15):e167629.

[35] McShane CM, Murray LJ, Landgren O, et al. Prior autoimmune disease and risk of monoclonal gammopathy of undetermined significance and multiple myeloma: a systematic review. Cancer Epidemiol Biomarkers Prev 2014;23(2):332–42.

[36] Rustad EH, Yellapantula V, Leongamornlert D, et al. Timing the initiation of multi- ple myeloma. Nat Commun 2020;11(1):1917.

[37] Maura F, Rustad EH, Yellapantula V, et al. Role of AID in the temporal pattern of acquisition of driver mutations in multiple myeloma. Leukemia 2020;34(5): 1476–80.

[38] Koduru S, Wong E, Strowig T, et al. Dendritic cell-mediated activation-induced cytidine deaminase (AID)-dependent induction of genomic instability in human myeloma. Blood 2012;119(10):2302–9.

[39] Weinreb NJ, Mistry PK, Rosenbloom BE, et al. MGUS, lymphoplasmacytic malig- nancies, and Gaucher disease: the significance of the clinical association. Blood 2018;131(22):2500–1.

[40] Nair S, Branagan AR, Liu J, et al. Clonal Immunoglobulin against Lysolipids in the Origin of Myeloma. N Engl J Med 2016;374(6):555–61.

[41] Nair S, Sng J, Boddupalli CS, et al. Antigen-mediated regulation in monoclonal gammopathies and myeloma. JCI Insight 2018;3(8):e98259.

[42] Claflin JL, Rudikoff S, Potter M, et al. Structural, functional, and idiotypic characteristics of a phosphorylcholine-binding IgA myeloma protein of C57BL/ka allo- type. J Exp Med 1975;141(3):608–19.

[43] Chesi M, Robbiani DF, Sebag M, et al. AID-dependent activation of a MYC trans- gene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies. Cancer Cell 2008;13(2):167–80.

[44] Kumar S, Larson DR, Dispenzieri A, et al. Polyclonal serum free light chain elevation is associated with increased risk of monoclonal gammopathies. Blood Can- cer J 2019;9(6):49.

[45] Nair S, Bar N, Xu ML, et al. Glucosylsphingosine but not Saposin C, is the target antigen in Gaucher disease-associated gammopathy. Mol Genet Metab 2020; 129(4):286–91.

[46] Pavlova EV, Archer J, S ZW, et al. Inhibition of UDP-glucosylceramide synthase in mice prevents Gaucher disease-associated B-cell malignancy. J Pathol 2015; 235(1):113–24.

[47] Chen JW, Rice TA, Bannock JM, et al. Autoreactivity in naive human fetal B cells is associated with commensal bacteria recognition. Science 2020;369(6501): 320–5.

[48] Myles A, Sanz I, Cancro MP. T-bet(+) B cells: A common denominator in protec- tive and autoreactive antibody responses? Curr Opin Immunol 2019;57:40–5.

[49] Azeem MI, Nooka AK, Shanmugasundaram U, et al. Impaired SARS-CoV-2 Variant Neutralization and CD8+ T-cell Responses Following 3 Doses of mRNA Vaccines in Myeloma: Correlation with Breakthrough Infections. Blood Cancer Discov 2023;4(2):106–17.

[50] Calcinotto A, Brevi A, Chesi M, et al. Microbiota-driven interleukin-17-producing cells and eosinophils synergize to accelerate multiple myeloma progression. Nat Commun 2018;9(1):4832.

[51] Dhodapkar MV, Sexton R, Hoering A, et al. Race-Dependent Differences in Risk, Genomics, and Epstein-Barr Virus Exposure in Monoclonal Gammopathies: Re- sults of SWOG S0120. Clin Cancer Res 2020;26(22):5814–9.

[52] Bosseboeuf A, Feron D, Tallet A, et al. Monoclonal IgG in MGUS and multiple myeloma targets infectious pathogens. JCI Insight 2017;2(19):e95367.

[53] Kaushal A, Nooka AK, Carr AR, et al. Aberrant Extrafollicular B Cells, Immune Dysfunction, Myeloid Inflammation, and MyD88-Mutant Progenitors Precede Waldenstrom Macroglobulinemia. Blood Cancer Discov 2021;2(6):600–15.

[54] Rodriguez S, Celay J, Goicoechea I, et al. Preneoplastic somatic mutations including MYD88(L265P) in lymphoplasmacytic lymphoma. Sci Adv 2022;8(3): eabl4644.

[55] Nooka AK, Shanmugasundaram U, Cheedarla N, et al. Determinants of Neutralizing Antibody Response After SARS CoV-2 Vaccination in Patients With Myeloma. J Clin Oncol 2022;JCO2102257

[56] Chung DJ, Pronschinske KB, Shyer JA, et al. T-cell Exhaustion in Multiple Myeloma Relapse after Autotransplant: Optimal Timing of Immunotherapy. Can- cer Immunol Res 2016;4(1):61–71.

[57] Joshua DE, Vuckovic S, Favaloro J, et al. Treg and Oligoclonal Expansion of Terminal Effector CD8(+) T Cell as Key Players in Multiple Myeloma. Front Immunol 2021;12:620596.

[58] Dhodapkar KM, Barbuto S, Matthews P, et al. Dendritic cells mediate the induc- tion of polyfunctional human IL17-producing cells (Th17-1 cells) enriched in the bone marrow of patients with myeloma. Blood 2008;112(7):2878–85.

[59] Prabhala RH, Pelluru D, Fulciniti M, et al. Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma. Blood 2010;115(26):5385–92.

[60] Perumal D, Imai N, Lagana A, et al. Mutation-derived Neoantigen-specific T-cell Responses in Multiple Myeloma. Clin Cancer Res 2020;26(2):450–64.

[61] Bar N, Costa F, Das R, et al. Differential effects of PD-L1 versus PD-1 blockade on myeloid inflammation in human cancer. JCI Insight 2020;5(12):e129353.

[62] Costa F, Das R, Kini Bailur J, et al. Checkpoint Inhibition in Myeloma: Opportunities and Challenges. Front Immunol 2018;9:2204.

[63] Andrews LP, Yano H, Vignali DAA. Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups. Nat Immunol 2019;20(11): 1425–34.

[64] Guillerey C, Harjunpaa H, Carrie N, et al. TIGIT immune checkpoint blockade restores CD8(+) T cell immunity against multiple myeloma. Blood 2018;132(16): 1689–94.

[65] Minnie SA, Kuns RD, Gartlan KH, et al. Myeloma escape after stem cell transplantation is a consequence of T cell exhaustion and is reversed by TIGIT inhibition. Blood 2018;132(16):1675–88.

[66] Akhmetzyanova I, Aaron T, Galbo P, et al. Tissue-resident macrophages promote early dissemination of multiple myeloma via IL-6 and TNFalpha. Blood Adv 2021; 5(18):3592–608.

[67] Hayashi T, Hideshima T, Nguyen AN, et al. Transforming growth factor beta re- ceptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment. Clin Cancer Res 2004;10(22): 7540–6.

[68] Wang S, Yang J, Qian J, et al. Tumor evasion of the immune system: inhibiting p38 MAPK signaling restores the function of dendritic cells in multiple myeloma. Blood 2006;107(6):2432–9.

[69] Brimnes MK, Vangsted AJ, Knudsen LM, et al. Increased Level of both CD4+FOXP3+ Regulatory T Cells and CD14+HLA-DR-/low Myeloid-Derived Suppressor Cells and Decreased Level of Dendritic Cells in Patients with Multiple Myeloma 2010;72(6):540–7.

[70] Guillerey C, Nakamura K, Vuckovic S, et al. Immune responses in multiple myeloma: role of the natural immune surveillance and potential of immunother- apies. Cell Mol Life Sci 2016;73(8):1569–89.

[71] Alrasheed N, Lee L, Ghorani E, et al. Marrow-Infiltrating Regulatory T Cells Corre- late with the Presence of Dysfunctional CD4(+)PD-1(+) Cells and Inferior Survival in Patients with Newly Diagnosed Multiple Myeloma. Clin Cancer Res 2020; 26(13):3443–54.

[72] Prabhala RH, Neri P, Bae JE, et al. Dysfunctional T regulatory cells in multiple myeloma. Blood 2006;107(1):301–4.

[73] Tai YT, Lin L, Xing L, et al. APRIL signaling via TACI mediates immunosuppression by T regulatory cells in multiple myeloma: therapeutic implications. Leukemia 2019;33(2):426–38.

[74] Tai YT, Cho SF, Anderson KC. Osteoclast Immunosuppressive Effects in Multiple Myeloma: Role of Programmed Cell Death Ligand 1. Front Immunol 2018;9:1822.

[75] Wu X, Wang Y, Xu J, et al. MM-BMSCs induce naive CD4+ T lymphocytes dysfunction through fibroblast activation protein alpha. Oncotarget 2017;8(32): 52614–28.

[76] Ramachandran IR, Martner A, Pisklakova A, et al. Myeloid-Derived Suppressor Cells Regulate Growth of Multiple Myeloma by Inhibiting T Cells in. Bone Marrow 2013;190(7):3815–23.

[77] Gorgun GT, Whitehill G, Anderson JL, et al. Tumor-promoting immune- suppressive myeloid-derived suppressor cells in the multiple myeloma microen- vironment in humans. Blood 2013;121(15):2975–87.

[78] Serafini P, Meckel K, Kelso M, et al.

Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J Exp Med 2006;203(12):2691–702.

[79] Asimakopoulos F, Hope C, Johnson MG, et al. Extracellular matrix and the myeloid-in-myeloma compartment: balancing tolerogenic and immunogenic inflammation in the myeloma niche. J Leukoc Biol 2017;102(2):265–75.

[80] Hope C, Foulcer S, Jagodinsky J, et al. Immunoregulatory roles of versican proteolysis in the myeloma microenvironment. Blood 2016;128(5):680–5.

[81] Jinushi M, Vanneman M, Munshi NC, et al. MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma. Proc Natl Acad Sci 2008;105(4):1285–90.

[82] Neparidze N, Dhodapkar MV. Harnessing CD1d-restricted T cells toward anti- tumor immunity in humans. Ann N Y Acad Sci 2009;1174:61–7.

[83] Dhodapkar MV, Krasovsky J, Olson K. Tcells from the tumor microenvironment of patients with progressive myeloma can generate strong tumor specific cytolytic responses to autologous tumor loaded dendritic cells. Proc Natl Acad Sci USA 2002;99:13009–13.

[84] Dhodapkar MV, Geller MD, Chang DH, et al. A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multi- ple myeloma. J Exp Med 2003;197(12):1667–76.

[85] Noonan K, Matsui W, Serafini P, et al. Activated marrow-infiltrating lymphocytes effectively target plasma cells and their clonogenic precursors. Cancer Res 2005;65(5):2026–34.

[86] Lancman G, Sastow DL, Cho HJ, et al. Bispecific Antibodies in Multiple Myeloma: Present and Future. Blood Cancer Discov 2021;2(5):423–33.

[87] Kukreja A, Hutchinson A, Dhodapkar KM, et al. Enhancement of clonogenicity of human multiple myeloma by dendritic cells. J Exp Med 2006;203(8):1859–65.

[88] Chauhan D, Singh AV, Brahmandam M, et al. Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target. Cancer Cell 2009;16(4):309–23.

[89] Dhodapkar KM, Cohen AD, Kaushal A, et al. Changes in Bone Marrow Tumor and Immune Cells Correlate with Durability of Remissions Following BCMA CAR T Therapy in Myeloma. Blood Cancer Discov 2022;3(6):490–501.

[90] Kukreja A, Radfar S, Sun BH, et al. Dominant role of CD47-thrombospondin-1 in- teractions in myeloma-induced fusion of human dendritic cells: implications for bone disease. Blood 2009;114(16):3413–21.

3 冒烟型多发性骨髓瘤：观察、控制与根治

[1] Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am J Hematol 2020;95:548–67.

[2] Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 2014;15:e538–48.

[3] Kyle RA, Therneau TM, Rajkumar SV, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 2006;354:1362–9.

[4] Dispenzieri A, Katzmann JA, Kyle RA, et al. Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study. Lancet 2010;375:1721–8.

[5] Murray D, Kumar SK, Kyle RA, et al. Detection and prevalence of monoclonal gammopathy of undetermined significance: a study utilizing mass spectrometry-based monoclonal immunoglobulin rapid accurate mass measurement. Blood Cancer J 2019;9:102.

[6] Kyle RA, Therneau TM, Rajkumar SV, et al. A long-term study of prognosis of monoclonal gammopathy of undetermined significance. N Engl J Med 2002; 346:564–9.

[7] Kyle RA, Larson DR, Therneau TM, et al. Long-term follow-up of monoclonal gammopathy of undetermined significance. N Engl J Med 2018;378:241–9.

[8] Thorsteinsdottir S, Gislason GK, Aspelund T, et al. Prevalence of smoldering multiple myeloma: results from the Iceland screens, treats, or prevents multiple myeloma (iStopMM) study. Blood 2021;138:151.

[9] Kyle RA, Remstein ED, Therneau TM, et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med 2007;356:2582–90.

[10] Mateos MV, Kumar S, Dimopoulos MA, et al. International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM). Blood Cancer J 2020;10:102.

[11] Chaudhry HM, Mauermann ML, Rajkumar SV. Monoclonal gammopathyassociated peripheral neuropathy: diagnosis and management. Mayo Clin Proc 2017;92:838–50.

[12] Sethi S, Rajkumar SV. Monoclonal gammopathy-associated proliferative glomerulonephritis. Mayo Clin Proc 2013;88:1284–93.

[13] Kyle RA, Durie BGM, Rajkumar SV, et al, International Myeloma Working Group. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia 2010;24: 1121–7.

[14] Hillengass J, Usmani S, Rajkumar SV, et al. International Myeloma Working Group consensus recommendations on imaging in

monoclonal plasma cell disorders. Lancet Oncol 2019;20:e302–12.

[15] Perez-Persona E, Vidriales MB, Mateo G, et al. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood 2007;110:2586–92.

[16] Dispenzieri A, Kyle RA, Katzmann JA, et al. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood 2008;111:785–9.

[17] Rosinol L, Blade J, Esteve J, et al. Smoldering multiple myeloma: natural history and recognition of an evolving type. Br J Haematol 2003;123:631–6.

[18] Rajkumar SV, Gupta V, Fonseca R, et al. Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma. Leukemia 2013;27:1738–44.

[19] Neben K, Jauch A, Hielscher T, et al. Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load. J Clin Oncol 2013;31:4325–32.

[20] Dhodapkar MV, Sexton R, Waheed S, et al. Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120). Blood 2014;123:78–85.

[21] Bianchi G, Kyle RA, Larson DR, et al. High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma. Leukemia 2013;27:680–5.

[22] Hillengass J, Fechtner K, Weber MA, et al. Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma. J Clin Oncol 2010;28:1606–10.

[23] Merz M, Hielscher T, Wagner B, et al. Predictive value of longitudinal whole-body magnetic resonance imaging in patients with smoldering multiple myeloma. Leukemia 2014;28:1902–8.

[24] Zamagni E, Nanni C, Gay F, et al. 18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease. Leukemia 2016;30:417–22.

[25] Mateos M-V, Herna´ndez M-T, Giraldo P, et al. Lenalidomide plus Dexamethasone for High-Risk Smoldering Multiple Myeloma. N Engl J Med 2013;369:438–47.

[26] Lakshman A, Paul S, Rajkumar SV, et al. Prognostic significance of interphase FISH in monoclonal gammopathy of undetermined significance. Leukemia 2018;32(8):1811–5.

[27] Lakshman A, Rajkumar SV, Buadi FK, et al. Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. Blood Cancer J 2018;8:59.

[28] Fernandez de Larrea C, Isola I, Pereira A, et al. Evolving M-protein pattern in patients with smoldering multiple myeloma: impact on early progression. Leukemia 2018;32:1427–34.

[29] Ravi P, Kumar S, Larsen JT, et al. Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma. Blood Cancer J 2016;6:e454.

[30] Rajkumar SV, Landgren O, Mateos MV. Smoldering multiple myeloma. Blood

2015;125:3069–75.

[31] Mateos MV, Hernandez MT, Giraldo P, et al. Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial. Lancet Oncol 2016;17:1127–36.

[32] Lonial S, Jacobus S, Fonseca R, et al. Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma. J Clin Oncol 2020;38:1126–37.

[33] Lonial S, Jacobus SJ, Weiss M, et al. E3A06: Randomized phase Ill trial of lenalidomide versus observation alone in patients with asymptomatic high-risk smoldering multiple myeloma. J Clin Oncol 2019;37.

[34] Tsuda K, Tanimoto T, Komatsu T. Treatment for high-risk smoldering myeloma. N Engl J Med 2013;369:1763.

[35] Mateos MV, San Miguel JF. Treatment for high-risk smoldering myeloma. N Engl J Med 2013;369:1764–5.

[36] D'Arena G, Gobbi PG, Broglia C, et al, Gimema Gruppo Italiano Malattie Ematologiche Dell'Adulto, Multiple Myeloma Working Party, Gisl Gruppo Italiano Studio Linfomi Cooperative Group. Pamidronate versus observation in asymptomatic myeloma: final results with long-term follow-up of a randomized study. Leuk Lymphoma 2011;52:771–5.

[37] Musto P, Petrucci MT, Bringhen S, et al, GIMEMA Italian Group for Adult Hematologic Diseases/Multiple Myeloma Working Party and the Italian Myeloma Network. A multicenter, randomized clinical trial comparing zoledronic acid ersus observation in patients with asymptomatic myeloma. Cancer 2008;113: 1588–95.

[38] Mateos M-V, Martinez Lopez J, Rodriguez-Otero P, et al. Curative strategy for high-risk smoldering myeloma (GEM-CESAR): carfilzomib, lenalidomide and dexamethasone (KRd) as induction followed by HDT-ASCT, consolidation with KRd and maintenance with Rd. Blood 2017;130:402.

4　靶向 cereblon 连接酶降解剂治疗骨髓瘤：作用及耐药机制

[1] Ito T, Ando H, Suzuki T, et al. Identification of a primary target of thalidomide teratogenicity. Science (New York, NY) 2010;327(5971):1345–50.

[2] Chamberlain PP, Lopez-Girona A, Miller K, et al. Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs. Nat Struct Mol Biol 2014;21(9):803–9.

[3] Lu G, Middleton RE, Sun H, et al. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science (New York, NY) 2014;343(6168):305–9.

[4] Krönke J, Udeshi ND, Narla A, et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science (New York, NY) 2014; 343(6168):301–5.

[5] Georgopoulos K, Bigby M, Wang JH, et al. The Ikaros gene is required for thedevelopment of all lymphoid lineages. Cell 1994;79(1):143–56.

[6] Cortes M, Wong E, Koipally J, et al. Control of lymphocyte development by the Ikaros gene family. Curr Opin Immunol 1999;11(2):167–71.

[7] Zhu YX, Braggio E, Shi CX, et al. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood 2011;118(18):4771–9.

[8] Nückel H, Frey UH, Sellmann L, et al. The IKZF3 (Aiolos) transcription factor is highly upregulated and inversely correlated with clinical progression in chronic lymphocytic leukaemia. Br J Haematol 2009;144(2):268–70.

[9] Morgan B, Sun L, Avitahl N, et al. Aiolos, a lymphoid restricted transcription factor that interacts with Ikaros to regulate lymphocyte differentiation. Embo j 1997; 16(8):2004–13.

[10] Corte´s M, Georgopoulos K. Aiolos is required for the generation of high affinity bone marrow plasma cells responsible for long-term immunity. J Exp Med 2004;199(2): 209–19.

[11] Matyskiela ME, Zhang W, Man HW, et al. A Cereblon Modulator (CC-220) with Improved Degradation of Ikaros and Aiolos. J Med Chem 2018;61(2):535–42.

[12] Hansen JD, Correa M, Nagy MA, et al. Discovery of CRBN E3 Ligase Modulator CC-92480 for the Treatment of Relapsed and Refractory Multiple Myeloma. J Med Chem 2020;63(13):6648–76.

[13] Bjorklund CC, Kang J, Amatangelo M, et al. Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN. Leukemia 2020;34(4):1197–201.

[14] Watson ER, Novick S, Matyskiela ME, et al. Molecular glue CELMoD compounds are

regulators of cereblon conformation. Science (New York, NY) 2022;378(6619):549–53.

[15] Ichikawa S, Flaxman HA, Xu W, et al. The E3 ligase adapter cereblon targets the C-terminal cyclic imide degron. Nature 2022;610(7933):775–82.

[16] Sievers QL, Petzold G, Bunker RD, et al. Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN. Science (New York,NY) 2018;362(6414).

[17] An J, Ponthier CM, Sack R, et al. pSILAC mass spectrometry reveals ZFP91 as IMiD-dependent substrate of the CRL4(CRBN) ubiquitin ligase. Nat Commun 2017;8:15398.

[18] Donovan KA, An J, Nowak RP, et al. Thalidomide promotes degradation of SALL4, a transcription factor implicated in Duane Radial Ray syndrome. Elife 2018;7:e38430.

[19] Bird S, Pawlyn C. IMiD resistance in multiple myeloma: current understanding of the underpinning biology and clinical impact. Blood 2023;142(2):131–40.

[20] Krönke J, Fink EC, Hollenbach PW, et al. Lenalidomide induces ubiquitination and degradation of CK1 a in del(5q) MDS. Nature 2015;523(7559):183–8.

[21] Petzold G, Fischer ES, Thomä NH. Structural basis of lenalidomide-induced CK1 a degradation by the CRL4(CRBN) ubiquitin ligase. Nature 2016; 532(7597):127–30.

[22] Matyskiela ME, Lu G, Ito T, et al. A novel cereblon modulator recruits GSPT1 to the CRL4(CRBN) ubiquitin ligase. Nature 2016;535(7611):252–7.

[23] Lopez-Girona A, Mendy D, Ito T, et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia 2012;26(11):2326–35.

[24] Eichner R, Heider M, Ferna´ndez-Sa´iz V, et al. Immunomodulatory drugs disrupt the cereblon-CD147-MCT1 axis to exert antitumor activity and teratogenicity. Nat Med 2016;22(7):735–43.

[25] Zhu YX, Shi C-X, Bruins LA, et al. Identification of lenalidomide resistance pathways in myeloma and targeted resensitization using cereblon replacement, inhibition of STAT3 or targeting of IRF4. Blood Cancer J 2019;9(2):19.

[26] Sebastian S, Zhu YX, Braggio E, et al. Multiple myeloma cells' capacity to decompose H(2)O(2) determines lenalidomide sensitivity. Blood 2017;129(8):991–1007.

[27] LeBlanc R, Hideshima T, Catley LP, et al. Immunomodulatory drug costimulatesT cells via the B7-CD28 pathway. Blood 2004;103(5):1787–90.

[28] Haslett PA, Corral LG, Albert M, et al. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8 1 subset. J Exp Med 1998;187(11):1885–92.

[29] Schafer PH, Gandhi AK, Loveland MA, et al. Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs. J Pharmacol Exp Therapeut 2003;305(3):1222–32.

[30] Payvandi F, Wu L, Naziruddin SD, et al. Immunomodulatory drugs (IMiDs) in-crease the production of IL-2 from stimulated T cells by increasing PKC-theta activation and enhancing the DNA-binding activity of

AP-1 but not NF-kappaB,OCT-1, or NF-AT. J Interferon Cytokine Res 2005;25(10):604–16.

[31] Thompson EC, Cobb BS, Sabbattini P, et al. Ikaros DNA-binding proteins as integral components of B cell developmental-stage-specific regulatory circuits. Immunity 2007;26(3):335–44.

[32] Avitahl N, Winandy S, Friedrich C, et al. Ikaros sets thresholds for T cell activation and regulates chromosome propagation. Immunity 1999;10(3):333–43.

[33] Quintana FJ, Jin H, Burns EJ, et al. Aiolos promotes TH17 differentiation by directly silencing Il2 expression. Nat Immunol 2012;13(8):770–7.

[34] Gandhi AK, Kang J, Havens CG, et al. Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repres-sors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.). Br J Haematol 2014;164(6):811–21.

[35.Quach H, Ritchie D, Stewart AK, et al. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia 2010;24(1):22–32.

[36] Davies FE, Raje N, Hideshima T, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001; 98(1):210–6.

[37] Hayashi T, Hideshima T, Akiyama M, et al. Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. Br J Haematol 2005;128(2):192–203.

[38] Chang DH, Liu N, Klimek V, et al. Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. Blood 2006; 108(2):618–21.

[39] Zhu D, Corral LG, Fleming YW, et al. Immunomodulatory drugs Revlimid (lenali-domide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation. Cancer immunology, immunotherapy CII 2008;57(12):1849–59.

[40.Roda JM, Parihar R, Magro C, et al. Natural killer cells produce T cell-recruiting chemokines in response to antibody-coated tumor cells. Cancer Res 2006; 66(1):517–26.

[41.Galustian C, Meyer B, Labarthe MC, et al. The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer immunology, immunotherapy CII 2009;58(7):1033–45.

[42] Dredge K, Marriott JB, Macdonald CD, et al. Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects. Br J Cancer 2002;87(10):1166–72.

[43] Dredge K, Horsfall R, Robinson SP, et al. Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. Microvasc Res 2005;69(1–2):56–63.

[44] Gupta D, Treon SP, Shima Y, et al. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion:therapeutic applications. Leukemia 2001;15(12):1950–61.

[45] D'Amato RJ, Loughnan MS, Flynn E, et al. Thalidomide is an inhibitor of angiogenesis.

Proc Natl Acad Sci USA 1994;91(9):4082–5.

[46] Geitz H, Handt S, Zwingenberger K. Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade. Immunopharmacology 1996;31(2–3):213–21.

[47] Breitkreutz I, Raab MS, Vallet S, et al. Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma. Leukemia 2008;22(10):1925–32.

[48] Bolzoni M, Storti P, Bonomini S, et al. Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and theRANKL/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules. Exp Hematol 2013;41(4):387–97.e381.

[49] Gooding S, Ansari-Pour N, Towfic F, et al. Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma. Blood 2021;137(2):232–7.

[50] Kortüm KM, Mai EK, Hanafiah NH, et al. Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes.Blood 2016;128(9):1226–33.

[51] Neri P, Maity R, Keats JJ, et al. Cereblon Splicing of Exon 10 Mediates IMiDs Resistance in Multiple Myeloma: Clinical Validation in the CoMMpass Trial. Blood 2016;128(22):120.

[52] Gupta VA, Barwick BG, Matulis SM, et al. Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression. Blood 2021;137(26):3604–15.

[53] Karagoz K, Stokes M, Ortiz-Este´vez M, et al. Multiple Myeloma Patient Tumors With High Levels of Cereblon Exon-10 Deletion Splice Variant Upregulate Clinically Targetable Pro-Inflammatory Cytokine Pathways. Front Genet 2022;13:831779.

[54] Haertle L, Barrio S, Munawar U, et al. Cereblon enhancer methylation and IMiD resistance in multiple myeloma. Blood 2021;138(18):1721–6.

[55] Zhou N, Gutierrez-Uzquiza A, Zheng XY, et al. RUNX proteins desensitize multiple myeloma to lenalidomide via protecting IKZFs from degradation. Leukemia 2019; 33(8):2006–21.

[56] Sperling AS, Burgess M, Keshishian H, et al. Patterns of substrate affinity, competition, and degradation kinetics underlie biological activity of thalidomide analogs. Blood 2019;134(2):160–70.

[57] Barwick BG, Neri P, Bahlis NJ, et al. Multiple myeloma immunoglobulin lambdatranslocations portend poor prognosis. Nat Commun 2019;10(1):1911.

[58] Neri P, Barwick BG, Jung D, et al. ETV4-Dependent Transcriptional PlasticityMaintains MYC Expression and Results in IMiD Resistance in Multiple Myeloma.Blood Cancer Discov 2024;5(1):56–73.

[59] Welsh SJ, Barwick BG, Meermeier EW, et al. Transcriptional Heterogeneity Overcomes Super-Enhancer Disrupting Drug Combinations in Multiple Myeloma.Blood Cancer Discov 2024;5(1):34–55.

[60] Nicosia L, Spencer GJ, Brooks N, et al. Therapeutic targeting of EP300/CBP by bromodomain inhibition in hematologic malignancies. Cancer Cell 2023;41(12):2136–53.e2113.

[61] Sievers QL, Gasser JA, Cowley GS, et al. Genome-wide screen identifies cullin-RING ligase machinery required for lenalidomide-dependent CRL4CRBN activity.Blood 2018;132(12):1293–303.

[62] Liu J, Song T, Zhou W, et al. A genome-scale CRISPR-Cas9 screening inmyeloma cells identifies regulators of immunomodulatory drug sensitivity. Leuke-mia 2019;33(1):171–80.

[63] Tateno S, Iida M, Fujii S, et al. Genome-wide screening reveals a role for subcellular localization of CRBN in the anti-myeloma activity of pomalidomide. Sci Rep 2020;10(1):4012.

[64] Costacurta M, Vervoort SJ, Hogg SJ, et al. Whole genome CRISPR screening identifies TOP2B as a potential target for IMiD sensitization in multiple myeloma. Haematologica 2021;106(7):2013–7.

[65] Cavadini S, Fischer ES, Bunker RD, et al. Cullin–RING ubiquitin E3 ligase regulation by the COP9 signalosome. Nature 2016;531(7596):598–603.

[66] Lu G, Weng S, Matyskiela M, et al. UBE2G1 governs the destruction of cereblonneomorphic substrates. Elife 2018;7.

[67] Gooding S, Ansari-Pour N, Kazeroun M, et al. Loss of COP9 signalosome genesat 2q37 is associated with IMiD resistance in multiple myeloma. Blood 2022;140(16):1816–21.

[68] Liu J, Hideshima T, Xing L, et al. ERK signaling mediates resistance to immunomodulatory drugs in the bone marrow microenvironment. Sci Adv 2021;7(23).

[69] Ocio EM, Ferna´ndez-La´zaro D, San-Segundo L, et al. In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide Lee et al 318and pomalidomide in combination with dexamethasone. Leukemia 2015;29(3):705–14.

[70] Dimopoulos K, Søgaard Helbo A, Fibiger Munch-Petersen H, et al. Dual inhibition of DNMTs and EZH2 can overcome both intrinsic and acquired resistance of myeloma cells to IMiDs in a cereblon-independent manner. Mol Oncol 2018;12(2):180–95.

5 蛋白酶体抑制剂治疗多发性骨髓瘤：基于功能基因组学作用或耐药机制的生物学见解

[1] Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999;341:1565–71.

[2] Orlowski RZ, Stinchcombe TE, Mitchell BS, et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 2002;20:4420–7.

[3] Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348:2609–17.

[4] Richardson PG, Sonneveld P, Schuster MW, et al. Assessment of Proteasome Inhibition for Extending Remissions I. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352:2487–98.

[5] Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001;61:3071–6.

[6] Adams J. Proteasome inhibition: a novel approach to cancer therapy. Trends Mol Med 2002;8:S49–54.

[7] Adams J. Development of the proteasome inhibitor PS-341. Oncol 2002;7:9–16.

[8] Adams J, Kauffman M. Development of the proteasome inhibitor Velcade (Bortezomib). Cancer Invest 2004;22:304–11.

[9] LeBlanc R, Catley LP, Hideshima T, et al. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model.Cancer Res 2002;62:4996–5000.

[10] Mitsiades N, Mitsiades CS, Poulaki V, et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci U S A 2002;99:14374–9.

[11] Chesi M, Robbiani DF, Sebag M, et al. AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies. Cancer Cell 2008;13:167–80.

[12] Chesi M, Matthews GM, Garbitt VM, et al. Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy. Blood 2012;120:376–85.

[13] Larrayoz M, Garcia-Barchino MJ, Celay J, et al. Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma. Nat Med 2023;29:632–45.

[14] Mitsiades N, Mitsiades CS, Poulaki V, et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 2002;99:4525–30.

[15] Hideshima T, Chauhan D, Ishitsuka K, et al. Molecular characterization of PS-

341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)-beta inhibitors. Oncogene 2005;24:3121–9.

[16] Sharma A, Nair R, Achreja A, et al. Therapeutic implications of mitochondrial stress-induced proteasome inhibitor resistance in multiple myeloma. Sci Adv 2022;8:eabq5575.

[17] Gu Y, Barwick BG, Shanmugam M, et al. Downregulation of PA28alpha induces proteasome remodeling and results in resistance to proteasome inhibitors in multiple myeloma. Blood Cancer J 2020;10:125.

[18] Catley L, Weisberg E, Tai YT, et al. NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood 2003;102:2615–22.

[19] Chauhan D, Li G, Shringarpure R, et al. Blockade of Hsp27 overcomes Bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells. Cancer Res 2003;63:6174–7.

[20] Hideshima T, Chauhan D, Hayashi T, et al. Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma. Oncogene 2003;22:8386–93.

[21] Mitsiades N, Mitsiades CS, Richardson PG, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 2003;101:2377–80.

[22] Chauhan D, Li G, Podar K, et al. Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells. Blood 2004;104:2458–66.

[23] Chauhan D, Li G, Podar K, et al. The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance. Blood 2004;103:3158–66.

[24] Catley L, Weisberg E, Kiziltepe T, et al. Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. Blood 2006;108:3441–9.

[25] Garcia-Gomez A, Quwaider D, Canavese M, et al. Preclinical activity of the oral proteasome inhibitor MLN9708 in Myeloma bone disease. Clin Cancer Res 2014;20:1542–54.

[26] Mulligan G, Lichter DI, Di Bacco A, et al. Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy. Blood 2014;123:632–9.

[27] Mulligan G, Mitsiades C, Bryant B, et al. Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood 2007;109:3177–88.

[28] Chng WJ, Kumar S, Vanwier S, et al. Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling. Cancer Res 2007;67:2982–9.

[29] Jakubowiak A, Usmani SZ, Krishnan A, et al. Daratumumab Plus Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple

Myeloma. Clin Lymphoma Myeloma Leuk 2021;21:701–10.

[30] Jakubowiak AJ, Dytfeld D, Griffith KA, et al. A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood 2012;120:1801–9.

[31] Jakubowiak AJ, Jasielec JK, Rosenbaum CA, et al. Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma. Br J Haematol 2019;186:549–60.

[32] Jakubowiak AJ, Siegel DS, Martin T, et al. Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study. Leukemia 2013;27:2351–6.

[33] Costa LJ, Davies FE, Monohan GP, et al. Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma. Blood Adv 2021;5:3748–59.

[34] Derman BA, Zonder J, Reece D, et al. Phase 1/2 study of carfilzomib, pomalidomide, and dexamethasone with and without daratumumab in relapsed multiple myeloma. Blood Adv 2023;7:5703–12.

[35] de Matos Simoes R, Shirasaki R, Downey-Kopyscinski SL, et al. Genome-scale functional genomics identify genes preferentially essential for multiple myeloma cells compared to other neoplasias. Nat Cancer 2023;4:754–73.

[36] Boise LH, Kaufman JL, Bahlis NJ, et al. The Tao of myeloma. Blood 2014;124:1873–9.

[37] Finley D. Recognition and processing of ubiquitin-protein conjugates by the proteasome. Annu Rev Biochem 2009;78:477–513.

[38] Goldberg AL. Protein degradation and protection against misfolded or damaged proteins. Nature 2003;426:895–9.

[39] Goldberg AL, Dice JF. Intracellular protein degradation in mammalian and bacterial cells. Annu Rev Biochem 1974;43:835–69.

[40] Pohl C, Dikic I. Cellular quality control by the ubiquitin-proteasome system and autophagy. Science 2019;366:818–22.

[41] Kannt A, Dikic I. Expanding the arsenal of E3 ubiquitin ligases for proximityinduced protein degradation. Cell Chem Biol 2021;28:1014–31.

[42] Cable J, Weber-Ban E, Clausen T, et al. Targeted protein degradation: from small molecules to complex organelles-a Keystone Symposia report. Ann N Y Acad Sci 2022;1510:79–99.

[43] Dikic I, Schulman BA. An expanded lexicon for the ubiquitin code. Nat Rev Mol Cell Biol 2023;24:273–87.

[44] Berndsen CE, Wolberger C. New insights into ubiquitin E3 ligase mechanism. Nat Struct Mol Biol 2014;21:301–7.

[45] Adams J. The proteasome: structure, function, and role in the cell. Cancer Treat Rev 2003;29(Suppl 1):3–9.

[46] Dong Y, Zhang S, Wu Z, et al. Cryo-EM structures and dynamics of substrateengaged human 26S proteasome. Nature 2019;565:49–55.

[47] Murata S, Takahama Y, Kasahara M, et al. The immunoproteasome and thymoproteasome: functions, evolution and human disease. Nat Immunol 2018;19:923–31.

[48] Herndon TM, Deisseroth A, Kaminskas E, et al. Food and Drug Administration approval:

carfilzomib for the treatment of multiple myeloma. Clin Cancer Res 2013;19:4559–63.

[49] Landgren O, Sonneveld P, Jakubowiak A, et al. Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma. Leukemia 2019;33:2127–43.

[50] Chim CS, Kumar SK, Orlowski RZ, et al. Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond.Leukemia 2018;32:252–62.

[51] Wang J, Fang Y, Fan RA, et al. Proteasome Inhibitors and Their Pharmacokinetics, Pharmacodynamics, and Metabolism. Int J Mol Sci 2021;22.

[52] Voorhees PM, Orlowski RZ. The proteasome and proteasome inhibitors in cancer therapy. Annu Rev Pharmacol Toxicol 2006;46:189–213.

[53] Elliott PJ, Ross JS. The proteasome: a new target for novel drug therapies. Am J Clin Pathol 2001;116:637–46.

[54] Kisselev AF. Site-Specific Proteasome Inhibitors. Biomolecules 2021;12.

[55] Fogli S, Galimberti S, Gori V, et al. Pharmacology differences among proteasome inhibitors: Implications for their use in clinical practice. Pharmacol Res 2021;167:105537.

[56] Fricker LD. Proteasome Inhibitor Drugs. Annu Rev Pharmacol Toxicol 2020;60:457–76.

[57] Wang Z, Yang J, Kirk C, et al. Clinical pharmacokinetics, metabolism, and drugdrug interaction of carfilzomib. Drug Metab Dispos 2013;41:230–7.

[58] Besse A, Besse L, Kraus M, et al. Proteasome Inhibition in Multiple Myeloma:Head-to-Head Comparison of Currently Available Proteasome Inhibitors. Cell Chem Biol 2019;26:340–351 e343.

[59] Obeng EA, Carlson LM, Gutman DM, et al. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 2006;107:4907–16.

[60] Hideshima T, Chauhan D, Richardson P, et al. NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem 2002;277:16639–47.

[61] Bianchi G, Oliva L, Cascio P, et al. The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition. Blood 2009;113:3040–9.

[62] Cenci S, Mezghrani A, Cascio P, et al. Progressively impaired proteasomal capacity during terminal plasma cell differentiation. EMBO J 2006;25:1104–13.

[63] Masciarelli S, Fra AM, Pengo N, et al. CHOP-independent apoptosis and pathway-selective induction of the UPR in developing plasma cells. Mol Immunol 2010;47:1356–65.

[64] Cenci S. The proteasome in terminal plasma cell differentiation. Semin Hematol 2012;49:215–22.

[65] Pengo N, Scolari M, Oliva L, et al. Plasma cells require autophagy for sustainable immunoglobulin production. Nat Immunol 2013;14:298–305.

[66] Carpenter RO, Evbuomwan MO, Pittaluga S, et al. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Clin Cancer Res 2013;19:2048–60.

[67] Ali SA, Shi V, Maric I, et al. T cells

expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. Blood 2016;128:1688–700.

[68] Brudno JN, Maric I, Hartman SD, et al. T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma. J Clin Oncol 2018;36:2267–80.

[69] Raje N, Berdeja J, Lin Y, et al. Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma. N Engl J Med 2019;380:1726–37.

[70] Cappell KM, Kochenderfer JN. Long-term outcomes following CAR T cell therapy: what we know so far. Nat Rev Clin Oncol 2023;20:359–71.

[71] Lin Y, Raje NS, Berdeja JG, et al. Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial. Nat Med 2023;29:2286–94.

[72] Ramadoss NS, Schulman AD, Choi SH, et al. An anti-B cell maturation antigen bispecific antibody for multiple myeloma. J Am Chem Soc 2015;137:5288–91.

[73] Usmani SZ, Garfall AL, van de Donk N, et al. Teclistamab, a B-cell maturation antigen x CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study. Lancet 2021;398:665–74.

[74] Bahlis NJ, Costello CL, Raje NS, et al. Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial. Nat Med 2023;29:2570–6.

[75] Lesokhin AM, Tomasson MH, Arnulf B, et al. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med 2023;29:2259–67.

[76] Atamaniuk J, Gleiss A, Porpaczy E, et al. Overexpression of G protein-coupled receptor 5D in the bone marrow is associated with poor prognosis in patients with multiple myeloma. Eur J Clin Invest 2012;42:953–60.

[77] Kodama T, Kochi Y, Nakai W, et al. Anti-GPRC5D/CD3 Bispecific T-Cell-Redirecting Antibody for the Treatment of Multiple Myeloma. Mol Cancer Ther 2019;18:1555–64.

[78] Smith EL, Harrington K, Staehr M, et al. GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells. Sci Transl Med 2019;11.

[79] Leung-Hagesteijn C, Erdmann N, Cheung G, et al. Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma. Cancer Cell 2013;24:289–304.

[80] Neubert K, Meister S, Moser K, et al. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med 2008;14:748–55.

[81] Walhelm T, Gunnarsson I, Heijke R, et al. Clinical Experience of Proteasome Inhibitor Bortezomib Regarding Efficacy and Safety in Severe Systemic Lupus Erythematosus: A Nationwide Study. Front Immunol 2021;12:756941.

[82] Sjowall C, Hjorth M, Eriksson P. Successful treatment of refractory systemic lupus erythematosus using proteasome inhibitor bortezomib followed by belimumab: description of two cases. Lupus 2017;26:1333–8.

[83] Alexander T, Sarfert R, Klotsche J, et al. The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus. Ann Rheum Dis 2015;74:1474–8.

[84] Keats JJ, Fonseca R, Chesi M, et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 2007;12:131–44.

[85] Annunziata CM, Davis RE, Demchenko Y, et al. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 2007;12:115–30.

[86] Shabaneh TB, Downey SL, Goddard AL, et al. Molecular basis of differential sensitivity of myeloma cells to clinically relevant bolus treatment with bortezomib. PLoS One 2013;8:e56132.

[87] Downey-Kopyscinski S, Daily EW, Gautier M, et al. An inhibitor of proteasome beta2 sites sensitizes myeloma cells to immunoproteasome inhibitors. Blood Adv 2018;2:2443–51.

[88] Chen T, Ho M, Briere J, et al. Multiple myeloma cells depend on the DDI2/NRF1-mediated proteasome stress response for survival. Blood Adv 2022;6:429–40.

[89] Downey-Kopyscinski SL, Srinivasa S, Kisselev AF. A clinically relevant pulse treatment generates a bortezomib-resistant myeloma cell line that lacks proteasome mutations and is sensitive to Bcl-2 inhibitor venetoclax. Sci Rep 2022;12:12788.

[90] Barretina J, Caponigro G, Stransky N, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012;483:603–7.

[91] Richardson PG, Weller E, Jagannath S, et al. Multicenter, phase I, doseescalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma. J Clin Oncol 2009;27:5713–9.

[92] Richardson PG, Xie W, Jagannath S, et al. A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma. Blood 2014;123:1461–9.

[93] Franke NE, Niewerth D, Assaraf YG, et al. Impaired bortezomib binding to mutant beta5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells. Leukemia 2012;26:757–68.

[94] Meng L, Carpenter K, Mollard A, et al. Inhibition of Nek2 by small molecules affects proteasome activity. BioMed Res Int 2014;2014:273180.

[95] Acosta-Alvear D, Cho MY, Wild T, et al. Paradoxical resistance of multiple myeloma to proteasome inhibitors by decreased levels of 19S proteasomal subunits. Elife 2015;4:e08153.

[96] Tsvetkov P, Sokol E, Jin D, et al. Suppression of 19S proteasome subunits marks emergence of an altered cell state in diverse cancers. Proc Natl Acad Sci U S A 2017;114:382–7.

[97] Tsvetkov P, Detappe A, Cai K, et al. Mitochondrial metabolism promotes adaptation to proteotoxic stress. Nat Chem Biol 2019;15:681–9.

[98] Wallington-Beddoe CT, Sobieraj-Teague M, Kuss BJ, et al. Resistance to proteasome inhibitors and other targeted therapies in myeloma. Br J Haematol 2018;182:11–28.

[99] Gonzalez-Santamarta M, Quinet G, Reyes-Garau D, et al. Resistance to the Proteasome

Inhibitors: Lessons from Multiple Myeloma and Mantle Cell Lymphoma.Adv Exp Med Biol 2020;1233:153–74.

[100] Besse L, Besse A, Mendez-Lopez M, et al. A metabolic switch in proteasome inhibitor-resistant multiple myeloma ensures higher mitochondrial metabolism, protein folding and sphingomyelin synthesis. Haematologica 2019;104:e415–9.

[101] Besse A, Stolze SC, Rasche L, et al. Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma. Leukemia 2018;32:391–401.

[102] Farrell ML, Reagan MR. Soluble and Cell-Cell-Mediated Drivers of Proteasome Inhibitor Resistance in Multiple Myeloma. Front Endocrinol 2018;9:218.

[103] Meul T, Berschneider K, Schmitt S, et al. Mitochondrial Regulation of the 26S Proteasome. Cell Rep 2020;32:108059.

[104] Allmeroth K, Horn M, Kroef V, et al. Bortezomib resistance mutations in PSMB5 determine response to second-generation proteasome inhibitors in multiple myeloma. Leukemia 2021;35:887–92.

[105] Leonardo-Sousa C, Carvalho AN, Guedes RA, et al. Revisiting Proteasome Inhibitors: Molecular Underpinnings of Their Development, Mechanisms of Resistance and Strategies to Overcome Anti-Cancer Drug Resistance. Molecules 2022;27.

[106] Ferguson ID, Lin YT, Lam C, et al. Allosteric HSP70 inhibitors perturb mitochondrial proteostasis and overcome proteasome inhibitor resistance in multiple myeloma. Cell Chem Biol 2022;29:1288–302.e7.

[107] Haertle L, Buenache N, Cuesta Hernandez HN, et al. Genetic Alterations in Members of the Proteasome 26S Subunit, AAA-ATPase (PSMC) Gene Family in the Light of Proteasome Inhibitor Resistance in Multiple Myeloma. Cancers 2023;15.

[108] Haertle L, Barrio S, Munawar U, et al. Single-Nucleotide Variants and Epimutations Induce Proteasome Inhibitor Resistance in Multiple Myeloma. Clin Cancer Res 2023;29:279–88.

[109] Wang Q, Zhao D, Xian M, et al. MIF as a biomarker and therapeutic target for overcoming resistance to proteasome inhibitors in human myeloma. Blood 2020;136:2557–73.

[110] Wang Q, Shinkre BA, Lee JG, et al. The ERAD inhibitor Eeyarestatin I is a bifunctional compound with a membrane-binding domain and a p97/VCP inhibitory group. PLoS One 2010;5:e15479.

[111] Wang Q, Mora-Jensen H, Weniger MA, et al. ERAD inhibitors integrate ER stress with an epigenetic mechanism to activate BH3-only protein NOXA in cancer cells. Proc Natl Acad Sci U S A 2009;106:2200–5.

[112] Darawshi O, Muz B, Naamat SG, et al. An mTORC1 to HRI signaling axis promotes cytotoxicity of proteasome inhibitors in multiple myeloma. Cell Death Dis 2022;13:969.

[113] Cohen YC, Zada M, Wang SY, et al. Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing. Nat Med 2021;27:491–503.

[114] McConkey DJ, Zhu K. Mechanisms of proteasome inhibitor action and resistance in cancer. Drug Resist Updat 2008;11:164–79.

[115] Niewerth D, Jansen G, Assaraf YG, et al. Molecular basis of resistance to proteasome

inhibitors in hematological malignancies. Drug Resist Updat 2015;18:18–35.

[116] Bo Kim K. Proteasomal adaptations to FDA-approved proteasome inhibitors: a potential mechanism for drug resistance? Cancer Drug Resist 2021;4:634–45.

[117] Patino-Escobar B, Talbot A, Wiita AP. Overcoming proteasome inhibitor resistance in the immunotherapy era. Trends Pharmacol Sci 2023;44:507–18.

[118] Barrio S, Stuhmer T, Da-Via M, et al. Spectrum and functional validation of PSMB5 mutations in multiple myeloma. Leukemia 2019;33:447–56.

[119] Cloos J, Roeten MS, Franke NE, et al. (Immuno)proteasomes as therapeutic target in acute leukemia. Cancer Metastasis Rev 2017;36:599–615.

[120] Verbrugge SE, Assaraf YG, Dijkmans BA, et al. Inactivating PSMB5 mutations and P-glycoprotein (multidrug resistance-associated protein/ATP-binding cassette B1) mediate resistance to proteasome inhibitors: ex vivo efficacy of (immuno)proteasome inhibitors in mononuclear blood cells from patients with rheumatoid arthritis. J Pharmacol Exp Ther 2012;341:174–82.

[121] Ri M, Iida S, Nakashima T, et al. Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress. Leukemia 2010;24:1506–12.

[122] Oerlemans R, Franke NE, Assaraf YG, et al. Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood 2008;112:2489–99.

[123] Hideshima T, Bradner JE, Wong J, et al. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci U S A 2005;102:8567–72.

[124] Nawrocki ST, Carew JS, Pino MS, et al. Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells. Cancer Res 2006;66:3773–81.

6　多发性骨髓瘤中的单克隆抗体治疗

[1] Brink M, Visser O, Zweegman S, et al. First-line treatment and survival of newly diagnosed primary plasma cell leukemia patients in the Netherlands: a population-based study, 1989-2018. Blood Cancer J 2021;11(2):22.

[2] van de Donk N, Richardson PG, Malavasi F. CD38 antibodies in multiple myeloma: back to the future. Blood 2018;131(1):13–29.

[3] van de Donk NW, Moreau P, Plesner T, et al. Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma.

[4] Zhu C, Song Z, Wang A, et al. Isatuximab Acts Through Fc-Dependent, Independent, and Direct Pathways to Kill Multiple Myeloma Cells. Front Immunol 2020;11:1771.

[5] Deckert J, Wetzel MC, Bartle LM, et al. SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD381 hematologic malignancies. Clin Cancer Res 2014;20(17):4574–83.

[6] Jiang H, Acharya C, An G, et al. SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide. Leukemia 2016;30(2):399–408.

[7] de WM, Tai YT, van d V, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol 2011;186(3):1840–8.

[8] Krejcik J, Casneuf T, Nijhof IS, et al. Daratumumab depletes CD381 immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood 2016;128(3):384–94.

[9] Adams HC 3rd, Stevenaert F, Krejcik J, et al. High-Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action. Cytometry Part A : The Journal of the International Society for Analytical Cytology 2019;95(3):279–89.

[10] Feng X, Zhang L, Acharya C, et al. Targeting CD38 Suppresses Induction and Function of T Regulatory Cells to Mitigate Immunosuppression in Multiple Myeloma. Clin Cancer Res 2017;23(15):4290–300.

[11] Lammerts van Bueren J, Jakobs D, Kaldenhoven N, et al. Direct in Vitro Comparison of Daratumumab with Surrogate Analogs of CD38 Antibodies MOR03087, SAR650984 and Ab79. Blood 2014;124(21):3474.

[12] Kinder M, Bahlis NJ, Malavasi F, et al. Comparison of CD38 antibodies in vitro and ex vivo mechanisms of action in multiple myeloma. Haematologica 2021;106(7):2004–8.

[13] Quach H, Ritchie D, Stewart AK, et al. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma.

Leukemia 2010;24(1):22–32.

[14] van de Donk NW, Görgün G, Groen RW, et al. Lenalidomide for the treatment of relapsed and refractory multiple myeloma. Cancer Manag Res 2012;4:253–68.

[15] Nijhof IS, Groen RW, Noort WA, et al. Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib. Clin Cancer Res 2015;21(12):2802–10.

[16] van der Veer MS, de WM, van KB, et al. The therapeutic human CD38 antibody daratumumab improves the anti-myeloma effect of newly emerging multi-drug therapies. Blood Cancer J 2011;1(10):e41.

[17] Cai T, Wetzel M, Nicolazzi C, et al. Preclinical chracterization of SAR650984, a humanized anti-CD38 antibody for the treatment of multiple myeloma. Clin Lymphoma Myeloma Leuk 2013;288.

[18] Krejcik J, Frerichs KA, Nijhof IS, et al. Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab. Clin Cancer Res 2017;23(24):7498–511.

[19] Nijhof IS, Casneuf T, van VJ, et al. CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma. Blood 2016;128(7):959–70.

[20] Verkleij CPM, Frerichs KA, Broekmans MEC, et al. NK Cell Phenotype Is Associated With Response and Resistance to Daratumumab in Relapsed/Refractory Multiple Myeloma. Hemasphere 2023;7(5):e881.

[21] Casneuf T, Xu XS, Adams HC 3rd, et al. Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma. Blood advances 2017;1(23):2105–14.

[22] de Haart SJ, Holthof L, Noort WA, et al. Sepantronium bromide (YM155) improves daratumumab-mediated cellular lysis of multiple myeloma cells by abrogation of bone marrow stromal cell-induced resistance. Haematologica 2016;101(8):e339–42.

[23] Giri S, Grimshaw A, Bal S, et al. Evaluation of Daratumumab for the Treatment of Multiple Myeloma in Patients With High-risk Cytogenetic Factors: A Systematic Review and Meta-analysis. JAMA Oncol 2020;6(11):1759–65.

[24] Mateos MV, Cavo M,Blade J, et al.Overall survival withdaratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial. Lancet 2020;395(10218):132–41.

[25] Mateos MV, Dimopoulos MA, Cavo M, et al, ALCYONE Trial Investigators. Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma. N Engl J Med 2018;378(6):518–28.

[26] Facon T, Kumar S, Plesner T, et al, MAIA Trial Investigators. Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma. N Engl J Med 2019;380(22):2104–15.

[27] Moreau P, Attal M, Hulin C, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, openlabel, phase 3 study. Lancet 2019;394(10192):29–38.

[28] Chari A, Kaufman JL, Laubach JP, et al. Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): Final Analysis of Griffin Among Clinically Relevant Subgroups. Blood 2022;140(Supplement 1):7278–81.

[29] Moreau P, Facon T, Usmani S, et al. Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Transplant-Ineligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM):Clinical Assessment of Key Subgroups of the Phase 3 Maia Study. Blood 2022;140(Supplement 1):7297–300.

[30] Costa LJ, Chhabra S, Medvedova E, et al. Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy inNewlyDiagnosed Multiple Myeloma. J ClinOncol 2022;40(25):2901–12.

[31] Usmani SZ, Nahi H, Plesner T, et al. Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials. Lancet Haematol 2020;7(6):e447–55.

[32] Lokhorst HM, Plesner T, Laubach JP, et al. Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma. N Engl J Med 2015;373(13):1207–19.

[33] Lonial S, Weiss BM, Usmani SZ, et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet 2016;387(10027):1551–60.

[34] Dimopoulos M, Bringhen S, Anttila P, et al. Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed/refractory multiple myeloma. Blood 2021;137(9):1154–65.

[35] Mateos MV, Nahi H, Legiec W, et al. Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA):a multicentre, open-label, non-inferiority, randomised, phase 3 trial. Lancet Haematol 2020;7(5):e370–80.

[36] Usmani SZ, Nahi H, Mateos MV, et al. Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma. Blood 2019;134(8):668–77.

[37] Oostendorp M, Lammerts van Bueren JJ, Doshi P, et al. When blood transfusion medicine becomes complicated due to interference by monoclonal antibody therapy. Transfusion 2015;55(6 Pt 2):1555–62.

[38] van de Donk NW, Otten HG, El Haddad O, et al. Interference of daratumumab in monitoring multiple myeloma patients using serum immunofixation electrophoresis can be abrogated using the daratumumab IFE reflex assay (DIRA). Clin Chem Lab Med 2016;54(6):1105–9.

[39] Martin T, Dimopoulos MA, Mikhael J, et al. Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study. Blood Cancer J 2023;13(1):72.

[40] Attal M, Richardson PG, Rajkumar SV, et al, ICARIA-MM study group. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase

3 study. Lancet 2019;394(10214):2096–107.

[41] Lonial S, Dimopoulos M, Palumbo A, et al, ELOQUENT-2 Investigators. Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. N Engl J Med 2015;373(7):621–31.

[42] Cavo M, San-Miguel J, Usmani SZ, et al. Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA. Blood 2022;139(6):835–44.

[43] Facon T, Kumar SK, Plesner T, et al. Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, openlabel, phase 3 trial. Lancet Oncol 2021;22(11):1582–96.

[44] Moreau P, Hulin C, Perrot A, et al. Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial. Lancet Oncol 2021;22(10):1378–90.

[45] Voorhees PM, Kaufman JL, Laubach J, et al. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood 2020;136(8):936–45.

[46] Mateos MV, Dimopoulos MA, Cavo M, et al. Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE. Clin Lymphoma, Myeloma & Leukemia 2021;21(11):785–98.

[47] Facon T, Cook G, Usmani SZ, et al. Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA. Leukemia 2022;36(4):1066–77.

[48] Palumbo A, Bringhen S, Mateos MV, et al. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood 2015;125(13):2068–74.

[49] Facon T, Dimopoulos MA, Meuleman N, et al. A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial. Leukemia 2020;34(1):224–33.

[50] Stege CAM, Nasserinejad K, van der Spek E, et al. Ixazomib, Daratumumab, and Low-Dose Dexamethasone in Frail Patients With Newly Diagnosed Multiple Myeloma: The Hovon 143 Study. J Clin Oncol 2021;39(25):2758–67.

[51] Korst C, van de Donk N. Should all newly diagnosed MM patients receive CD38 antibody-based treatment? Hematology American Society of Hematology Education Program 2020;2020(1):259–63.

[52] Krishnan A, Hoering A, Hari P, et al. Phase III Study of Daratumumab/rhuph20 (nsc-810307) 1 Lenalidomide or Lenalidomide As Post-Autologous Stem Cell Transplant Maintenance Therapyin Patients with Multiple Myeloma (mm) Using Minimal Residual Disease Todirect Therapy Duration (DRAMMATIC study):SWOG s1803. Blood 2020;136:21–2.

[53] Goldschmidt H, Mai EK, Bertsch U, et al, German-Speaking Myeloma Multicenter Group GMMG HD7 investigators. Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial. Lancet Haematol 2022;9(11):e810–21.

[54] Leypoldt LB, Besemer B, Asemissen AM, et al. Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: interim analysis of the GMMG-CONCEPT trial. Leukemia 2022;36(3): 885–8.

[55] Royle KL, Coulson AB, Ramasamy K, et al. Risk and response adapted therapy following autologous stem cell transplant in patients with newly diagnosed multiple myeloma (RADAR (UK-MRA Myeloma XV Trial): study protocol for a phase II/III randomised controlled trial. BMJ Open 2022;12(11):e063037.

[56] Plesner T, Arkenau T, Lokhorst H, et al. Preliminary Safety and Efficacy Data Of Daratumumab In Combination With Lenalidomide and Dexamethasone In Relapsed Or Refractory Multiple Myeloma. Blood 2013;122(21):1986.

[57] Martin T, Baz R, Benson DM, et al. A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma. Blood 2017;129(25):3294–303.

[58] Dimopoulos MA, Oriol A, Nahi H, et al, POLLUX Investigators. Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med 2016; 375(14):1319–31.

[59] Dimopoulos MA, San-Miguel J, Belch A, et al. Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX. Haematologica 2018; 103(12):2088–96.

[60] Dimopoulos MA, Oriol A, Nahi H, et al. Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial. J Clin Oncol 2023;41(8):1590–9.

[61] Chari A, Suvannasankha A, Fay JW, et al. Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. Blood 2017;130(8):974–81.

[62] Dimopoulos MA, Terpos E, Boccadoro M, et al, APOLLO Trial Investigators. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. Lancet Oncol 2021;22(6):801–12.

[63] Richardson PG, Perrot A, San-Miguel J, et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study. Lancet Oncol 2022;23(3): 416–27.

[64] Sonneveld P, Chanan-Khan A, Weisel K, et al. Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in

Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial. J Clin Oncol 2023;41(8):1600–9.

[65] Palumbo A, Chanan-Khan A, Weisel K, et al, CASTOR Investigators. Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. N Engl J Med 2016;375(8):754–66.

[66] Dimopoulos M, Quach H, Mateos MV, et al. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. Lancet 2020;396(10245):186–97.

[67] Usmani SZ, Quach H, Mateos MV, et al. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study. Lancet Oncol 2022;23(1):65–76.

[68] Usmani SZ, Quach H, Mateos MV, et al. Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR study. Blood Advances 2023;7(14):3739–48.

[69] Bringhen S, Milan A, Ferri C, et al, European Hematology Association, the European Myeloma Network and the Italian Society of Arterial Hypertension. Cardiovascular adverse events in modern myeloma therapy - Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA). Haematologica 2018;103(9):1422–32.

[70] Dimopoulos MA, Goldschmidt H, Niesvizky R, et al. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Lancet Oncol 2017; 18(10):1327–37.

[71] van de Donk NW. Carfilzomib versus bortezomib: no longer an ENDEAVOR. Lancet Oncol 2017;18(10):1288–90.

[72] Nooka AK, Joseph NS, Kaufman JL, et al. Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients. Cancer 2019;125(17):2991–3000.

[73] Hussain MJ, Robinson MM, Hamadeh I, et al. Daratumumab, pomalidomide and dexamethasone combination therapy in daratumumab and/or pomalidomide refractory multiple myeloma. Br J Haematol 2019;186(1):140–4.

[74] Alici E, Chrobok M, Lund J, et al. Re-challenging with anti-CD38 monotherapy in triple-refractory multiple myeloma patients is a feasible and safe approach. Br J Haematol 2016;174(3):473–7.

[75] Bahlis NJ, Zonder JA, Wroblewski S, et al. Subcutaneous daratumumab in patients with multiple myeloma who have been previously treated with intravenous daratumumab: A multicenter, randomized, phase II study (LYNX). J Clin Oncol 2020;38(15_suppl):TPS8553.

[76] Hsi ED, Steinle R, Balasa B, et al. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin Cancer Res 2008;14(9):2775–84.

[77] Kurdi AT, Glavey SV, Bezman NA, et al. Antibody-Dependent Cellular Phagocytosis by Macrophages is a Novel Mechanism of Action of Elotuzumab. Mol Cancer Therapeut 2018;17(7):1454–63.

[78] Tai YT, Dillon M, Song W, et al. Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood 2008;112(4):1329–37.

[79] Collins SM, Bakan CE, Swartzel GD, et al. Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC. Cancer Immunol Immunother 2013;62(12):1841–9.

[80] Hoylman E, Brown A, Perissinotti AJ, et al. Optimal sequence of daratumumab and elotuzumab in relapsed and refractory multiple myeloma. Leuk Lymphoma 2020;61(3):691–8.

[81] Becnel M, Rubin L, Nair R, et al. Effect of Timing of Monoclonal Antibody Therapy on the Time to Next Treatment and Response Rate in Heavily Pre-Treated Patients with Myeloma Who Separately Received Both Daratumumab and Elotuzumab-Based Regimens. Blood 2018;132:3258.

[82] Dimopoulos MA, Richardson PG, Bahlis NJ, et al, ELOQUENT-1 investigators. Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial. Lancet Haematol 2022; 9(6):e403–14.

[83] Goldschmidt H, Mai EK, Bertsch U, et al. Elotuzumab in Combination with Lenalidomide, Bortezomib, Dexamethasone and Autologous Transplantation for Newly-Diagnosed Multiple Myeloma: Results from the Randomized Phase III GMMG-HD6 Trial. Blood 2021;138:486.

[84] Usmani SZ, Hoering A, Ailawadhi S, et al, SWOG1211 Trial Investigators. Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial. Lancet Haematol 2021;8(1):e45–54.

[85] Knop S, Stuebig T, Kull M, et al. Carfilzomib, lenalidomide, and dexamethasone (KRd) versus elotuzumab and KRd in transplant-eligible patients with newly diagnosed multiple myeloma: Post-induction response and MRD results from an open-label randomized phase 3 study. J Clin Oncol 2023;41(16_suppl):8000.

[86] Zonder JA, Mohrbacher AF, Singhal S, et al. A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma. Blood 2012;120(3):552–9 %19.

[87] Dimopoulos MA, Lonial S, Betts KA, et al. Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trial. Cancer 2018;124(20):4032–43.

[88] Dimopoulos MA, Lonial S, White D, et al. Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study. Blood Cancer J 2020;10(9):91.

[89] Dimopoulos MA, Dytfeld D, Grosicki S, et al. Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma. N Engl J Med 2018;379(19):1811–22.

[90] Dimopoulos MA, Dytfeld D, Grosicki S, et al. Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial. J Clin Oncol 2023;41(3):568–78.

[91] van RF, Szmania SM, Dillon M, et al. Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma. Mol Cancer Ther 2009;8(9):2616–24.

[92] Jakubowiak A, Offidani M, Pegourie B, et al. Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM. Blood 2016;127(23):2833–40.

[93] Moreau P, Garfall AL, van de Donk N, et al. Teclistamab in Relapsed or Refractory Multiple Myeloma. N Engl J Med 2022;387(6):495–505.

[94] Martin T, Usmani SZ, Berdeja JG, et al. Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up. J Clin Oncol 2023;41(6):1265–74.

[95] Lonial S, Lee HC, Badros A, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol 2020;21(2):207–21.

[96] van de Donk N, Usmani SZ, Yong K. CAR T-cell therapy for multiple myeloma: state of the art and prospects. Lancet Haematol 2021;8(6):e446–61.

[97] O'Neill C, van de Donk N. T-cell redirecting bispecific antibodies in multiple myeloma: Current landscape and future directions. EJHaem 2023;4(3):811–22.

[98] van de Donk N, Zweegman S. T-cell-engaging bispecific antibodies in cancer. Lancet 2023;402(10396):142–58.

[99] Ryan MC, Hering M, Peckham D, et al. Antibody targeting of B-cell maturation antigen on malignant plasma cells. Mol Cancer Therapeut 2007;6(11):3009–18.

[100] Hoffman JE, Lipe B, Melear J, et al. SEA-BCMA, an Investigational Nonfucosylated Monoclonal Antibody: Ongoing Results of a Phase 1 Study in Patients with Relapsed/Refractory Multiple Myeloma (SGNBCMA-001). Blood 2021;138:2740.

[101] Hoffman JE, Lipe B, Melear J, et al. Sea-BCMA Mono- and Combination Therapy in Patients with Relapsed/Refractory Multiple Myeloma: Updated Results of a Phase 1 Study (SGNBCMA-001). Blood 2022;140(Supplement 1):10160–2.

[102] Lonial S, Popat R, Hulin C, et al. Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trial. Lancet Haematol 2022;9(11):e822–32.

[103] Richardson PG, Trudel S, Quach H, et al. Mezigdomide (CC-92480), a Potent, Novel Cereblon E3 Ligase Modulator (CELMoD), Combined with Dexamethasone(DEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results from the Dose-Expansion Phase of the CC-92480-MM-001 Trial.Blood

2022;140(Supplement 1):1366–8.

[104] Lonial S, Amatangelo M, Popat R, et al. Preclinical, Translational, and Clinical Evidence of a Differentiated Profile for the Novel CELMoD, Iberdomide (CC220). Blood 2019;134:3119.

[105] van de Donk NWCJ, Popat R, Larsen J, et al. First Results of Iberdomide (IBER;CC-220) in Combination with Dexamethasone (DEX) and Daratumumab (DARA) or Bortezomib (BORT) in Patients with Relapsed/Refractory Multiple Myeloma(RRMM). Blood 2020;136(Supplement 1):16–7.

[106] Cortes-Selva D, Casneuf T, Vishwamitra D, et al. Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Correlative Analyses from MajesTEC-1. Blood 2022;140(Supplement 1):241–3.

[107] Frerichs KA, Broekmans MEC, Marin Soto JA, et al. Preclinical Activity of JNJ7957, a Novel BCMACD3 Bispecific Antibody for the Treatment of Multiple Myeloma, Is Potentiated by Daratumumab. Clin Cancer Res 2020;26(9):2203–15.

[108] Verkleij CPM, Broekmans MEC, van Duin M, et al. Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma. Blood Advances 2021;5(8):2196–215.

[109] Rodr´ıguez-Otero P, D'Souza A, Reece DE, et al. A novel, immunotherapy-based approach for the treatment of relapsed/refractory multiple myeloma (RRMM): Updated phase 1b results for daratumumab in combination with teclistamab (a BCMA x CD3 bispecific antibody). J Clin Oncol 2022;40(16_suppl):8032.

[110] Dholaria B, Weisel K, Mateos M-V, et al. Talquetamab (tal) 1 daratumumab(dara) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Updated TRIMM-2 results. J Clin Oncol 2023;41(16_suppl):8003.

[111] Naeimi Kararoudi M, Nagai Y, Elmas E, et al. CD38 deletion of human primary NK cells eliminates daratumumab-induced fratricide and boosts their effector activity. Blood 2020;136(21):2416–27.

[112] Frerichs KA, Minnema MC, Levin MD, et al. Efficacy and safety of daratumumab combined with all-trans retinoic acid in relapsed/refractory multiple myeloma. Blood Advances 2021;5(23):5128–39.

[113] Kassem S, Diallo BK, El-Murr N, et al. SAR442085, a novel anti-CD38 antibody with enhanced antitumor activity against multiple myeloma. Blood 2022;139(8):1160–76.

[114] Hiemstra IH, Santegoets KCM, Janmaat ML, et al. Preclinical anti-tumour activity of HexaBody-CD38, a next-generation CD38 antibody with superior complement dependent cytotoxic activity. EBioMedicine 2023;93:104663.

[115] Spencer A, Iversen KF, Dhakal B, et al. Preliminary Dose-Escalation Results from a Phase 1/2 Study of GEN3014 (HexaBody-CD38) in Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM). Blood 2022;140(Supplement 1):7320–1.

[116] Spencer A, Lentzsch S, Weisel K, et al. Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR. Haematologica

2018;103(12):2079–87.

[117] Moreau P, Dimopoulos MA, Mikhael J, et al, IKEMA study group. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. Lancet 2021;397(10292):2361–71.

7　双特异性抗体在多发性骨髓瘤治疗中的应用

[1] Rajkumar SV. Multiple myeloma: 2022 update on diagnosis, risk stratification,and management. Am J Hematol 2022;97(8):1086–107.

[2] Attal M, Lauwers-Cances V, Hulin C, et al. Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma. N Engl J Med 2017;376(14):1311–20.

[3] Goldschmidt H, Lokhorst HM, Mai EK, et al. Bortezomib before and after highdose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial. Leukemia 2018;32(2):383–90.

[4] Chetter I, Arundel C, Bell K, et al. The epidemiology, management and impact of surgical wounds healing by secondary intention: a research programmeincluding the SWHSI feasibility RCT. Southampton (UK): Programme Grantsfor Applied Research; 2020.

[5] Durie BGM, Hoering A, Abidi MH, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet2017;389(10068):519–27.

[6] Facon T, Kumar SK, Plesner T, et al. Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, openlabel, phase 3 trial. Lancet Oncol 2021;22(11):1582–96.

[7] Zhou X, Einsele H, Danhof S. Bispecific Antibodies: A New Era of Treatment for Multiple Myeloma. J Clin Med 2020;9(7):2166.

[8] Ho WY, Blattman JN, Dossett ML, et al. Adoptive immunotherapy: engineering T cell responses as biologic weapons for tumor mass destruction. Cancer Cell 2003;3(5):431–7.

[9] Yang Q, Li X, Zhang F, et al. Efficacy and Safety of CAR-T Therapy for Relapse or Refractory Multiple Myeloma: A systematic review and meta-analysis. Int J Med Sci 2021;18(8):1786–97.

[10] Cipkar C, Chen C, Trudel S. Antibodies and bispecifics for multiple myeloma: effective effector therapy. Hematology Am Soc Hematol Educ Program 2022; 2022(1):163–72.

[11] Mullard A. FDA approves first BCMA-targeted CAR-T cell therapy. Nat Rev Drug Discov 2021;20(5):332.

[12] Mullard A. FDA approves second BCMA-targeted CAR-T cell therapy. Nat Rev Drug Discov 2022;21(4):249.

[13] Kang C. Teclistamab: First Approval. Drugs 2022;82(16):1613–9.

[14] Rendo MJ, Joseph JJ, Phan LM, et al. CAR T-Cell Therapy for Patients with Multiple Myeloma: Current Evidence and Challenges. Blood Lymphat Cancer 2022;12:119–36.

[15] Kazandjian D, Kowalski A, Landgren O. T cell redirecting bispecific antibodies for multiple myeloma: emerging therapeutic strategies in a changing treatment landscape. Leuk Lymphoma 2022;63(13):3032–43.

[16] Granger K, Gaffney KJ, Davis JA. Newly approved and forthcoming T-cell-redirecting bispecific antibodies for the treatment of relapsed/refractory multiple myeloma. J Oncol Pharm Pract 2023;29(3):722–6.

[17] Link BK, Kostelny SA, Cole MS, et al. Anti-CD3-based bispecific antibody designed for therapy of human B-cell malignancy can induce T-cell activation by antigen-dependent and antigen-independent mechanisms. Int J Cancer 1998;77(2):251–6.

[18] Shah N, Chari A, Scott E, et al. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. Leukemia 2020;34(4):985–1005.

[19] Li J, Stagg NJ, Johnston J, et al. Membrane-Proximal Epitope Facilitates Efficient T Cell Synapse Formation by Anti-FcRH5/CD3 and Is a Requirement for Myeloma Cell Killing. Cancer Cell 2017;31(3):383–95.

[20] Seckinger A, Delgado JA, Moser S, et al. Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment. Cancer Cell 2017;31(3):396–410.

[21] Goldstein RL, Goyos A, Li CM, et al. AMG 701 induces cytotoxicity of multiple myeloma cells and depletes plasma cells in cynomolgus monkeys. Blood Adv2020;4(17):4180–94.

[22] Brinkmann U, Kontermann RE. The making of bispecific antibodies. mAbs 2017;9(2):182–212.

[23] Madduri D, Dhodapkar MV, Lonial S, et al. SOHO State of the Art Updates and Next Questions: T-Cell-Directed Immune Therapies for Multiple Myeloma: Chimeric Antigen Receptor-Modified T Cells and Bispecific T-Cell-Engaging Agents. Clin Lymphoma, Myeloma & Leukemia 2019;19(9):537–44.

[24] Kontermann RE, Brinkmann U. Bispecific antibodies. Drug Discov Today 2015;20(7):838–47.

[25] Moreau P, Touzeau C. T-cell-redirecting bispecific antibodies in multiple myeloma:a revolution? Blood 2022;139(26):3681–7

[26] Zhou X, Rasche L, Kortum KM, et al. BCMA loss in the epoch of novel immunotherapy for multiple myeloma: from biology to clinical practice. Haematologica 2023;108(4):958–68.

[27] Tai YT, Acharya C, An G, et al. APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment. Blood 2016;127(25):3225–36.

[28] Moreaux J, Legouffe E, Jourdan E, et al. BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood 2004;103(8):3148–57.

[29] Tai YT, Li XF, Breitkreutz I, et al. Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment.Cancer Res 2006;66(13):6675–82.

[30] Cho SF, Anderson KC, Tai YT. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy. Front

Immunol 2018;9:1821.

[31] Demchenko YN, Glebov OK, Zingone A, et al. Classical and/or alternative NFkappaB pathway activation in multiple myeloma. Blood 2010;115(17):3541–52.

[32] Pillarisetti K, Powers G, Luistro L, et al. Teclistamab is an active T cell-redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma.Blood Adv 2020;4(18):4538–49.

[33] Hipp S, Tai YT, Blanset D, et al. A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo.Leukemia 2017;31(8):1743–51.

[34] Gao Y, Wang X, Yan H, et al. Comparative Transcriptome Analysis of Fetal Skin Reveals Key Genes Related to Hair Follicle Morphogenesis in Cashmere Goats.PLoS One 2016;11(3):e0151118.

[35] Inoue S, Nambu T, Shimomura T. The RAIG family member, GPRC5D, is associated with hard-keratinized structures. J Invest Dermatol 2004;122(3):565–73.

[36] Kim YJ, Yoon B, Han K, et al. Comprehensive Transcriptome Profiling of Balding and Non-Balding Scalps in Trichorhinophalangeal Syndrome Type I Patient. Ann Dermatol 2017;29(5):597–601.

[37] Atamaniuk J, Gleiss A, Porpaczy E, et al. Overexpression of G protein-coupled receptor 5D in the bone marrow is associated with poor prognosis in patients with multiple myeloma. Eur J Clin Invest 2012;42(9):953–60.

[38] Cohen Y, Gutwein O, Garach-Jehoshua O, et al. GPRC5D is a promising marker for monitoring the tumor load and to target multiple myeloma cells. Hematology 2013;18(6):348–51.

[39] Smith EL, Harrington K, Staehr M, et al. GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells. Sci Transl Med 2019;11(485):eaau7746.

[40] Pillarisetti K, Edavettal S, Mendonca M, et al. A T-cell-redirecting bispecific G-protein-coupled receptor class 5 member D x CD3 antibody to treat multiple myeloma. Blood 2020;135(15):1232–43.

[41] Elkins K, Zheng B, Go M, et al. FcRL5 as a target of antibody-drug conjugates for the treatment of multiple myeloma. Mol Cancer Therapeut 2012;11(10):2222–32.

[42] Polson AG, Zheng B, Elkins K, et al. Expression pattern of the human FcRH/IRTA receptors in normal tissue and in B-chronic lymphocytic leukemia. Int Immunol 2006;18(9):1363–73.

[43] Stewart AK, Krishnan AY, Singhal S, et al. Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma. Blood Cancer J 2019;9(2):17.

[44] Inoue J, Otsuki T, Hirasawa A, et al. Overexpression of PDZK1 within the 1q12-q22 amplicon is likely to be associated with drug-resistance phenotype in multiple myeloma. Am J Pathol 2004;165(1):71–81.

[45] Funaro A, Malavasi F. Human CD38, a surface receptor, an enzyme, an adhesion molecule and not a simple marker. J Biol Regul Homeost Agents 1999;13(1):54–61.

[46] Lin P, Owens R, Tricot G, et al. Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. Am J Clin Pathol 2004;121(4):482–8.

[47] de Weers M, Tai YT, van der Veer MS, et al.

Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol 2011;186(3):1840–8.

[48] Zhu C, Song Z, Wang A, et al. Isatuximab Acts Through Fc-Dependent, Independent, and Direct Pathways to Kill Multiple Myeloma Cells. Front Immunol 2020;11:1771.

[49] Zuch de Zafra CL, Fajardo F, Zhong W, et al. Targeting Multiple Myeloma with AMG 424, a Novel Anti-CD38/CD3 Bispecific T-cell-recruiting Antibody Optimized for Cytotoxicity and Cytokine Release. Clin Cancer Res 2019;25(13): 3921–33.

[50] Akhmetzyanova I, McCarron MJ, Parekh S, et al. Dynamic CD138 surface expression regulates switch between myeloma growth and dissemination. Leukemia 2020;34(1):245–56.

[51] Gotte M. Syndecans in inflammation. Faseb J 2003;17(6):575–91.

[52] Chen D, Zou J, Zong Y, et al. Anti-human CD138 monoclonal antibodies and their bispecific formats: generation and characterization. Immunopharmacol Immunotoxicol 2016;38(3):175–83.

[53] Robillard N, Wuilleme S, Moreau P, et al. Immunophenotype of normal and myelomatous plasma-cell subsets. Front Immunol 2014;5:137.

[54] Tembhare PR, Yuan CM, Venzon D, et al. Flow cytometric differentiation of abnormal and normal plasma cells in the bone marrow in patients with multiple myeloma and its precursor diseases. Leuk Res 2014;38(3):371–6.

[55] Nerreter T, Letschert S, Gotz R, et al. Super-resolution microscopy reveals ultralow CD19 expression on myeloma cells that triggers elimination by CD19 CAR-T.Nat Commun 2019;10(1):3137.

[56] Ali S, Moreau A, Melchiorri D, et al. Blinatumomab for Acute Lymphoblastic Leukemia: The First Bispecific T-Cell Engager Antibody to Be Approved by the EMA for Minimal Residual Disease. Oncol 2020;25(4):e709–15.

[57] Bargou R, Leo E, Zugmaier G, et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 2008;321(5891):974–7.

[58] Kantarjian H, Stein A, Gokbuget N, et al. Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia. N Engl J Med 2017;376(9):836–47.

[59] Topp MS, Gokbuget N, Stein AS, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol 2015;16(1):57–66.

[60] Hsi ED, Steinle R, Balasa B, et al. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin Cancer Res 2008;14(9):2775–84.

[61] Tai YT, Soydan E, Song W, et al. CS1 promotes multiple myeloma cell adhesion,clonogenic growth, and tumorigenicity via c-maf-mediated interactions with bone marrow stromal cells. Blood 2009;113(18):4309–18.

[62] Tai YT, Dillon M, Song W, et al. Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood 2008;112(4):1329–37.

[63] Wang Y, Sanchez L, Siegel DS, et al. Elotuzumab for the treatment of multiple myeloma. J Hematol Oncol 2016;9(1):55.

[64] Magen H, Muchtar E. Elotuzumab: the first approved monoclonal antibody for multiple myeloma treatment. Ther Adv Hematol 2016;7(4):187–95.

[65] Ratner M. FDA approves three different multiple myeloma drugs in one month.Nat Biotechnol 2016;34(2):126.

[66] Chan WK, Kang S, Youssef Y, et al. A CS1-NKG2D Bispecific Antibody Collectively Activates Cytolytic Immune Cells against Multiple Myeloma. Cancer Immunol Res 2018;6(7):776–87.

[67] Topp MS, Duell J, Zugmaier G, et al. Anti-B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma. J Clin Oncol 2020;38(8):775–83.

[68] Harrison SJ, Minnema MC, Lee HC, et al. A Phase 1 First in Human (FIH) Study of AMG 701, an Anti-B-Cell Maturation Antigen (BCMA) Half-Life Extended

(HLE) BiTE (bispecific T-cell engager) Molecule, in Relapsed/Refractory(RR) Multiple Myeloma (MM). Blood 2020;136(Supplement 1):28–9.

[69] Moreau P, Garfall AL, van de Donk N, et al. Teclistamab in Relapsed or Refractory Multiple Myeloma. N Engl J Med 2022;387(6):495–505.

[70] Searle E, Quach H, Wong SW, et al. Teclistamab in Combination with Subcutaneous Daratumumab and Lenalidomide in Patients with Multiple Myeloma: Results from One Cohort of MajesTEC-2, a Phase1b, Multicohort Study. Blood 2022;140(Supplement 1):394–6.

[71] Rodrı´guez-Otero P, D'Souza A, Reece DE, et al. A novel, immunotherapy-based approach for the treatment of relapsed/refractory multiple myeloma (RRMM): Updated phase 1b results for daratumumab in combination with teclistamab (a BCMA x CD3 bispecific antibody). J Clin Oncol 2022;40(16_suppl):8032.

[72] Krejcik J, Casneuf T, Nijhof IS, et al. Daratumumab depletes CD381 immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood 2016;128(3):384–94.

[73] Rodriguez-Otero P, Dholaria B, Askari E, et al. Subcutaneous Teclistamab in Combination with Daratumumab for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma: Results from a Phase 1b Multicohort Study. Blood 2021;138(Supplement 1):1647.

[74] Zamagni E, Boccadoro M, Spencer A, et al. MajesTEC-4 (EMN30): A Phase 3 Trial of Teclistamab 1 Lenalidomide Versus Lenalidomide Alone As Maintenance Therapy Following Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma. Blood 2022;140(Supplement 1):7289–91.

[75] Krishnan AY, Manier S, Terpos E, et al. MajesTEC-7: A Phase 3, Randomized Study of Teclistamab 1 Daratumumab 1 Lenalidomide (Tec-DR) Versus Daratumumab 1 Lenalidomide 1 Dexamethasone (DRd) in Patients with Newly Diagnosed Multiple Myeloma Who Are Either Ineligible or Not Intended for Autologous Stem Cell Transplant. Blood 2022;140(Supplement 1):10148–9.

[76] Sebag M, Raje NS, Bahlis NJ, et al. Elranatamab (PF-06863135), a B-Cell Maturation Antigen (BCMA) Targeted

CD3-Engaging Bispecific Molecule, for Patientswith Relapsed or Refractory Multiple Myeloma: Results from Magnetismm-1. Blood 2021;138(Supplement 1):895.

[77] Lesokhin A, Iida S, Stevens D, et al. Magnetismm-3: An Open-Label, Multicenter,Non-Randomized Phase 2 Study of Elranatamab (PF-06863135) in Patients with Relapsed or Refractory Multiple Myeloma. Blood 2021;138(Supplement 1):1674.

[78] Tomasson MH, Arnulf B, Bahlis NJ, et al. Elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, for patients (pts) with relapsed/refractory multiple myeloma (RRMM): Extended follow up and biweekly administration from the MagnetisMM-3 study. J Clin Oncol 2023;41(16_suppl):8039.

[79] Costa LJ, Wong SW, Bermu´dez A, et al. First Clinical Study of the B-Cell Maturation Antigen (BCMA) 211 T Cell Engager (TCE) CC-93269 in Patients (Pts) with Relapsed/ Refractory Multiple Myeloma (RRMM): Interim Results of a Phase 1 Multicenter Trial. Blood 2019;134(Supplement_1):143.

[80] Wong SW, Bar N, Paris L, et al. Alnuctamab (ALNUC; BMS-986349; CC-93269),a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients(pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from a Phase1 First-in-Human Clinical Study. Blood 2022;140(Supplement 1):400–2.

[81] Bumma N, Richter JR, Dhodapkar MV, et al. LINKER-MM1 study: Linvoseltamab(REGN5458) in patients with relapsed/refractory multiple myeloma. J Clin Oncol 2023;41(16_suppl):8006.

[82] D'Souza A, Shah N, Rodriguez C, et al. A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen x CD3 Bispecific T-Cell Redirecting Antibody,in Patients With Relapsed/Refractory Multiple Myeloma. J Clin Oncol 2022;40(31):3576–86.

[83] Verkleij CPM, Broekmans MEC, van Duin M, et al. Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma. Blood Adv 2021;5(8):2196–215.

[84] Chari A, Minnema MC, Berdeja JG, et al. Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma. N Engl J Med 2022; 387(24):2232–44.

[85] Krishnan AY, Minnema MC, Berdeja JG, et al. Updated Phase 1 Results from MonumenTAL-1: First-in-Human Study of Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma. Blood 2021;138(Supplement 1):158.

[86] Cohn Y, Morillo D. First results from the RedirecTT-1 study with teclistamab (tec)1 talquetamab (tal) simultaneously targeting BCMA and GPRC5D in patients(pts) with relapsed/refractory multiple myeloma (RRMM), J Clin Oncol, 41,(16_suppl), 2023, 8002.

[87] Morillo D, Gatt ME, Sebag M, et al. First results from the RedirecTT-1 study with teclistamab (tec) 1 talquetamab (tal) simultaneously targeting BCMA and GPRC5D in patients (pts) with relapsed/ refractory multiple myeloma (RRMM). J Clin Oncol 2023;41(16_suppl):8002.

[88] Hasselbalch Riley C, Hutchings M,

Yoon S-S, et al. S180: RG6234, A NOVELGPRC5D T-CELL ENGAGING BISPECIFIC ANTIBODY, INDUCES RAPID RESPONSES IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: PRELIMINARY RESULTS FROM A FIRST-IN-HUMAN TRIAL. HemaSphere 2022;6:81–2.

[89] Sim BZ, Longhitano A, Er J, et al. Infectious complications of bispecific antibody therapy in patients with multiple myeloma. Blood Cancer J 2023;13(1):34.

[90] Mazahreh F, Mazahreh L, Schinke C, et al. Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis. Blood Adv 2023;7(13):3069–74.

[91] Cohen AD, Harrison SJ, Krishnan A, et al. Initial Clinical Activity and Safety of BFCR4350A, a FcRH5/CD3 T-Cell-Engaging Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma. Blood 2020;136(Supplement 1):42–3.

[92] Trudel S, Cohen AD, Krishnan AY, et al. Cevostamab Monotherapy Continues to Show Clinically Meaningful Activity and Manageable Safety in Patients with Heavily Pre-Treated Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from an Ongoing Phase I Study. Blood 2021;138(Supplement 1):157.

[93] Lesokhin AM, Richter J, Trudel S, et al. Enduring Responses after 1-Year, FixedDuration Cevostamab Therapy in Patients with Relapsed/Refractory Multiple Myeloma: Early Experience from a Phase I Study. Blood 2022;140(Supplement 1):4415–7.

[94] Mohan SR, Costa Chase C, Berdeja JG, et al. Initial Results of Dose Escalation of ISB 1342, a Novel CD3xCD38 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM). Blood 2022;140(Supplement 1):7264–6.

[95] Viardot A, Bargou R. Bispecific antibodies in haematological malignancies.Cancer Treat Rev 2018;65:87–95.

[96] Ahn S, Leblay N, Neri P. Understanding the Mechanisms of Resistance to T Cellbased Immunotherapies to Develop More Favorable Strategies in Multiple Myeloma. Hemasphere 2021;5(6):e575.

[97] Da Via MC, Dietrich O, Truger M, et al. Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma. NatMed 2021;27(4):616–9.

[98] Samur MK, Fulciniti M, Aktas Samur A, et al. Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma. Nat Commun 2021;12(1):868.

[99] Bannerji R, Allan JN, Arnason JE, et al. Clinical Activity of REGN1979, a Bispecific Human, Anti-CD20 x Anti-CD3 Antibody, in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL). Blood 2019;134(Supplement_1):762.

[100] Bannerji R, Arnason JE, Advani R, et al. Emerging Clinical Activity of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Follicular Lymphoma (FL), Diffuse Large B-Cell Lymphoma (DLBCL), and Other B-Cell Non-Hodgkin Lymphoma (B-NHL) Subtypes. Blood 2018;132(Supplement1):1690.

[101] Verkleij CPM, Broekmans M, Wong A, et al.

Mechanisms of Resistance and Determinants of Response of the GPRC5D-Targeting T-Cell Redirecting Bispecific Antibody JNJ-7564 in Multiple Myeloma. Blood 2020;136(Supplement 1):8–9.

[102] Truger MS, Duell J, Zhou X, et al. Single- and double-hit events in genes encoding immune targets before and after T cell-engaging antibody therapy in MM. Blood Adv 2021;5(19):3794–8.

[103] Lee H, Neri P, Ahn S, et al. Role of TNFRSF17 and GPRC5D Structural and Point Mutations in Resistance to Targeted Immunotherapies in Multiple Myeloma (MM). Blood 2022;140(Supplement 1):252–3.

[104] Bahlis N, Lee H, Ahn S, et al. Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma. Nat Med 2023;29(9):2295–306.

[105] Leblay N, Maity R, Barakat E, et al. Cite-Seq Profiling of T Cells in Multiple Myeloma Patients Undergoing BCMA Targeting CAR-T or Bites Immunotherapy.Blood 2020;136(Supplement 1):11–2.

[106] Philipp N, Kazerani M, Nicholls A, et al. T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals. Blood 2022;140(10):1104–18.

[107] Karlin L, Benboubker L, Nahi H, et al. Durability of responses with biweekly dosing of teclistamab in patients with relapsed/refractory multiple myeloma achieving a clinical response in the majesTEC-1 study. J Clin Oncol 2023; 41(16_suppl):8034.

[108] Neri P, Ahn S, Lee H, et al. Dysfunctional Hyper-Expanded Clonotypes and Lack of TCR Clonal Replacement Predict Resistance to T Cell Engagers in Multiple Myeloma. Blood 2022;140(Supplement 1):2093–4.

[109] Friedrich MJ, Neri P, Kehl N, et al. The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients. Cancer Cell 2023;41(4):711–725 e6.

[110] Cho SF, Lin L, Xing L, et al. The immunomodulatory drugs lenalidomide and pomalidomide enhance the potency of AMG 701 in multiple myeloma preclinical models. Blood Adv 2020;4(17):4195–207.

[111] Meermeier EW, Welsh SJ, Sharik ME, et al. Tumor burden limits bispecific antibody efficacy through T cell exhaustion averted by concurrent cytotoxic therapy. Blood Cancer Discov 2021;2(4):354–69.

[112] Meermeier EW, Welsh SJ, Sharik M, et al. Abstract 5588: PD-1 blockade synergizes with IMiDs to enhance bispecific T cell engager immune responses to Vk*MYChCRBN multiple myeloma by preventing T cell exhaustion. Cancer Res 2022;82(12_Supplement):5588.

[113] Ravi G, Costa LJ. Bispecific T-cell engagers for treatment of multiple myeloma.Am J Hematol 2023;98(Suppl 2):S13–21.

8 嵌合抗原受体 T 细胞在多发性骨髓瘤治疗中的应用

[1] Eshhar Z, Waks T, Gross G, et al. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci USA 1993;90:720–4.

[2] Milone MC, Fish JD, Carpenito C, et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther 2009;17:1453–64.

[3] Savoldo B, Ramos CA, Liu E, et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest 2011;121:1822–6.

[4] Scholler J, Brady TL, Binder-Scholl G, et al. Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci Transl Med 2012;4: 132ra53.

[5] Levine BL, Humeau LM, Boyer J, et al. Gene transfer in humans using a conditionally replicating lentiviral vector. Proc Natl Acad Sci USA 2006;103:17372–7.

[6] Turtle CJ, Hanafi LA, Berger C, et al. Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD81 and CD41 CD19-specific chimeric antigen receptor-modified T cells. Sci Transl Med 2016;8:355ra116.

[7] Porter DL, Hwang WT, Frey NV, et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med 2015;7:303ra139.

[8] Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med 2018;378: 439–48.

[9] Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N Engl J Med 2017;377:2531–44.

[10] Garfall AL, Maus MV, Hwang WT, et al. Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma. N Engl J Med 2015;373:1040–7.

[11] Matsui W, Wang Q, Barber JP, et al. Clonogenic multiple myeloma progenitors,stem cell properties, and drug resistance. Cancer Res 2008;68:190–7.

[12] Garfall AL, Stadtmauer EA, Hwang WT, et al. Anti-CD19 CAR T cells with highdose melphalan and autologous stem cell transplantation for refractory multiple myeloma. JCI insight 2018;3:e120505.

[13] Guo B, Chen M, Han Q, et al. CD138-directed adoptive immunotherapy of chimeric antigen receptor (CAR)-modified T cells for multiple myeloma. J Cell Immunother 2016;2:28–35.

[14] Ramos CA, Savoldo B, Torrano V, et al. Clinical responses with T lymphocytes targeting malignancy-associated k light chains. J Clin Invest 2016;126:2588–96.

15. Salem DA, Maric I, Yuan CM, et al.

Quantification of B-cell maturation antigen, a target for novel chimeric antigen receptor T-cell therapy in Myeloma. Leuk Res 2018;71:106–11.

[16] Carpenter RO, Evbuomwan MO, Pittaluga S, et al. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Clin Cancer Res 2013;19:2048–60.

[17] Brudno JN, Maric I, Hartman SD, et al. T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma. J Clin Oncol 2018;36:2267–80.

[18] Cohen AD, Garfall AL, Stadtmauer EA, et al. B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. J Clin Invest 2019;129:2210–21.

[19] Raje N, Berdeja J, Lin Y, et al. Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma. N Engl J Med 2019;380:1726–37.

[20] Zhao W-H, Liu J, Wang BY, et al. A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma. J Hematol Oncol 2018;11:141.

[21] Munshi NC, Anderson LD Jr, Shah N, et al. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. N Engl J Med 2021;384:705–16.

[22] Manier S, Kansagra AJ, Anderson, Jr LD, et al. Characteristics of neurotoxicity associated with idecabtagene vicleucel (ide-cel, bb2121) in patients with relapsed and refractory multiple myeloma (RRMM) in the pivotal phase II KarMMa study. J Clin Oncol 2021;39:8036.

[23] Shah N, Mojebi A, Ayers D, et al. Indirect treatment comparison of idecabtagene vicleucel versus conventional care in triple-class exposed multiple myeloma. J Comp Eff Res 2022;11:737–49.

[24] Rodriguez-Otero P, Ayers D, Cope S, et al. Matching adjusted indirect comparisons of efficacy outcomes for idecabtagene vicleucel (ide-cel, bb2121) versus selinexor 1 dexamethasone and belantamab mafodotin in relapsed and refractory multiple myeloma. Leuk Lymphoma 2021;62:2482–91.

[25] Jagannath S, Lin Y, Goldschmidt H, et al. KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma. Blood Cancer J 2021;11:116.

[26] Sanoyan DA, Seipel K, Bacher U, et al. Real-life experiences with CAR T-cell therapy with idecabtagene vicleucel (ide-cel) for triple-class exposed relapsed/refractory multiple myeloma patients. BMC Cancer 2023;23:345.

[27] Hansen DK, Sidana S, Peres LC, et al. Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium. J Clin Oncol 2023;41:2087–97.

[28] Ferreri CJ, Hildebrandt MA, Hashmi H, et al. Idecabtagene Vicleucel (Ide-cel) Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Who Have Received a Prior BCMA-Targeted Therapy: Real World, Multi-Institutional Experience. Blood 2022;140:1856–8.

[29] Rodriguez-Otero P, Ailawadhi S, Arnulf B, et al. Ide-cel or Standard Regimens in Relapsed

and Refractory Multiple Myeloma. N Engl J Med 2023;388:1002–14.

[30] Mi J-Q, Zhao WH, Chen LJ, et al. Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment of LCAR-B38M CAR-T: At least 5-year follow-up in LEGEND-2. J Clin Oncol 2023;41:8010.

[31] Martin T, Lin Y, Agha M, et al. Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b-2, open-label study. Lancet Haematol 2022;9:e897–905.

[32] Berdeja JG, Madduri D, Usmani SZ, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet (London, England) 2021;398:314–24.

[33] Lin Y, Martin TG, Usmani SZ, et al. CARTITUDE-1 final results: Phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory multiple myeloma. J Clin Oncol 2023;41:8009.

[34] Martin T, Usmani SZ, Schecter JM, et al. Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma. Curr Med Res Opin 2021;37:1779–88.

[35] Weisel K, Martin T, Krishnan A, et al. Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 vs Physician's Choice of Therapy in the Long-Term Follow-Up of POLLUX, CASTOR, and EQUULEUS Clinical Trials for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma. Clin Drug Investig 2022;42:29–41.

[36] Hansen DK, Patel KK, Peres LC, et al. Safety and efficacy of standard of care (SOC) ciltacabtagene autoleucel (Cilta-cel) for relapsed/refractory multiple myeloma (RRMM). J Clin Oncol 2023;41:8012.

[37] Cohen AD, Mateos MV, Cohen YC, et al. Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents. Blood 2023;141:219–30.

[38] San-Miguel J, Dhakal B, Yong K, et al. Cilta-cel or Standard Care in LenalidomideRefractory Multiple Myeloma. N Engl J Med 2023. https://doi.org/10.1056/NEJMoa2303379.

[39] Dhakal B, Yong K, Harrison SJ, et al. First phase 3 results from CARTITUDE-4:Cilta-cel versus standard of care (PVd or DPd) in lenalidomide-refractory multiple myeloma. J Clin Oncol 2023;41:LBA106.

[40] Garfall AL, Cohen AD, Susanibar-Adaniya SP, et al. Anti-BCMA/CD19 CAR T Cells with Early Immunomodulatory Maintenance for Multiple Myeloma Responding to Initial or Later-Line Therapy. Blood cancer Discov 2023;4:118–33.

[41] Chen W, Fu C, Fang B, et al. Phase II Study of Fully Human BCMA-Targeting CAR-T Cells (Zevorcabtagene Autoleucel) in Patients with Relapsed/Refractory Multiple Myeloma. Blood 2022;140:4564–5.

[42] Li C, Wang D, Song Y, et al. CT103A, a novel fully human BCMA-targeting CAR-

Tcells, in patients with relapsed/refractory multiple myeloma: Updated results of phase 1b/2 study (FUMANBA-1). J Clin Oncol 2023;41:8025.

[43] Frigault MJ, Bishop MR, Rosenblatt J, et al. Phase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma. Blood Adv 2023;7:768–77.

[44] Raje NS, Shah N, Jagannath S, et al. Updated Clinical and Correlative Results from the Phase I CRB-402 Study of the BCMA-Targeted CAR T Cell Therapy bb21217 in Patients with Relapsed and Refractory Multiple Myeloma. Blood 2021;138:548.

[45.Costello CL, Cohen AD, Patel KK, et al. Phase 1/2 Study of the Safety and Response of P-BCMA-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM) (PRIME) with Novel Therapeutic Strategies. Blood 2020;136:29–30.

46. Mailankody S, Jakubowiak AJ, Htut M, et al. Orvacabtagene autoleucel (orvacel), a B-cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts) with relapsed/refractory multiple myeloma (RRMM): update of the phase 1/2 EVOLVE study (NCT03430011). J Clin Oncol 2020;38:8504.

[47] Costa LJ, Kumar SK, Atrash S, et al. Results from the First Phase 1 Clinical Study of the B-Cell Maturation Antigen (BCMA) Nex T Chimeric Antigen Receptor (CAR) T Cell Therapy CC-98633/BMS-986354 in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM). Blood 2022;140:1360–2.

[48] Sperling AS, Derman BA, Nikiforow S, et al. Updated phase I study results of PHE885, a T-Charge manufactured BCMA-directed CAR-T cell therapy, for patients (pts) with r/r multiple myeloma (RRMM). J Clin Oncol 2023;41:8004.

[49] Du J, Fu WJ, Jiang H, et al. Updated results of a phase I, open-label study of BCMA/CD19 dual-targeting fast CAR-T GC012F for patients with relapsed/refractory multiple myeloma (RRMM). J Clin Oncol 2023;41:8005.

[50] Mailankody S, Matous JV, Chhabra S, et al. Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results. Nat Med 2023;29:422–9.

[51] Frey N, Porter D. Cytokine release syndrome with chimeric antigen receptor T cell therapy. J Am Soc Blood Marrow Transplant 2019;25:e123–7.

[52] Hines MR, Knight TE, McNerney KO, et al. Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome. Transplant Cell Ther 2023;29:438.e1–16.

[53] Martin T, Usmani SZ, Berdeja JG, et al. Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up. J Clin Oncol 2023;41:1265–74.

[54] Cohen AD, Parekh S, Santomasso BD, et al. Incidence and management of CART neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies. Blood Cancer J 2022;12:32.

[55] Karschnia P, Miller KC, Yee AJ, et al. Neurologic toxicities following adoptive immunotherapy with BCMA-directed CAR

T-cells. Blood 2023;2023020571.https://doi.org/10.1182/blood.2023020571.

[56] Van Oekelen O, Aleman A, Upadhyaya B, et al. Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy. Nat Med 2021;27:2099–103.

[57] Davis JA, Sborov DW, Wesson W, et al. Efficacy and Safety of CD341 Stem Cell Boost for Delayed Hematopoietic Recovery After BCMA Directed CAR T-cell Therapy. Transplant Cell Ther 2023. https://doi.org/10.1016/j.jtct.2023.05.012.

[58] Kambhampati S, Sheng Y, Huang CY, et al. Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy. Blood Adv 2022;6:2045–54.

[59] Mohan M, Chakraborty R, Bal S, et al. Recommendations on prevention of infections during chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma. Br J Haematol 2023;203(5):736–46.

[60] Billadeau D, Ahmann G, Greipp P, et al. The bone marrow of multiple myeloma patients contains B cell populations at different stages of differentiation that are clonally related to the malignant plasma cell. J Exp Med 1993;178:1023–31.

[61] Wang Y, Cao J, Gu W, et al. Long-Term Follow-Up of Combination of B-Cell Maturation Antigen and CD19 Chimeric Antigen Receptor T Cells in Multiple Myeloma. J Clin Oncol 2022;40:2246–56.

[62.Du J, Jiang H, Dong B, et al. Updated results of a multicenter first-in-human study of BCMA/CD19 dual-targeting fast CAR-T GC012F for patients with relapsed/refractory multiple myeloma (RRMM). J Clin Oncol 2022;40:8005.

[63] Chari A, Minnema MC, Berdeja JG, et al. Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma. N Engl J Med 2022;387: 2232–44.

[64] Mailankody S, Devlin SM, Landa J, et al. GPRC5D-Targeted CAR T Cells for Myeloma. N Engl J Med 2022;387:1196–206.

[65] Zhang M, Wei G, Zhou L, et al. GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trial. Lancet Haematol 2023;10:e107–16.

[66] Xia J, Li H, Yan Z, et al. Anti-G Protein-Coupled Receptor, Class C Group 5 Member D Chimeric Antigen Receptor T Cells in Patients With Relapsed or Refractory Multiple Myeloma: A Single-Arm, Phase II Trial. J Clin Oncol 2023;41:2583–93.

[67] Bal, S. et al. BMS-986393 (CC-95266), a G protein–coupled receptor class C group5 member D (GPRC5D)–targeted CAR T-cell therapy for relapsed/refractory multiple myeloma (RRMM): results from a phase 1 study. EHA Libr. (2023).

[68] Bahlis, N. et al. Tumor Intrinsic Mechanisms of Antigen Escape to Anti-BCMA and Anti-GPRC5D Targeted Immunotherapies in Multiple Myeloma. (2023) doi:10.21203/rs.3.rs-2657360/v1.

[69] Dimopoulos MA, Dytfeld D, Grosicki S, et al. Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma. N Engl J Med 2018;379:1811–22.

[70] O'Neal J, Ritchey JK, Cooper ML, et al. CS1 CAR-T targeting the distal domain of CS1

(SLAMF7) shows efficacy in high tumor burden myeloma model despite fratricide of CD81CS1 expressing CAR-T cells. Leukemia 2022;36:1625–34.

[71] Wang X, Walter M, Urak R, et al. Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor-Redirected T Cells Against Multiple Myeloma. Clin Cancer Res 2018;24:106–19.

[72] Li C, Wang X, Wu Z, et al. Bispecific CS1-BCMA CAR-T Cells Are Clinically Active in Relapsed or Refractory Multiple Myeloma: An Updated Clinical Study. Blood 2022;140:4573–4.

[73] Sallman DA, Kerre T, Havelange V, et al. CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial. Lancet Haematol 2023;10: e191–202.

[74] Lonial S, Weiss BM, Usmani SZ, et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet 2016;387:1551–60.

[75] Drent E, Themeli M, Poels R, et al. A Rational Strategy for Reducing On-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors by Affinity Optimization. Mol Ther 2017;25:1946–58.

[76] Sun C, Mahendravada A, Ballard B, et al. Safety and efficacy of targeting CD138 with a chimeric antigen receptor for the treatment of multiple myeloma. Oncotarget 2019;10:2369–83.

[77] Jiang D, Huang H, Qin H, et al. Chimeric antigen receptor T cells targeting FcRH5 provide robust tumour-specific responses in murine xenograft models of multiple myeloma. Nat Commun 2023;14:3642.

[78] Radhakrishnan SV, Luetkens T, Scherer SD, et al. CD229 CAR T cells eliminate multiple myeloma and tumor propagating cells without fratricide. Nat Commun 2020;11:798.

[79] Wong DP, Roy NK, Zhang K, et al. A BAFF ligand-based CAR-T cell targeting three receptors and multiple B cell cancers. Nat Commun 2022;13:217.

[80] Shah N, Munshi NC, Berdeja JG, et al. Baseline Correlates of Complete Response to Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy in Patients with Relapsed and Refractory Multiple Myeloma: Subanalysis of the KarMMa Trial. Blood 2021;138:1739.

[81] Rytlewski J, Fuller J, Mertz DR, et al. Correlative analysis to define patient profiles associated with manufacturing and clinical endpoints in relapsed/refractory multiple myeloma (RRMM) patients treated with idecabtagene vicleucel (ide-cel; bb2121), an anti-BCMA CAR T cell therapy. J Clin Oncol 2022;40:8021.

[82] Dhodapkar KM, Cohen AD, Kaushal A, et al. Changes in Bone Marrow Tumor and Immune Cells Correlate with Durability of Remissions Following BCMA CAR T Therapy in Myeloma. Blood cancer Discov 2022;3:490–501.

[83] Friedrich MJ, Neri P, Kehl N, et al. The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients. Cancer Cell 2023;41:711–25.e6.

[84] Garfall AL, Dancy EK, Cohen AD, et al.

T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma. Blood Adv 2019;3:2812–5.

[85] Samur MK, Fulciniti M, Aktas Samur A, et al. Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma. Nat Commun 2021;12:868.

[86] Da Vià MC, Dietrich O, Truger M, et al. Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma. Nat Med 2021;27:616–9.

[87] Cowan AJ, Pont MJ, Sather BD, et al. g-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial. Lancet Oncol 2023;24:811–22.

[88] Ferna´ndez de Larrea C, Staehr M, Lopez AV, et al. Defining an Optimal DualTargeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape-Driven Relapse in Multiple Myeloma. Blood cancer Discov 2020;1:146–54.

[89] Chong EA, Gerson JN, Nasta SD, et al. Outcomes with bendamustine lymphodepletion prior to brexucabtagene autoleucel for mantle cell lymphoma. J Clin Oncol 2023;41:e19540.

[90] Zhang Q, Hresko ME, Picton LK, et al. A human orthogonal IL-2 and IL-2Rb system enhances CAR T cell expansion and antitumor activity in a murine model of leukemia. Sci Transl Med 2023;13:eabg6986.

[91] Imbach KJ, Patel A, Levine AD. Ethical Considerations in the Translation of CAR-T Cell Therapies. Cell Gene Ther Insights 2018;4:295–307.

[92] Derman BA, Parker WF. Fair Allocation of Scarce CAR T-Cell Therapies for Relapsed/ Refractory Multiple Myeloma. JAMA 2023. https://doi.org/10.1001/ jama.2023.11846.

[93] Petersen CT, Hassan M, Morris AB, et al. Improving T-cell expansion and function for adoptive T-cell therapy using ex vivo treatment with PI3Kd inhibitors and VIP antagonists. Blood Adv 2018;2:210–23.

[94] Yan Z, Cao J, Cheng H, et al. A combination of humanised anti-CD19 and antiBCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial. Lancet Haematol 2019;6:e521–9.

9 造血干细胞移植在多发性骨髓瘤治疗中是否仍有重要地位

[1] Singh S, Sharma R, Singh J, et al. Autologous stem cell transplantation for multiple myeloma in the novel agent era: Systematic review of Indian data and implications for resource constrained settings. J Cancer Res Ther 2023;19(Supplement):S12–s19.

[2] Lamm W, Wohlfarth P, Bojic M, et al. Outcome in Multiple Myeloma Patients Eligible for Stem Cell Transplantation: A Single-Center Experience. Oncology 2015;89(4):196–204.

[3] Belotti A, Ribolla R, Cancelli V, et al. Transplant eligibility in elderly multiple myeloma patients: Prospective external validation of the international myeloma working group frailty score and comparison with clinical judgment and other comorbidity scores in unselected patients aged 65-75 years. Am J Hematol 2020;95(7):759–65.

[4] Vaxman I, Visram A, Kumar S, et al. Autologous stem cell transplantation for multiple myeloma patients aged 75 treated with novel agents. Bone Marrow Transplant 2021;56(5):1144–50.

[5] Kumar L, Sahoo RK, Kumar S, et al. Autologous stem cell transplant for multiple myeloma: Impact of melphalan dose on the transplant outcome. Leuk Lymphoma 2023;64(2):378–87.

[6] Zhai Y, Yan L, Jin S, et al. Autologous stem cell transplantation in multiple myeloma patients with renal impairment. Ann Hematol 2023;102(3):621–8.

[7] Lazana I, Floro L, Christmas T, et al. Autologous stem cell transplantation for multiple myeloma patients with chronic kidney disease: a safe and effective option. Bone Marrow Transplant 2022;57(6):959–65.

[8] Waszczuk-Gajda A, Gras L, de Wreede LC, et al. Safety and efficacy of autologous stem cell transplantation in dialysis-dependent myeloma patients-The DIADEM study from the chronic malignancies working party of the EBMT. Bone Marrow Transplant 2023;58(4):424–9.

[9] Awada H, Hajj Ali A, Ali MF, et al. Validation of the role of corrected DLCO in predicting outcomes post autologous hematopoietic cell transplant for multiple myeloma. Eur J Haematol 2023;110(6):780–3.

[10] Pasvolsky O, Saliba RM, Masood A, et al. Impact of gender on outcomes of patients with multiple myeloma undergoing autologous Haematopoietic stem cell transplant. Br J Haematol 2023;201(4):e37–41.

[11] Prakash VS, Malik PS, Sahoo RK, et al. Multiple myeloma: risk adapted use of plerixafor for stem cell mobilization prior to autologous stem cell transplantation is effective and cost efficient. Clin Lymphoma Myeloma Leuk 2022;22(1):44–51.

[12] Chhabra S, Callander N, Watts NL, et al. Stem cell mobilization yields with daratumumab- and lenalidomide-containing quadruplet induction therapy in newly diagnosed multiple myeloma: findings from the MASTER and GRIFFIN trials. Transplant Cell Ther 2022;06:06.

[13] Thurlapati A, Roubal K, Davis JA, et al. Stem cell mobilization for multiple myeloma patients receiving daratumumab-based induction therapy: a real- world experience. Transplant Cell Ther 2023;29(5):340.e341–4.

[14] Crees ZD, Rettig MP, Jayasinghe RG, et al. Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial. Nat Med 2023;29(4):869–79.

[15] Gomez-Arteaga A, Mark TM, Guarneri D, et al. High-dose bendamustine and melphalan conditioning for autologous stem cell transplantation for patients with multiple myeloma. Bone Marrow Transplant 2019;54(12):2027–38.

[16] Cailleteau A, Maingon P, Choquet S, et al. Phase 1 study of the combination of escalated total marrow irradiation using helical tomotherapy and fixed highdose melphalan (140 mg/m2) followed by autologous stem cell transplantation at first relapse in multiple myeloma. Int J Radiat Oncol Biol Phys 2023;115(3):677–85.

[17] Li N, Liang L, Xiang P, et al. Clonal haematopoiesis of indeterminate potential predicts delayed platelet engraftment after autologous stem cell transplantation for multiple myeloma. Br J Haematol 2023;201(3):577–80.

[18] Scordo M, Gilbert LJ, Hanley DM, et al. Open-label pilot study of romiplostim for thrombocytopenia after autologous hematopoietic cell transplantation. Blood Adv 2023;7(8):1536–44.

[19] Pandya C, Hashmi S, Khera N, et al. Cost-effectiveness analysis of early vs. late autologous stem cell transplantation in multiple myeloma. Clin Transplant 2014;28(10):1084–91.

[20] Asrar MM, Lad DP, Bansal D, et al. Health-related quality of life in transplant eligible multiple myeloma patients with or without early ASCT in the real-world setting. Leuk Lymphoma 2021;62(13):3271–7.

[21] Yong K, Wilson W, de Tute RM, et al. Upfront autologous haematopoietic stem-cell transplantation versus carfilzomib-cyclophosphamide-dexamethasone consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myeloma in England and Wales (CARDAMON): a randomised, phase 2, noninferiority trial. Lancet Haematol 2023;10(2):e93–106.

[22] Lemieux C, Muffly LS, Iberri DJ, et al. Outcomes after delayed and second autologous stem cell transplant in patients with relapsed multiple myeloma. Bone Marrow Transplant 2021;56(11):2664–71.

[23] Khan AM, Ozga M, Bhatt H, et al. Outcomes after salvage autologous hematopoietic cell transplant for patients with relapsed/refractory multiple myeloma: a single-institution experience. Clin Lymphoma Myeloma Leuk 2022;05:05.

[24] Hashmi H, Atrash S, Jain J, et al. Daratumumab, pomalidomide, and dexamethasone (DPd) followed by high dose chemotherapy-Autologous Stem Cell

Transplantation leads to superior outcomes when compared to DPd-alone for patients with Relapsed Refractory Multiple Myeloma. Transplant Cell Ther 2023;20:20.

[25] Jain T, Sonbol MB, Firwana B, et al. High-dose chemotherapy with early autologous stem cell transplantation compared to standard dose chemotherapy or delayed transplantation in patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis. Biol Blood Marrow Transplant 2019;25(2):239–47.

[26] Khan S, Reece D, Atenafu EG, et al. Post salvage therapy autologous transplant for relapsed myeloma, ongoing relevance within modern treatment paradigms? Clin Lymphoma Myeloma Leuk 2023;23(2):e97–106.Role for Stem Cell Transplantation in Multiple Myeloma 417

[27] Cook G, Ashcroft AJ, Cairns DA, et al. The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial. Lancet Haematol 2016;3(7):e340–51.

[28] Goldschmidt H, Baertsch MA, Schlenzka J, et al. Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE. Leukemia 2021;35(4):1134–44.

[29] Richardson PG, Jacobus SJ, Weller EA, et al. Triplet therapy, transplantation, and maintenance until progression in myeloma. N Engl J Med 2022;387(2):132–47.

[30] Stadtmauer EA, Pasquini MC, Blackwell B, et al. Autologous transplantation, consolidation, and maintenance therapy in multiple myeloma: results of the BMT CTN 0702 Trial. J Clin Oncol 2019;37(7):589–97.

[31] Dispenzieri A, Krishnan A, Arendt B, et al. Mass-fix better predicts for PFS and OS than standard methods among multiple myeloma patients participating on the STAMINA trial (BMT CTN 0702/07LT). Blood Cancer J 2022;12(2):27.

[32] Jung J, Kim K, Jung SH, et al. Cyclophosphamide, Bortezomib, and Dexamethasone Consolidation in Patients with Multiple Myeloma after Stem Cell Transplantation: The KMM130 Study. Cancer Res Treat 2023;55(2):693–703.

[33] Lawless S, Iacobelli S, Knelange NS, et al. Comparison of autologous and allogeneic hematopoietic cell transplantation strategies in patients with primary plasma cell leukemia, with dynamic prediction modelling. Haematologica 2022;30:30.

[34] Kriz T, Jungova A, Lysak D, et al. Allogeneic stem cell transplantation in patients with multiple myeloma-single center experience. Neoplasma 2023;23:23.

[35] Gay F, Musto P, Rota-Scalabrini D, et al. Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial. Lancet Oncol 2021;22(12):1705–20.

[36] Lin CM, Chang LC, Shau WY, et al. Treatment benefit of upfront autologous

stem cell transplantation for newly diagnosed multiple myeloma: a systematic review and meta-analysis. BMC Cancer 2023;23(1):446.37. Sato S, Tsunoda S, Kawahigashi T, et al. Clinical significance of high-dose chemotherapy with autologous stem cell transplantation in the era of novel agentsin patients older than 65 years with multiple myeloma. Ann Hematol 2023;102(5):1185–91.

[38] Pasvolsky O, Milton DR, Rauf M, et al. Impact of clonal plasma cells in autografts on outcomes in high-risk multiple myeloma patients. Blood Cancer J 2023;13(1):68.

[39] Pasvolsky O, Gaballa MR, Milton DR, et al. Autologous Stem Cell Transplantation for Patients with Multiple Myeloma with Translocation (4;14): The MD Anderson Cancer Center Experience. Transplant Cell Ther 2023;29(4):260.e1-6.

[40] Gertz MA, Buadi FK, Hayman SR, et al. Safety Outcomes for Autologous Stem Cell Transplant in Multiple Myeloma. Mayo Clin Proc 2018;93(1):56–8.

[41.Kim DJ, Jeong S, Kong SG, et al. Incidence and risk factors of opportunistic infections after autologous stem cell transplantation: a nationwide, populationbased cohort study in Korea. Sci Rep 2023;13(1):2551.

[42] D'Souza A, Brazauskas R, Stadtmauer EA, et al. Trajectories of quality of life recovery and symptom burden after autologous hematopoietic cell transplantation in multiple myeloma. Am J Hematol 2023;98(1):140–7.

[43] Ullrich CK, Baker KK, Carpenter PA, et al. Fatigue in Hematopoietic Cell Transplantation Survivors: Correlates, Care Team Communication, and PatientIdentified Mitigation Strategies. Transplant Cell Ther 2023;29(3):200.e1-8.

[44] Samur MK, Roncador M, Aktas Samur A, et al. High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma. Blood 2023;141(14):1724–36.

[45] Nishimura KK, Barlogie B, van Rhee F, et al. Long-term outcomes after autologous stem cell transplantation for multiple myeloma. Blood Adv 2020;4(2):422–31.

[46] Tang S, Lu Y, Zhang P, et al. Lenalidomide, bortezomib and dexamethasone followed by tandem- autologous stem cell transplantation is an effective treatment modality for multi-hit multiple myeloma. Leuk Res 2021;110:106710.

[47] Blocka J, Hielscher T, Goldschmidt H, et al. Response Improvement Rather than Response Status after First Autologous Stem Cell Transplantation Is a Significant Prognostic Factor for Survival Benefit from Tandem Compared with Single Transplantation in Multiple Myeloma Patients. Biol Blood Marrow Transplant 2020;26(7):1280–7.

[48] Mai EK, Benner A, Bertsch U, et al. Single versus tandem high-dose melphalan followed by autologous blood stem cell transplantation in multiple myeloma: long-term results from the phase III GMMG-HD2 trial. Br J Haematol 2016;173(5):731–41.

[49] Cavo M, Gay F, Beksac M, et al. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-

label, phase 3 study. Lancet Haematol 2020;7(6):e456–68.

[50] Baertsch M-A, Mai EK, Hielscher T, et al. Lenalidomide versus bortezomib main tenance after frontline autologous stem cell transplantation for multiple myeloma. Blood Cancer J 2021;11(1):1.

[51] Dytfeld D, Wrobel T, Jamroziak K, et al. Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol 2023;24(2):139–50.

[52] Mikulski D, Koscielny K, Nowicki M, et al. Neutrophil to lymphocyte ratio (NLR) impact on the progression-free survival and overall survival of multiple myeloma patients treated with high-dose chemotherapy and autologous stem cell transplantation. Leuk Lymphoma 2023;64(1):98–106.

[53] D'Angelo C, Sudakaran S, Asimakopoulos F, et al. Perturbation of the gut microbiome and association with outcomes following autologous stem cell transplantation in patients with multiple myeloma. Leuk Lymphoma 2023;64(1):87–97.

[54] Moreau P, Hulin C, Perrot A, et al. Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial. Lancet Oncol 2021;22(10):1378–90.

[55] Voorhees PM, Kaufman JL, Laubach J, et al. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood 2020;136(8):936–45.

[56] Jenner MW, Pawlyn C, Davies FE, et al. The addition of vorinostat to lenalidomide maintenance for patients with newly diagnosed multiple myeloma of all ages: results from 'Myeloma XI', a multicentre, open-label, randomised, phase III trial. Br J Haematol 2022;201(2):267–79.

10　巩固治疗和维持治疗的作用

[1] Cavo M, Brioli A, Tacchetti P, et al. Role of consolidation therapy in transplant eligible multiple myeloma patients. Semin Oncol 2013;40(5):610–7.

[2] Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996;335(2):91–7.

[3] Child JA, Morgan GJ, Davies FE, et al. High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma. N Engl J Med 2003;348(19):1875–83.

[4] Mellqvist UH, Gimsing P, Hjertner O, et al. Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial. Blood 2013;121(23):4647–54.

[5] Cavo M, Pantani L, Petrucci MT, et al. Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy afterautologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma. Blood 2012;120(1):9–19.

[6] Richardson PG, Weller E, Lonial S, et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 2010;116(5):679–86.

[7] Roussel M, Robillard N, Moreau P, et al. Bortezomib, lenalidomide, and dexamethasone (VRD) consolidation and lenalidomide maintenance in frontline multiple myeloma patients: updated results of the IFM 2008 phase II VRD intensive program. Blood 2011;118(21):1872.

[8] Attal M, Lauwers-Cances V, Hulin C, et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med 2017;376(14):1311–20.

[9] Stadtmauer EA, Pasquini MC, Blackwell B, et al. Autologous transplantation, consolidation, and maintenance therapy in multiple myeloma: results of the BMT CTN 0702 Trial. J Clin Oncol 2019;37(7):589–97.

[10] Hari P, Pasquini MC, Stadtmauer EA, et al. Long-term follow-up of BMT CTN 0702 (STaMINA) of postautologous hematopoietic cell transplantation (autoHCT) strategies in the upfront treatment of multiple myeloma (MM). J Clin Oncol 2020;38(15_suppl):8506.

[11] Sonneveld P, Dimopoulos MA, Beksac M, et al. Consolidation and maintenance in newly diagnosed multiple myeloma. J Clin Oncol 2021;39(32):3613–22.

[12] Cavo M, Gay F, Beksac M, et al. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomidedexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, openlabel, phase 3 study. Lancet Haematol

2020;7(6):e456–68.

[13] Dimopoulos M, Wang M, Maisnar V, et al. Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study. J Hematol OncolJ Hematol Oncol 2018;11(1):49.

[14] Roussel M, Lauwers-Cances V, Wuilleme S, et al. Up-front carfilzomib, lenalidomide, and dexamethasone with transplant for patients with multiple myeloma: the IFM KRd final results. Blood 2021;138(2):113–21.

[15] Gay F, Musto P, Rota-Scalabrini D, et al. Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial. Lancet Oncol 2021;22(12):1705–20.

[16] Voorhees PM, Kaufman JL, Laubach J, et al. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood 2020;136(8):936–45.

[17] Moreau P, Attal M, Hulin C, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, openlabel, phase 3 study. Lancet 2019;394(10192):29–38.

[18] Costa LJ, Chhabra S, Medvedova E, et al. Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma. J Clin Oncol 2022;40(25):2901–12.

[19] Costa LJ, Chhabra S, Medvedova E, et al. Outcomes of MRD-adapted treatment modulation in patients with newly diagnosed multiple myeloma receiving daratumumab, carfilzomib, lenalidomide and dexamethasone (Dara-KRd) and autologous transplantation: extended follow up of the master trial. Blood 2022; 140(Supplement 1):7275–7.

[20] Nørgaard JN, Abildgaard N, Lyse´n A, et al. Carfilzomib-Lenalidomide-Dexamethasone Consolidation in Myeloma Patients with a Positive FDG PET/CT after Upfront Autologous Stem Cell Transplantation: A Phase II Study (CONPET). Blood 2021;138:3939.

[21] Holstein SA, Suman VJ, Hillengass J, et al. Future directions in maintenance therapy in multiple myeloma. J Clin Med 2021;10(11):2261.

[22] Morgan GJ, Gregory WM, Davies FE, et al. The role of maintenance thalidomide therapy in multiple myeloma: MRC myeloma IX results and meta-analysis. Blood 2012;119(1):7–15.

[23] Attal M, Lauwers-Cances V, Marit G, et al. Lenalidomide maintenance after stemcell transplantation for multiple myeloma. N Engl J Med 2012;366(19):1782–91.

[24] Attal M, Lauwers VC, Marit G, et al. Maintenance treatment with lenalidomide after transplantation for MYELOMA: final

analysis of the IFM 2005-02. Blood 2010; 116(21):310.

[25] Holstein SA, Jung SH, Richardson PG, et al. Updated analysis of CALGB 100104 (Alliance): a randomised phase III study evaluating lenalidomide vs placebo maintenance after single autologous stem cell transplant for multiple myeloma. Lancet Haematol 2017;4(9):e431–42.

[26] Palumbo A, Cavallo F, Gay F, et al. Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med 2014;371(10):895–905.

[27] McCarthy PL, Holstein SA, Petrucci MT, et al. Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis. J Clin Oncol 2017;35(29):3279–89.

[28] Jackson GH, Davies FE, Pawlyn C, et al. Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2019;20(1):57–73.

[29] Pawlyn C, Menzies T, Davies FE, et al. Defining the optimal duration of lenalidomide maintenance after autologous stem cell transplant - data from the myeloma XI trial. Blood 2022;140(Supplement 1):1371–2.

[30] Atieh T, Hubben A, Faiman B, et al. Pomalidomide-based maintenance postautologous hematopoietic cell transplantation in multiple myeloma: a case series.Ann Hematol 2019;98(10):2457–9.

[31] Garderet L, Kuhnowski F, Berge B, et al. Pomalidomide and dexamethasone until progression after first salvage therapy in multiple myeloma. Br J Haematol 2023;201(6):1103–15.

[32] Sonneveld P, Schmidt-Wolf IGH, van der Holt B, et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/GMMG-HD4 trial. J Clin Oncol 2012;30(24):2946–55.

[33] Dimopoulos MA, Gay F, Schjesvold F, et al. Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet 2019;393(10168):253–64.

[34] Gregersen H, Peceliunas V, Remes K, et al. Carfilzomib and dexamethasone maintenance following salvage ASCT in multiple myeloma: A randomised phase 2 trial by the Nordic Myeloma Study Group. Eur J Haematol 2022;108(1):34–44.

[35] Moreau P, Hulin C, Perrot A, et al. Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial. Lancet Oncol 2021;22(10):1378–90.

[36] Clemens PL, Yan X, Lokhorst HM, et al. Pharmacokinetics of daratumumab following intravenous infusion in relapsed or refractory multiple myeloma after prior proteasome inhibitor and immunomodulatory drug treatment. Clin Pharmacokinet 2017;56(8):915–24.

[37] Nooka AK, Kaufman JL, Muppidi S, et al. Consolidation and maintenance

therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients. Leukemia 2014;28(3):690–3.

[38] Joseph NS, Kaufman JL, Dhodapkar MV, et al. Long-term follow-up results of lenalidomide, bortezomib, and dexamethasone induction therapy and riskadapted maintenance approach in newly diagnosed multiple myeloma. J Clin Oncol 2020;38(17):1928–37.

[39] Shah N, Patel S, Pei H, et al. Subcutaneous daratumumab (DARA SC) plus lenalidomide versus lenalidomide alone as maintenance therapy in patients (pts) with newly diagnosed multiple myeloma (NDMM) who are minimal residual disease (MRD) positive after frontline autologous stem cell transplant (ASCT): The phase 3 AURIGA study. J Clin Oncol 2021;39(15_suppl):TPS8054.

[40] Krishnan A, Hoering A, Hari P, et al. Phase III Study of daratumumab/rhuph20 (nsc-810307) 1 lenalidomide or lenalidomide as post-autologous stem cell transplant maintenance therapy in patients with multiple myeloma (mm) using minimal residual disease todirect therapy duration (DRAMMATIC study): SWOG s1803. Blood 2020;136(Supplement 1):21–2.

[41] Mina R, Musto P, Rota-Scalabrini D, et al. Carfilzomib induction, consolidation,and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial. Lancet Oncol 2023;24(1):64–76.

[42] Dytfeld D, Wro´bel T, Jamroziak K, et al. Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol 2023;24(2):139–50.

[43] Hajek R, Sliwka H, Stork M, et al. Patient characteristics and survival outcomes of lenalidomide exposed non- refractory vs. lenalidomide refractory multiple myeloma patients in the honeur federated data network. Blood 2022; 140(Supplement 1):7200–2.

[44] van de Donk NWCJ, Agha ME, Cohen AD, et al. Biological correlative analyses and updated clinical data of ciltacabtagene autoleucel (cilta-cel), a BCMAdirected CAR-T cell therapy, in patients with multiple myeloma (MM) and early relapse after initial therapy: CARTITUDE-2, cohort B. J Clin Oncol 2022; 40(16_suppl):8029.

11 新诊断多发性骨髓瘤管理的现状及未来

[1] Kristinsson SY, Anderson WF, Landgren O. Improved long-term survival in multiple myeloma up to the age of 80 years. Leukemia 2014;28(6):1346–8.

[2] Voorhees PM, Kaufman JL, Laubach J, et al. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood 2020;136(8):936–45.

[3] Moreau P, Attal M, Hulin C, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-celltransplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet 2019;394(10192):29–38.

[4] Facon T, Kumar SK, Plesner T, et al. Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol 2021;22(11):1582–96.

[5] Mateos MV, Cavo M, Blade J, et al. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial. Lancet 2020;395(10218):132–41.

[6] Fonseca R, Usmani SZ, Mehra M, et al. Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma. BMC Cancer 2020;20(1):1087.

[7] Yong K, Delforge M, Driessen C, et al. Multiple myeloma: patient outcomes in real-world practice. Br J Haematol 2016;175(2):252–64.

[8] Attal M, Lauwers-Cances V, Hulin C, et al. Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma. N Engl J Med 2017;376(14):1311–20.

[9] Richardson PG, Jacobus SJ, Weller EA, et al. Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma. N Engl J Med 2022;387(2):132–47.

[10] Gay F, Musto P, Rota-Scalabrini D, et al. Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial. Lancet Oncol 2021;22(12):1705–20.

[11] Perrot A, Lauwers-Cances V, Cazaubiel T, et al. Early Versus Late Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma: Long-Term Followup Analysis of the IFM 2009 Trial. Blood 2020;136(Supplement 1):39.

[12] Palumbo A, Bringhen S, Mateos M-V, et al. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group

report. Blood 2015;125(13):2068–74.

[13] Engelhardt M, Domm AS, Dold SM, et al. A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients. Haematologica 2017;102(5):910–21.

[14] Durie BGM, Hoering A, Abidi MH, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet 2017;389(10068): 519–27.

[15] Kumar S, Flinn I, Richardson PG, et al. Randomized, multicenter, phase 2 study(EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood 2012;119(19):4375–82.

[16] Sidana S, Kumar S, Fraser R, et al. Impact of Induction Therapy with VRD versus VCD on Outcomes in Patients with Multiple Myeloma in Partial Response or Better Undergoing Upfront Autologous Stem Cell Transplantation. Transplant Cell Ther 2022;28(2):83.e1–9.

[17] Cherniawsky HM, Kukreti V, Reece D, et al. The survival impact of maintenance lenalidomide: an analysis of real-world data from the Canadian Myeloma Research Group national database. Haematologica 2021;106(6):1733–6.

[18] Moreau P, Hulin C, Macro M, et al. VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial. Blood 2016;127(21):2569–74.

[19] Kumar SK, Jacobus SJ, Cohen AD, et al. Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol 2020;21(10):1317–30.

[20] Sweeney NW, Sborov DW, Martı´nez JAH, et al. Real-world analysis of D-RVd v. RVd at induction for newly diagnosed transplant eligible multiple myeloma patients. J Clin Oncol 2023;41(16_suppl):e20024.

[21] Costa LJ, Chhabra S, Medvedova E, et al. Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma. J Clin Oncol 2022;40(25):2901–12.

[22] Touzeau C, Perrot A, Hulin C, et al. Daratumumab carfilzomib lenalidomide and dexamethasone as induction therapy in high-risk, transplant-eligible patients with newly diagnosed myeloma: Results of the phase 2 study IFM 2018-04. J Clin Oncol 2022;40(16_suppl):8002.

[23] Yimer H, Melear J, Faber E, et al. Daratumumab, cyclophosphamide, bortezomib,and dexamethasone for multiple myeloma: final results of the LYRA study. Leuk Lymphoma 2022;63(10):2383–92.

[24] Kastritis E, Palladini G, Minnema MC, et al. Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis. N Engl J Med 2021;385(1):46–58.

[25] Palladini G, Kastritis E, Maurer MS, et al. Daratumumab plus CyBorD for patients with

newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA.Blood 2020;136(1):71–80.

[26] Aurore Perrot VL-C, Touzeau C, Decaux O, et al. Daratumumab Plus Ixazomib,Lenalidomide, and Dexamethasone as Extended Induction and Consolidation Followed by Lenalidomide Maintenance in Standard - Risk Transplant Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (IFM 2018-01): A Phase II Study of the Intergroupe Francophone Du Myeloma (IFM). Conference abstract presented at: ASH 2021; December 2021, Atlanta, USA; Session 1.

[27] Goldschmidt H, Mai EK, Bertsch U, et al. Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial. Lancet Haematol 2022;9(11):e810–21.

[28] Goldschmidt H, Mai EK, Bertsch U, et al. Elotuzumab in Combination with Lenalidomide, Bortezomib, Dexamethasone and Autologous Transplantation for Newly-Diagnosed Multiple Myeloma: Results from the Randomized Phase III GMMG-HD6 Trial. Blood 2021;138:486.

[29] Usmani SZ, Hoering A, Ailawadhi S, et al. Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial. Lancet Haematol 2021;8(1):e45–54.

[30] Stuebig T, Kull M, Greil R, et al. Carfilzomib, lenalidomide, and dexamethasone (KRd) versus elotuzumab and KRd in transplant-eligible patients with newly diagnosed multiple myeloma: Post-induction response and MRD results from an open-label randomized phase 3 study. J Clin Oncol 2023;41(16_suppl):8000.

[31] Moreau P, Hulin C, Perrot A, et al. Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with orwithout daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial. Lancet Oncol 2021;22(10):1378–90.

[32] Kaiser MF, Hall A, Walker K, et al. Depth of response and minimal residual disease status in ultra high-risk multiple myeloma and plasma cell leukemia treated with daratumumab, bortezomib, lenalidomide, cyclophosphamide and dexamethasone (Dara-CVRd): Results of the UK optimum/MUKnine trial. J Clin Oncol 2021;39(15_suppl):8001.

[33] Cavo M, Gay F, Beksac M, et al. Autologous haematopoietic stem-celltransplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomidedexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, openlabel, phase 3 study. Lancet Haematol 2020;7(6):e456–68.

[34] Cavo M, Goldschmidt H, Rosinol L, et al. Double Vs Single Autologous Stem Cell Transplantation for Newly Diagnosed

Multiple Myeloma: Long-Term Follow-up (10-Years) Analysis of Randomized Phase 3 Studies. Blood 2018;132:124.

[35] Hari P, Pasquini MC, Stadtmauer EA, et al. Long-term follow-up of BMT CTN 0702 (STaMINA) of postautologous hematopoietic cell transplantation (autoHCT) strategies in the upfront treatment of multiple myeloma (MM). J Clin Oncol 2020;38(15_suppl):8506.

[36] De La Torre A, Atenafu EG, Smith AC, et al. Myeloma Patients with Deletion of 17p:Impact of Tandem Transplant and Clone Size. Blood 2021;138(Supplement 1):460.

[37] Mateos MV, Dimopoulos MA, Cavo M, et al. Daratumumab Plus Bortezomib,Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE. Clin Lymphoma, Myeloma & Leukemia 2021;21(11):785–98.

[38] Palumbo A, Anderson K. Multiple Myeloma. N Engl J Med 2011;364(11):1046–60.

[39] Palumbo A, Bringhen S, Ludwig H, et al. Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). Blood 2011;118(17):4519–29.

[40] Benboubker L, Dimopoulos MA, Dispenzieri A, et al. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med 2014; 371(10):906–17.

[41] Durie BGM, Hoering A, Sexton R, et al. Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant(ASCT). Blood Cancer J 2020;10(5):53.

[42] O'Donnell EK, Laubach JP, Yee AJ, et al. Updated Results of a Phase 2 Study of Modified Lenalidomide, Bortezomib, and Dexamethasone (RVd-lite) in TransplantIneligible Multiple Myeloma. Blood 2019;134(Supplement_1):3178.

[43] Chari A, Romanus D, Palumbo A, et al. Randomized Clinical Trial Representativeness and Outcomes in Real-World Patients: Comparison of 6 Hallmark Randomized Clinical Trials of Relapsed/Refractory Multiple Myeloma. Clin Lymphoma, Myeloma & Leukemia 2020;20(1):8–17.e16.

[44] Lancman G, Sastow D, Aslanova M, et al. Effect of intravenous immunoglobulin on infections in multiple myeloma (MM) patients receiving daratumumab. Blood 2020;136:6–7.

[45] Facon T, Venner CP, Bahlis NJ, et al. Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma.Blood 2021;137(26):3616–28.

[46] Munshi NC, Anderson LD, Shah N, et al. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. N Engl J Med 2021;384(8):705–16.

[47] Rodriguez-Otero P, Ailawadhi S, Arnulf B, et al. Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma. N Engl J Med 2023;388(11):1002–14.

[48] Martin TG, Usmani SZ, Berdeja JG, et al. CARTITUDE-1 final results: Phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory

multiple myeloma. J Clin Oncol 2023;41(16_suppl):8009.

[49] Yong K, Harrison SJ, Mateos M-V, et al. First phase 3 results from CARTITUDE-4:Ciltacel versus standard of care (PVd or DPd) in lenalidomide-refractory multiple myeloma. J Clin Oncol 2023;41(17_suppl):LBA106.

[50] Moreau P, Garfall AL, van de Donk N, et al. Teclistamab in Relapsed or Refractory Multiple Myeloma. N Engl J Med 2022;387(6):495–505.

[51] Lancman G, Parsa K, Rodriguez C, et al. Infections and Severe Hypogammaglobulinemia in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies. Blood 2022;140(Supplement 1):10073–4.

12　克隆异质性对多发性骨髓瘤的影响

[1] Palumbo A, Anderson K. Multiple Myeloma. N Engl J Med 2011;1046-60. https://doi.org/10.1056/nejmra1011442.

[2] Rajkumar SV. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am J Hematol 2022;97(8):1086-107.

[3] Sonneveld P, Avet-Loiseau H, Lonial S, et al. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood 2016;127(24):2955-62.

[4] Lonial S. Relapsed Multiple Myeloma. Hematology Am Soc Hematol Educ Pro gram 2010;2010(1):303-9.

[5] Lannes R, Samur M, Perrot A, et al. In Multiple Myeloma, High-Risk Secondary Genetic Events Observed at Relapse Are Present From Diagnosis in Tiny, Unde tectable Subclonal Populations. J Clin Oncol 2023;41(9):1695-702.

[6] Cohen YC, Zada M, Wang S-Y, et al. Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing. Nat Med 2021;27(3):491-503.

[7] Walker BA, Mavrommatis K, Wardell CP, et al. A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis. Leukemia 2019; 33(1):159-70.

[8] Bolli N, Avet-Loiseau H, Wedge DC, et al. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nat Commun 2014;5:2997.

[9] Lohr JG, Stojanov P, Carter SL, et al. Widespread genetic heterogeneity in mul tiple myeloma: implications for targeted therapy. Cancer Cell 2014;25(1): 91-101.

[10] Morgan GJ, Walker BA, Davies FE. The genetic architecture of multiple myeloma. Nat Rev Cancer 2012;12(5):335-48.

[11] Walker BA, Mavrommatis K, Wardell CP, et al. Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma. Blood 2018; 132(6):587-97.

[12] Rasche L, Chavan SS, Stephens OW, et al. Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing. Nat Commun 2017; 8(1):268.

[13] Rasche L, Schinke C, Maura F, et al. The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states. Nat Commun 2022. https://doi.org/10.1038/s41467-022-32145-y.

[14] Manier S, Salem KZ, Park J, et al. Genomic complexity of multiple myeloma and its clinical implications. Nat Rev Clin Oncol 2017;14(2):100-13.

[15] Maura F, Bolli N, Angelopoulos N, et al. Genomic landscape and chronological reconstruction of driver events in multiple myeloma. Nat Commun 2019;10(1): 3835

[16] Boyd KD, Ross FM, Chiecchio L, et al. A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial. Leukemia 2012;26(2):349-55.

[17] Ross FM, Chiecchio L, Dagrada G, et al. The t(14;20) is a poor prognostic factor in myeloma but is associated with long-term stable disease in monoclonal gam mopathies of undetermined significance. Haematologica 2010;95(7):1221-5.

[18] Schinke C, Boyle EM, Ashby C, et al. Genomic analysis of primary plasma cell leukemia reveals complex structural alterations and high-risk mutational pat terns. Blood Cancer J 2020;10(6):70.

[19] Tuazon SA, Holmberg LA, Nadeem O, et al. A clinical perspective on plasma cell leukemia; current status and future directions. Blood Cancer J 2021; 11(2):23.

[20] Wiedmeier-Nutor JE, Bergsagel PL. Review of Multiple Myeloma Genetics including Effects on Prognosis, Response to Treatment, and Diagnostic Workup. Life 2022;12(6). https://doi.org/10.3390/life12060812.

[21] Chretien M-L, Corre J, Lauwers-Cances V, et al. Understanding the role of hyper diploidy in myeloma prognosis: which trisomies really matter? Blood 2015; 126(25):2713-9.

[22] Bolli N, Maura F, Minvielle S, et al. Genomic patterns of progression in smol dering multiple myeloma. Nat Commun 2018;9(1):3363.

[23] Walker BA, Wardell CP, Melchor L, et al. Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms. Leukemia 2014;28(2):384-90.

[24] Hanamura I. Multiple myeloma with high-risk cytogenetics and its treatment approach. Int J Hematol 2022;115(6):762-77.

[25] Schmidt TM, Fonseca R, Usmani SZ. Chromosome 1q21 abnormalities in multi ple myeloma. Blood Cancer J 2021;11(4):83.

[26] Shaughnessy J. Amplification and overexpression of CKS1B at chromosome band 1q21 is associated with reduced levels of p27 Kip1 and an aggressive clinical course in multiple myeloma. Hematology 2005;10(sup1):117-26.

[27] Chapman MA, Lawrence MS, Keats JJ, et al. Initial genome sequencing and analysis of multiple myeloma. Nature 2011;471(7339):467-72.

[28] Jang JS, Li Y, Mitra AK, et al. Molecular signatures of multiple myeloma progres sion through single cell RNA-Seq. Blood Cancer J 2019;9(1):2.

[29] Ledergor G, Weiner A, Zada M, et al. Single cell dissection of plasma cell het erogeneity in symptomatic and asymptomatic myeloma. Nat Med 2018;24(12): 1867-76.

[30] de Jong MME, Kellermayer Z, Papazian N, et al. The multiple myeloma microen vironment is defined by an inflammatory stromal cell landscape. Nat Immunol 2021;22(6):769-80.

[31] Liu R, Gao Q, Foltz SM, et al. Co-evolution of tumor and immune cells during progression of multiple myeloma. Nat Commun 2021;12(1):2559.

[32] Merz M, Merz AMA, Wang J, et al. Deciphering spatial genomic heterogeneity at a single cell resolution in multiple myeloma. Nat Commun 2022;13(1):807.

[33] Tirier SM, Mallm J-P, Steiger S, et al. Subclone-specific microenvironmental impact and drug response in refractory multiple myeloma revealed by single-cell transcriptomics. Nat Commun 2021;12(1):1-16.

[34] Dang M, Wang R, Lee HC, et al. Single cell clonotypic and transcriptional evo lution of

multiple myeloma precursor disease. Cancer Cell 2023;41(6): 1032-47.e4.

[35] Zamagni E, Tacchetti P, Cavo M. Imaging in multiple myeloma: How? When? Blood 2019;133(7):644-51.

[36] Bartel TB, Haessler J, Brown TLY, et al. F18-fluorodeoxyglucose positron emis sion tomography in the context of other imaging techniques and prognostic fac tors in multiple myeloma. Blood 2009;114(10):2068-76.

[37] Walker R, Barlogie B, Haessler J, et al. Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications. J Clin Oncol 2007;25(9):1121-8.

[38] Rasche L, Angtuaco EJ, Alpe TL, et al. The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma. Blood 2018;132(1): 59-66.

[39] Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 2014;15(12):e538-48.

[40] Zamagni E, Patriarca F, Nanni C, et al. Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autolo gous transplantation. Blood 2011;118(23):5989-95.

[41] Ley TJ, Mardis ER, Ding L, et al. DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature 2008;456(7218):66-72.

[42] Waldschmidt JM, Yee AJ, Vijaykumar T, et al. Cell-free DNA for the detection of emerging treatment failure in relapsed/refractory multiple myeloma. Leukemia 2022;36(4):1078-87.

[43] Deshpande S, Tytarenko RG, Wang Y, et al. Monitoring treatment response and disease progression in myeloma with circulating cell-free DNA. Eur J Haematol 2021;106(2):230-40.

[44] Rasche L, Alapat D, Kumar M, et al. Combination of flow cytometry and func tional imaging for monitoring of residual disease in myeloma. Leukemia 2019; 33(7):1713-22.

[45] Kaddoura M, Dingli D, Buadi FK, et al. Prognostic impact of posttransplant FDG PET/CT scan in multiple myeloma. Blood Adv 2021;5(13):2753-9.

[46] Moreau P, Attal M, Caillot D, et al. Prospective Evaluation of Magnetic Reso nance Imaging and [18F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009 Trial: Results of the IMAJEM Study. J Clin Oncol 2017;35(25):2911-8.

[47] Garca-Ortiz A, Rodrguez-Garca Y, Encinas J, et al. The Role of Tumor Micro environment in Multiple Myeloma Development and Progression. Cancers 2021;13(2). https://doi.org/10.3390/cancers13020217

[48] Schinke C, Weinhold N. The Immune Microenvironment in Multiple Myeloma Pro gression at a Single-cell Level. Hemasphere 2023;7(6):e894.

[49] McGranahan N, Swanton C. Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future. Cell 2017;168(4):613-28.

[50] Schinke C, Qu P, Mehdi SJ, et al. The Pattern of Mesenchymal Stem Cell Expres

sion Is an Independent Marker of Outcome in Multiple Myeloma. Clin Cancer Res 2018;24(12):2913-9.

[51] Adams HC 3rd, Stevenaert F, Krejcik J, et al. High-parameter mass cytometry evaluation of relapsed/refractory multiple myeloma patients treated with daratu mumab demonstrates immune modulation as a novel mechanism of action. Cy tometry 2019;95(3):279-89.

[52] Chung DJ, Pronschinske KB, Shyer JA, et al. T-cell Exhaustion in Multiple Myeloma Relapse after Autotransplant: Optimal Timing of Immunotherapy. Can cer Immunol Res 2016;4(1):61-71.

[53] Zavidij O, Haradhvala NJ, Mouhieddine TH, et al. Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma. Nat Cancer 2020;1(5):493-506.

[54] Schinke C, Poos AM, Bauer M, et al. Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level. Blood Adv 2022;6(22):5873-83.

[55] Bailur JK, McCachren SS, Doxie DB, et al. Early alterations in stem-like/resident T cells, innate and myeloid cells in the bone marrow in preneoplastic gammop athy. JCI Insight 2019;5(11). https://doi.org/10.1172/jci.insight.127807.

[56] John L, Poos A, Brobeil A, et al. Resolving the spatial architecture of myeloma and its microenvironment at the single-cell level. Nat Commun 2023;14(1):5011.

[57] Khoo WH, Ledergor G, Weiner A, et al. A niche-dependent myeloid transcriptome signature defines dormant myeloma cells. Blood 2019;134(1):30-43.

[58] Greaves M, Maley CC. Clonal evolution in cancer. Nature 2012;481(7381): 306-13.

[59] Brioli A, Melchor L, Cavo M, et al. The impact of intra-clonal heterogeneity on the treatment of multiple myeloma. Br J Haematol 2014;165(4):441-54.

[60] Keats JJ, Chesi M, Egan JB, et al. Clonal competition with alternating domi nance in multiple myeloma. Blood 2012;120(5):1067-76.

[61] Fonseca R, Barlogie B, Bataille R, et al. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res 2004;64(4):1546-58.

[62] Hanamura I. Gain/Amplification of Chromosome Arm 1q21 in Multiple Myeloma. Cancers 2021;13(2). https://doi.org/10.3390/cancers13020256.

[63] Mellors PW, Binder M, Ketterling RP, et al. Metaphase cytogenetics and plasma cell proliferation index for risk stratification in newly diagnosed multiple myeloma. Blood Adv 2020;4(10):2236-44.

[64] Qiang Y-W, Ye S, Chen Y, et al. MAF protein mediates innate resistance to pro teasome inhibition therapy in multiple myeloma. Blood, The Journal of the Amer ican Society of Hematology 2016;128(25):2919-30.

[65] Qiang Y-W, Ye S, Huang Y, et al. MAFb protein confers intrinsic resistance to pro teasome inhibitors in multiple myeloma. BMC Cancer 2018;18(1):724.

[66] Bird SA, Pawlyn C. IMiD Resistance in Multiple Myeloma: Current Understand ing of the Underpinning Biology and Clinical Impact. Blood 2023. https://doi.org/ 10.1182/blood.2023019637.

[67] Barwick BG, Neri P, Bahlis NJ, et al. Multiple myeloma immunoglobulin lambda

translocations portend poor prognosis. Nat Commun 2019;10(1):1911.

[68] Poos AM, Prokoph N, Przybilla MJ, et al. Resolving therapy resistance mecha nisms in multiple myeloma by multi-omics subclone analysis. Blood 2023. https://doi.org/10.1182/blood.2023019758.

[69] Vo JN, Wu Y-M, Mishler J, et al. The genetic heterogeneity and drug resistance mechanisms of relapsed refractory multiple myeloma. Nat Commun 2022;13(1): 3750.

[70] Melchor L, Jones JR, Lenive O, et al. Spatiotemporal Analysis of Intraclonal Het erogeneity in Multiple Myeloma: Unravelling the Impact of Treatment and the Propagating Capacity of Subclones Using Whole Exome Sequencing. Blood 2015;126(23):371.

[71] Landau HJ, Yellapantula V, Diamond BT, et al. Accelerated single cell seeding in relapsed multiple myeloma. Nat Commun 2020;11(1):3617.

[72] Ria R, Vacca A. Bone Marrow Stromal Cells-Induced Drug Resistance in Multi ple Myeloma. Int J Mol Sci 2020;21(2). https://doi.org/10.3390/ijms21020613.

[73] Di Marzo L, Desantis V, Solimando AG, et al. Microenvironment drug resistance in multiple myeloma: emerging new players. Oncotarget 2016;7(37):60698-711.

[74] Chauhan D, Kharbanda S, Ogata A, et al. Interleukin-6 inhibits Fas-induced apoptosis and stress-activated protein kinase activation in multiple myeloma cells. Blood 1997;89(1):227-34.

[75] Hideshima T, Mitsiades C, Tonon G, et al. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer 2007;7(8):585-98.

[76] Katz B-Z. Adhesion molecules—The lifelines of multiple myeloma cells. Semin Cancer Biol 2010;20(3):186-95.

[77] Hazlehurst LA, Damiano JS, Buyuksal I, et al. Adhesion to fibronectin via beta1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR). Oncogene 2000;19(38):4319-27.

[78] Neri P, Ren L, Azab AK, et al. Integrin β7-mediated regulation of multiple myeloma cell adhesion, migration, and invasion. Blood 2011;117(23):6202-13.

[79] Vaxman I, Gertz MA. How I approach smoldering multiple myeloma. Blood 2022;140(8):828-38.

[80] Zingone A, Kuehl WM. Pathogenesis of monoclonal gammopathy of undetermined significance and progression to multiple myeloma. Semin Hematol 2011;48(1):4-12.

[81] Visram A, Cook J, Warsame R. Smoldering multiple myeloma: evolving diag nostic criteria and treatment strategies. Hematology Am Soc Hematol Educ Pro gram 2021;2021(1):673-81.

[82] Prez-Persona E, Vidriales M-B, Mateo G, et al. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood. The Journal of the American Society of He matology 2007;110(7):2586-92.

[83] Dispenzieri A, Kyle RA, Katzmann JA, et al. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood 2008;111(2):785-9.

[84] Lakshman A, Rajkumar SV, Buadi FK, et al. Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. Blood Cancer J 2018;8(6):59.

[85] Mateos M-V, Kumar S, Dimopoulos MA, et al. International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM). Blood Cancer J 2020. https://doi.org/10.1038/s41408-020-00366-3

[86] Mateos M-V, Hernndez M-T, Giraldo P, et al. Lenalidomide plus dexametha sone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial. Lancet Oncol 2016;17(8):1127-36.

[87] Lonial S, Jacobus S, Fonseca R, et al. Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma. J Clin Oncol 2020;38(11): 1126-37.

[88] Landgren CO, Chari A, Cohen YC, et al. Daratumumab monotherapy for pa tients with intermediate-risk or high-risk smoldering multiple myeloma: a ran domized, open-label, multicenter, phase 2 study (CENTAURUS). Leukemia 2020;34(7):1840-52.

[89] Kumar SK, Abdallah A-O, Badros AZ, et al. Aggressive smoldering curative approach evaluating novel therapies (ASCENT): A phase 2 trial of induction, consolidation and maintenance in subjects with high risk smoldering multiple myeloma (SMM): Initial analysis of safety data. Blood 2020;136(Supplement 1):35-6.

[90] Mateos M-V, Martinez Lopez J, Rodrguez-Otero P, et al. Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Carfilzomib, Lenali domide and Dexamethasone (KRd) As Induction Followed By HDT-ASCT, Consolidation with Krd and Maintenance with Rd. Blood 2021;138:1829.

[91] Kazandjian D, Hill E, Dew A, et al. Carfilzomib, Lenalidomide, and Dexametha sone Followed by Lenalidomide Maintenance for Prevention of Symptomatic Multiple Myeloma in Patients With High-risk Smoldering Myeloma: A Phase 2 Nonrandomized Controlled Trial. JAMA Oncol 2021;7(11):1678-85.

[92] Cherry BM, Korde N, Kwok M, et al. Modeling progression risk for smoldering multiple myeloma: results from a prospective clinical study. Leuk Lymphoma 2013;54(10):2215-8.

[93] Dhodapkar MV, Sexton R, Waheed S, et al. Clinical, genomic, and imaging pre dictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120). Blood 2014;123(1):78-85.

[94] Zhan F, Huang Y, Colla S, et al. The molecular classification of multiple myeloma. Blood 2006;108(6):2020-8.

[95] Kuiper R, Zweegman S, van Duin M, et al. Prognostic and predictive perfor mance of R-ISS with SKY92 in older patients with multiple myeloma: the HOVON-87/NMSG-18 trial. Blood Adv 2020;4(24):6298-309.

[96] Broyl A, Hose D, Lokhorst H, et al. Gene expression profiling for molecular clas sification of multiple myeloma in newly diagnosed patients. Blood 2010;116(14): 2543-53.

[97] Usmani SZ, Crowley J, Hoering A, et al.

Improvement in long-term outcomes with successive Total Therapy trials for multiple myeloma: are patients now be ing cured? Leukemia 2013;27(1):226-32.

[98] Yellapantula V, Hultcrantz M, Rustad EH, et al. Comprehensive detection of recurring genomic abnormalities: a targeted sequencing approach for multiple myeloma. Blood Cancer J 2019;9(12):101.

[99] Bolli N, Genuardi E, Ziccheddu B, et al. Next-Generation Sequencing for Clinical Management of Multiple Myeloma: Ready for Prime Time? Front Oncol 2020; 10:189.

[100] Heuck CJ, Jethava Y, Khan R, et al. Inhibiting MEK in MAPK pathway-activated myeloma. Leukemia 2016;30(4):976-80

[101] epulyte. R,uenka A, Peeliunas V. Combination of Dabrafenib and Trametinib for the Treatment of Relapsed and Refractory Multiple Myeloma Harboring BRAF V600E Mutation. Case Rep Hematol 2020;2020:8894031.

[102] Giesen N, Chatterjee M, Scheid C, et al. A phase 2 clinical trial of combined BRAF/MEK inhibition for BRAFV600E-mutated multiple myeloma. Blood 2023; 141(14):1685-90.

[103] Subbiah V, Kreitman RJ, Wainberg ZA, et al. Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial. Nat Med 2023; 29(5):1103-12.

[104] Paner A, Patel P, Dhakal B. The evolving role of translocation t(11;14) in the biology, prognosis, and management of multiple myeloma. Blood Rev 2020; 41(100643):100643.

[105] Kumar S, Kaufman JL, Gasparetto C, et al. Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma. Blood 2017; 130(22):2401-9.

[106] Kumar SK, Harrison SJ, Cavo M, et al. Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory mul tiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol 2020;21(12):1630-42.

[107] Rogawski DS, Grembecka J, Cierpicki T. H3K36 methyltransferases as cancer drug targets: rationale and perspectives for inhibitor development. Future Med Chem 2016;8(13):1589-607.

[108] Martinez-Garcia E, Popovic R, Min D-J, et al. The MMSET histone methyl trans ferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells. Blood 2011;117(1):211-20.

[109] Popovic R, Martinez-Garcia E, Giannopoulou EG, et al. Histone methyltransfer ase MMSET/NSD2 alters EZH2 binding and reprograms the myeloma epige nome through global and focal changes in H3K36 and H3K27 methylation. PLoS Genet 2014;10(9):e1004566.

[110] Rasche L, Wsch R, Munder M, et al. Novel immunotherapies in multiple myeloma-chances and challenges. Haematologica 2021;106(10):2555-65.

[111] Da Vi MC, Dietrich O, Truger M, et al. Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma. Nat Med 2021;27(4):616-9.

[112] Samur MK, Fulciniti M, Aktas Samur A, et al. Biallelic loss of BCMA as a resis tance mechanism to CAR T cell therapy in a patient with multiple myeloma. Nat Commun 2021;12(1):868.

[113] Bianchi G, Ghobrial IM. Biological and Clinical Implications of Clonal Heterogeneity and Clonal Evolution in Multiple Myeloma. Curr Cancer Ther Rev 2014; 10(2):70-9.

13　多发性骨髓瘤可测量残留病和决策制订

[1] Paiva B, Cedena MT, Puig N, et al. Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients. Blood 2016;127(25): 3165 -74.

[2] Lahuerta JJ, Paiva B, Vidriales MB, et al. Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials. J Clin Oncol 2017; 35(25):2900 -10.

[3] Flores-Montero J, Sanoja-Flores L, Paiva B, et al. Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia 2017;31(10):2094 -103.

[4] Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 2016;17(8):e328 -46.

[5] Yanamandra U, Kumar SK. Minimal residual disease analysis in myeloma-when, why and where. Leuk Lymphoma 2017;1-13. https://doi.org/10.1080/10428194. 2017.1386304.

[6] Costa LJ, Chhabra S, Medvedova E, et al. Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma. J Clin Orthod 2021. https://doi. org/10.1200/JCO.21.01935. JCO.21.01935.

[7] Adaptive Biotechnologies Corporation. clonoSEQ Assay Technical Information. Available at: https://www.clonoseq.com/sites/default/files/clonoSEQ_TechnicalInformationSummary_21Sept2018.pdf.

[8] Attal M, Lauwers-Cances V, Hulin C, et al. Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma. N Engl J Med 2017;376(14): 1311 -20.

[9] Martinez-Lopez J, Lahuerta JJ, Pepin F, et al. Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. Blood 2014;123(20):3073 -9.

[10] Avet-Loiseau H, Lauwers-Cances V, Corre J, et al. Minimal Residual Disease in Multiple Myeloma: Final Analysis of the IFM2009 Trial. Blood 2017;130(Suppl 1):435.

[11] Perrot A, Lauwers-Cances V, Corre J, et al. Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. Blood 2018;132(23):2456 -64.

[12] Moreau P, Attal M, Caillot D, et al. Prospective Evaluation of Magnetic Resonance Imaging and [18F] Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009 Trial: Results of the IMAJEM Study. J Clin Oncol 2017;35(25):2911 -8.

[13] Zamagni E, Oliva S, Gay F, et al. Impact of minimal residual disease standardised

assessment by FDG-PET/CT in transplant-eligible patients with newly diagnosed multiple myeloma enrolled in the imaging sub-study of the FORTE trial. eClinicalMedicine 2023;60. https://doi.org/10.1016/j.eclinm.2023.102017.

[14] Kraeber-Bodr F, Zweegman S, Perrot A, et al. Prognostic value of positron emission tomography/computed tomography in transplant-eligible newly diagnosed multiple myeloma patients from CASSIOPEIA: the CASSIOPETstudy. Haematologica 2023;108(2):621 -6.

[15] Fonseca R, Arribas M, Wiedmeier-Nutor JE, et al. Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients. Blood Cancer J 2023;13(1):1 -9.

[16] Rasche L, Angtuaco E, McDonald JE, et al. Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma. Blood 2017;130(1):30 -4.

[17] Sachpekidis C, Mosebach J, Freitag MT, et al. Application of (18)F-FDG PET and diffusion weighted imaging (DWI) in multiple myeloma: comparison of functional imaging modalities. Am J Nucl Med Mol Imaging 2015;5(5):479 -92.

[18] Kaiser MF, Porta N, Sharma B, et al. Prospective comparison of whole body MRI and FDG PET/CT for detection of multiple myeloma and correlation with markers of disease burden: Results of the iTIMM trial. J Clin Orthod 2021;39(15_suppl): 8012.

[19] Sanoja-Flores L, Flores-Montero J, Garcs JJ, et al. Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC). Blood Cancer J 2018;8(12):117.

[20] Garcs JJ, Cedena MT, Puig N, et al. Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple Myeloma. J Clin On- col 2022;40(27):3151 -61.

[21] Jelinek T, Bezdekova R, Zihala D, et al. More Than 2% of Circulating Tumor Plasma Cells Defines Plasma Cell Leukemia-Like Multiple Myeloma. J Clin Orthod 2023;41(7):1383 -92.

[22] Bertamini L, Oliva S, Rota-Scalabrini D, et al. High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma. J Clin Oncol 2022;40(27): 3120 -31.

[23] Sanoja-Flores L, Flores-Montero J, Puig N, et al. Blood monitoring of circulating tumor plasma cells by next generation flow in multiple myeloma after therapy. Blood 2019;134(24):2218 -22.

[24] Notarfranchi L, Zherniakova A, Lasa M, et al. Ultra-Sensitive Assessment of Measurable Residual Disease (MRD) in Peripheral Blood (PB) of Multiple Myeloma (MM) Patients Using Bloodflow. Blood 2022;140(Supplement 1): 2095 -7.

[25] Vij R, Mazumder A, Klinger M, et al. Deep sequencing reveals myeloma cells in peripheral blood in majority of multiple myeloma patients. Clin Lymphoma Myeloma Leuk 2014;14(2):131 -9.e1.

[26] Mazzotti C, Buisson L, Maheo S, et al. Myeloma MRD by deep sequencing from circulating tumor DNA does not correlate with results obtained in the bone marrow. Blood Advances 2018;2(21):2811 -3.

[27] Dhakal B, Sharma S, Balcioglu M, et al. Assessment of Molecular Residual Disease Using Circulating Tumor DNA to Identify Multiple Myeloma Patients at High Risk of Relapse. Front Oncol 2022;12:786451.

[31] Thoren KL. Mass spectrometry methods for detecting monoclonal immunoglobulins in multiple myeloma minimal residual disease. Semin Hematol 2018; 55(1):41 -3.

[32] Kohlhagen MC, Barnidge DR, Mills JR, et al. Screening Method for M-Proteins in Serum Using Nanobody Enrichment Coupled to MALDI-TOF Mass Spectrometry. Clin Chem 2016;62(10):1345 -52.

[33] Mills JR, Kohlhagen MC, Dasari S, et al. Comprehensive Assessment of M-Proteins Using Nanobody Enrichment Coupled to MALDI-TOF Mass Spectrometry. Clin Chem 2016;62(10):1334 -44.

[34] Kohlhagen M, Dasari S, Willrich M, et al. Automation and validation of a MALDI- TOF MS (Mass-Fix) replacement of immunofixation electrophoresis in the clinical lab. Clin Chem Lab Med 2020;59(1):155 -63.

[35] Barnidge DR, Dasari S, Botz CM, et al. Using Mass Spectrometry to Monitor Monoclonal Immunoglobulins in Patients with a Monoclonal Gammopathy. J Proteome Res 2014;13(3):1419 -27.

[36] Zajec M, Langerhorst P, VanDuijn MM, et al. Mass Spectrometry for Identification, Monitoring, and Minimal Residual Disease Detection of M-Proteins. Clin Chem 2020;66(3):421 -33.

[37] Li K, Barnidge D, Krevvata M, et al. Comparison of the Analytical Performance of EXENT®, a Mass Spectrometry-Based Assessment of M-Protein, to SPEP and NGS-Based MRD in Multiple Myeloma Patient Samples. Blood 2022; 140(Supplement 1):12446 -7.

[38] Barnidge DR, Krick TP, Griffin TJ, et al. Using matrix-assisted laser desorption/ ionization time-of-flight mass spectrometry to detect monoclonal immunoglobulin light chains in serum and urine. Rapid Commun Mass Spectrom 2015;29(21): 2057 -60.

[39] Eveillard M, Rustad E, Roshal M, et al. Comparison of MALDI-TOF mass spectrometry analysis of peripheral blood and bone marrow-based flow cytometry for tracking measurable residual disease in patients with multiple myeloma. Br J Haematol 2020;189(5):904 -7.

[40] Puig N, Agull C, Contreras Sanfeliciano T, et al. Clinical Impact of Next Generation Flow in Bone Marrow Vs Qip-Mass Spectrometry in Peripheral Blood to Assess Minimal Residual Disease in Newly Diagnosed Multiple Myeloma Patients Receiving Maintenance As Part of the GEM2014MAIN Trial. Blood 2022; 140(Supplement 1):2098 -100.

[41] Derman BA, Stefka AT, Jiang K, et al. Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation. Blood Cancer J 2021;11(2):1 -4.

[42] Puig N, Contreras Sanfeliciano T, Paiva B, et al. Assessment of Treatment Response By Ife, Next Generation Flow Cytometry and Mass Spectrometry Coupled with Liquid Chromatography in the GEM2012MENOS65 Clinical Trial. Blood 2021;138(Supplement 1):544.

[43] Derman BA, Kansagra A, Zonder J, et al. Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent: A Phase 2 Measurable Residual Disease-Adapted Study. JAMA Oncol 2022;8(9):1278 -86.

[44] Liyasova M, McDonald Z, Taylor P, et al. A Personalized Mass Spectrometry-Based Assay to Monitor M-Protein in Patients with Multiple Myeloma (EasyM). Clin Cancer Res 2021;27(18):5028 -37.

[45] McDonald Z, Taylor P, Liyasova M, et al. Mass Spectrometry Provides a Highly Sensitive Noninvasive Means of Sequencing and Tracking M-Protein in the Blood of Multiple Myeloma Patients. J Proteome Res 2021;20(8):4176 -85.

[46] Bonifay V, Vimard V, Noori S, et al. P10 AN ULTRA-SENSITIVE METHOD FOR SEQUENCING AND MONITORING OF M-PROTEIN IN PERIPHERAL BLOOD (M-INSIGHT). HemaSphere 2023;7(S2):15.

[47] Slade MJ, Khalid A, Fiala MA, et al. Clonotypic Mass Spectrometry with Easym Assay for Detection of Measurable Residual Disease in Multiple Myeloma. Blood 2022;140(Supplement 1):4376 -7.

[48] Noori S, Wijnands C, Langerhorst P, et al. Dynamic monitoring of myeloma minimal residual disease with targeted mass spectrometry. Blood Cancer J 2023; 13(1):1 -3.

[49] Kendrick F, Harding S, Chappell MJ, et al. Immunoglobulin G (IgG) and neonatal Fc-receptor (FcRn) dynamics in IgG multiple myeloma**Felicity Kendrick is a member of the Midlands Integrative Biosciences Training Partnership funded by the Biotechnology and Bi-ological Sciences Research Council (BBSRC). IFAC-PapersOnLine 2015;48(20):106 -11.

[50] Kendrick F, Evans ND, Arnulf B, et al. Analysis of a Compartmental Model of Endogenous Immunoglobulin G Metabolism with Application to Multiple Myeloma. Front Physiol 2017;8:149.

[51] van de Velde HJK, Liu X, Chen G, et al. Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma. Haematologica 2007;92(10):1399 -406.

[52] Gay F, Larocca A, Wijermans P, et al. Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients. Blood 2011;117(11):3025 -31.

[53] Lahuerta JJ, Mateos MV, Martnez-Lpez J, et al. Influence of pre- and post- transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival. J Clin Oncol 2008;26(35):5775 -82.

[54] Martnez-Lpez J, Paiva B, Lpez-Anglada L, et al. Critical analysis of the stringent complete response in multiple myeloma: contribution of sFLC and bone marrow clonality. Blood 2015;126(7):858 -62.

[55] Cedena MT, Martin-Clavero E, Wong S, et al. The clinical significance of stringent complete response in multiple myeloma is surpassed by minimal residual disease measurements. PLoS One 2020;15(8):e0237155.

[56] Jimnez Ubieto A, Paiva B, Puig N, et al. Validation of the IMWG standard

response criteria in the PETHEMA/GEM2012MENOS65 study: are these times of change? Blood 2021. https://doi.org/10.1182/blood.2021012319.blood.2021012319.

[57] Munshi NC, Avet-Loiseau H, Rawstron AC, et al. Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-analysis. JAMA Oncol 2017;3(1):28.

[58] Munshi NC, Avet-Loiseau H, Anderson KC, et al. A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma. Blood Advances 2020;4(23):5988 -99.

[59] Bansal R, Baksh M, Larsen JT, et al. Prognostic value of early bone marrow MRD status in CAR-T therapy for myeloma. Blood Cancer J 2023;13(1):1 -5.

[60] Paiva B, Manrique I, Rytlewski J, et al. Time-dependent prognostic value of serological and measurable residual disease assessments after idecabtagene vicleucel. Blood Cancer Discovery 2023. https://doi.org/10.1158/2643-3230.BCD-23-0044.BCD-23-0044.

[61] Martin T, Usmani SZ, Berdeja JG, et al. Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up. JCO 2022. https:// doi.org/10.1200/JCO.22.00842.JCO.22.00842.

[62] Lin Y, Martin TG, Usmani SZ, et al. CARTITUDE-1 final results: Phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory multiple myeloma. J Clin Orthod 2023;41(16_suppl):8009.

[63] Gay F, Musto P, Rota-Scalabrini D, et al. Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial. Lancet Oncol 2021;22(12):1705 -20.

[64] San-Miguel J, Avet-Loiseau H, Paiva B, et al. Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE. Blood 2022;139(4):492 -501.

[65] Avet-Loiseau H, San-Miguel J, Casneuf T, et al. Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR. J Clin Oncol 2021;39(10):1139 -49.

[66] Mohan M, Kendrick S, Szabo A, et al. Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma. Blood Advances 2022;6(3):808 -17.

[67] Diamond B, Korde N, Lesokhin AM, et al. Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial. The Lancet Haematology 2021;8(6): e422 -32.

[68] Paiva B, Manrique I, Dimopoulos MA, et al. MRD dynamics during maintenance for improved prognostication of 1280 patients

with myeloma in the TOURMALINE-MM3 and -MM4 trials. Blood 2023;141(6):579 -91.

[69] Oliva S, Genuardi E, Paris L, et al. Prospective evaluation of minimal residual disease in the phase II FORTE trial: a head-to-head comparison between multiparameter flow cytometry and next-generation sequencing. eClinicalMedicine 2023;60.

[70] Costa LJ, Derman BA, Bal S, et al. International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials. Leukemia 2021;35(1):18 -30.

[71] Derman BA, Major A, Major S, et al. Prospective Trial Using Multimodal Measurable Residual Disease Negativity to Guide Discontinuation of Maintenance Therapy in Multiple Myeloma (MRD2STOP). Blood 2022;140(Supplement 1):2108 -9.

[72] Dispenzieri A, Krishnan A, Arendt B, et al. Mass-Fix better predicts for PFS and OS than standard methods among multiple myeloma patients participating on the STAMINA trial (BMT CTN 0702/07LT). Blood Cancer J 2022;12(2):1 -8.

[73] Claveau JS, Murray DL, Dispenzieri A, et al. Value of bone marrow examination in determining response to therapy in patients with multiple myeloma in the context of mass spectrometry-based M-protein assessment. Leukemia 2023;37(1):1 -4.

[74] Buyse M, Molenberghs G, Burzykowski T, et al. The validation of surrogate end-points in meta-analyses of randomized experiments. Biostatistics 2000;1(1): 49 -67.

[75] Etekal T, Koehn K, Sborov DW, et al. Time-to-event surrogate end-points in multiple myeloma randomised trials from 2005 to 2019: A surrogacy analysis. Br J Haematol 2023;200(5):587 -94.

[76] Xie W, Halabi S, Tierney JF, et al. A Systematic Review and Recommendation for Reporting of Surrogate Endpoint Evaluation Using Meta-analyses. JNCI Cancer Spectr 2019;3(1):kz002.

[77] Paiva B, Zherniakova A, Nuez-Crdoba JM, et al. Impact of treatment effect on MRD and PFS: an aggregate analysis from randomized clinical trials in multiple myeloma. Blood Adv 2023;1, bloodadvances.202301082.

[78] Costa LJ, Chhabra S, Medvedova E, et al. Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial. Lancet Haematol 2023;10(11): e890 -901.

[79] Research C for DE and. Hematologic Malignancies: Regulatory Considerations for Use of Minimal Residual Disease in Development of Drug and Biological Products for Treatment. U.S. Food and Drug Administration. Published January 24,2020. Available at: https://www. fda.gov/regulatory-information/search-fda-guidance-documents/hematologic-malignancies-regulatory-considerations-use- minimal-residual-disease-development-drug-and. Accessed June 30, 2023.

[80] Dhakal B, Usmani S. Daratumumab and Lenalidomide Maintenance Guided by Minimal Residual Disease in Multiple Myeloma. The Hematologist 2021;18(6). https://doi.org/10.1182/hem.V18.6. 202166.

[82] Dytfeld D, Wrbel T, Jamroziak K, et al. Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as

maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol 2023;24(2):139 -50.

[83] Correia N, Dowling E, Popat R, et al. Functional and psychological impact of minimal residual disease assessment on patients with multiple myeloma. Br J Haematol 2023. https://doi.org/10.1111/bjh.18948.

[84] Derman BA, Jakubowiak AJ, Thompson MA. Clinician survey regarding measurable residual disease-guided decision-making in multiple myeloma. Blood Cancer J 2022;12(7):108.

[85] Martinez-Lopez J, Alonso R, Wong SW, et al. Making clinical decisions based on measurable residual disease improves the outcome in multiple myeloma. J Hematol Oncol 2021;14(1):126.

[86] Derman BA, Major A, Rosenblatt J, et al. A Phase 2 Study of Extended Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma. Blood 2021;138(Supplement 1):2759.

[87] de Tute RM, Pawlyn C, Cairns DA, et al. Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk. J Clin Orthod 2022;40(25):2889 -900.

[88] Alonso R, Cedena MT, Wong S, et al. Prolonged lenalidomide maintenance therapy improves the depth of response in multiple myeloma. Blood Advances 2020; 4(10):2163 -71.

[89] Hahn TE, Wallace PK, Fraser R, et al. Minimal Residual Disease (MRD) Assessment before and after Autologous Hematopoietic Cell Transplantation (AutoHCT) and Maintenance for Multiple Myeloma (MM): Results of the Prognostic Immuno-phenotyping for Myeloma Response (PRIMeR) Study. Biol Blood Marrow Transplant 2019;25(3):S4 -6.

[90] Paiva B, Puig N, Cedena MT, et al. Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma. J Clin Orthod 2019. https:// doi.org/10.1200/JCO.19.01231. JCO.19.01231.

14　高危多发性骨髓瘤的治疗方法

[1] Majithia N, Rajkumar SV, Lacy MQ, et al. Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agents. Leukemia 2016;30:2208–13.

[2] Bygrave C, Pawlyn C, Davies F, et al. Early relapse after high-dose melphalan autologous stem cell transplant predicts inferior survival and is associated with high disease burden and genetically high-risk disease in multiple myeloma. Br J Haematol 2021;193:551–5.

[3] Sonneveld P, Avet-Loiseau H, Lonial S, et al. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood 2016;127:2955–62.

[4] Jagosky MH, Usmani SZ. Extramedullary disease in multiple myeloma. Curr Hematol Malig Rep 2020;15:62–71.

[5] Bansal R, Rakshit S, Kumar S. Extramedullary disease in multiple myeloma. Blood Cancer J 2021;11:161.

[6] Schinke C, Boyle EM, Ashby C, et al. Genomic analysis of primary plasma cell leukemia reveals complex structural alterations and high-risk mutational patterns. Blood Cancer J 2020;10:70.

[7] Chng WJ, Dispenzieri A, Chim CS, et al. IMWG consensus on risk stratification in multiple myeloma. Leukemia 2014;28:269–77.

[8] Greipp PR, San Miguel J, Durie BG, et al. International staging system for mul- tiple myeloma. J Clin Oncol 2005;23:3412–20.

[9] Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised international staging system for multiple myeloma: a report from International Myeloma Working Group. J Clin Oncol 2015;33:2863–9.

[10] Boyle EM, Rosenthal A, Wang Y, et al. High-risk transcriptional profiles in multi- ple myeloma are an acquired feature that can occur in any subtype and more frequently with each subsequent relapse. Br J Haematol 2021;195:283–6.

[11] D'Agostino M, Cairns DA, Lahuerta JJ, et al. Second Revision of the International Staging System (R2-ISS) for overall survival in multiple myeloma: a Euro- pean Myeloma Network (EMN) report within the HARMONY Project. J Clin Oncol 2022;40:3406–18.

[12] Pawlyn C, Morgan GJ. Evolutionary biology of high-risk multiple myeloma. Nat Rev Cancer 2017;17:543–56.

[13] Maura F, Rustad EH, Boyle EM, et al. Reconstructing the evolutionary history of multiple myeloma. Best Pract Res Clin Haematol 2020;33:101145.

[14] Melchor L, Brioli A, Wardell CP, et al. Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and par- allel evolution in myeloma. Leukemia 2014;28:1705–15.

[15] Walker BA, Wardell CP, Melchor L, et al. Intraclonal heterogeneity is a critical early event in the development of myeloma

and precedes the development of clinical symptoms. Leukemia 2014;28:384–90.

[16] Landgren O, Morgan GJ. Biologic frontiers in multiple myeloma: from biomarker identification to clinical practice. Clin Cancer Res 2014;20:804–13.

[17] Bergsagel PL, Kuehl WM, Zhan F, et al. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood 2005;106:296–303.

[18] Zhan F, Huang Y, Colla S, et al. The molecular classification of multiple myeloma. Blood 2006;108:2020–8.

[19] Joseph NS, Gentili S, Kaufman JL, et al. High-risk multiple myeloma: definition and management. Clin Lymphoma Myeloma Leuk 2017;17S:S80–7.

[20] Maura F, Boyle EM, Rustad EH, et al. Chromothripsis as a pathogenic driver of multiple myeloma. Semin Cell Dev Biol 2022;123:115–23.

[21] Maura F, Bolli N, Angelopoulos N, et al. Genomic landscape and chronological reconstruction of driver events in multiple myeloma. Nat Commun 2019;10:3835.

[22] Shaughnessy JD Jr, Zhan F, Burington BE, et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 2007;109:2276–84.

[23] Walker BA, Leone PE, Chiecchio L, et al. A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value. Blood 2010;116:e56–65.

[24] Walker BA, Mavrommatis K, Wardell CP, et al. A high-risk, double-hit, group of newly diagnosed myeloma identified by genomic analysis. Leukemia 2019;33: 159–70.

[25] Panopoulou A, Cairns DA, Holroyd A, et al. Optimizing the value of lenalidomide maintenance by extended genetic profiling: an analysis of 556 patients in the Myeloma XI trial. Blood 2023;141:1666–74.

[26] Panopoulou A, Easdale S, Ethell M, et al. Impact of ultra high-risk genetics on real-world outcomes of transplant-eligible multiple myeloma patients. Hema- sphere 2023;7:e831.

[27] Messiou C, Giles S, Collins DJ, et al. Assessing response of myeloma bone disease with diffusion-weighted MRI. Br J Radiol 2012;85:e1198–203.

[28] Giles SL, Messiou C, Collins DJ, et al. Whole-body diffusion-weighted MR imaging for assessment of treatment response in myeloma. Radiology 2014;271: 785–94.

[29] Rasche L, Alapat D, Kumar M, et al. Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma. Leukemia 2019; 33:1713–22.

[30] Dimopoulos M, Terpos E, Comenzo RL, et al. International myeloma working group consensus statement and guidelines regarding the current role of imag- ing techniques in the diagnosis and monitoring of multiple myeloma. Leukemia 2009;23:1545–56.

[31] Rasche L, Angtuaco EJ, Alpe TL, et al. The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma. Blood 2018;132: 59–66.

[32] McDonald JE, Kessler MM, Gardner MW, et al. Assessment of total lesion glycolysis by (18)F FDG PET/CT significantly improves prognostic value of GEP and ISS in myeloma. Clin Cancer Res 2017;23:1981–7.

[33] Morgan GJ, Walker BA, Davies FE. The

genetic architecture of multiple myeloma. Nat Rev Cancer 2012;12:335–48.

[34] Hoang PH, Dobbins SE, Cornish AJ, et al. Whole-genome sequencing of multi- ple myeloma reveals oncogenic pathways are targeted somatically through mul- tiple mechanisms. Leukemia 2018;32:2459–70.

[35] Stein CK, Pawlyn C, Chavan S, et al. The varied distribution and impact of RAS codon and other key DNA alterations across the translocation cyclin D sub- groups in multiple myeloma. Oncotarget 2017;8:27854–67.

[36] Heuck CJ, Jethava Y, Khan R, et al. Inhibiting MEK in MAPK pathway-activated myeloma. Leukemia 2016;30:976–80.

[37] Hose D, Reme T, Hielscher T, et al. Proliferation is a central independent prog- nostic factor and target for personalized and risk-adapted treatment in multiple myeloma. Haematologica 2011;96:87–95.

[38] Thanendrarajan S, Tian E, Qu P, et al. The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma. Haematologica 2017;102:e364–7.

[39] Dring AM, Davies FE, Fenton JA, et al. A global expression-based analysis of the consequences of the t(4;14) translocation in myeloma. Clin Cancer Res 2004;10:5692–701.

[40] Woo JS, Alberti MO, Tirado CA. Childhood B-acute lymphoblastic leukemia: a genetic update. Exp Hematol Oncol 2014;3:16.

[41] Topchu I, Pangeni RP, Bychkov I, et al. The role of NSD1, NSD2, and NSD3 his- tone methyltransferases in solid tumors. Cell Mol Life Sci 2022;79:285.

[42] Popovic R, Martinez-Garcia E, Giannopoulou EG, et al. Histone methyltransfer- ase MMSET/NSD2 alters EZH2 binding and reprograms the myeloma epige- nome through global and focal changes in H3K36 and H3K27 methylation. PLoS Genet 2014;10:e1004566.

[43] Walker BA, Wardell CP, Chiecchio L, et al. Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma. Blood 2011;117:553–62.

[44] Pawlyn C, Kaiser MF, Heuck C, et al. The spectrum and clinical impact of epige- netic modifier mutations in myeloma. Clin Cancer Res 2016;22:5783–94.

[45] Pawlyn C, Kaiser MF, Davies FE, et al. Current and potential epigenetic targets in multiple myeloma. Epigenomics 2014;6:215–28.

[46] Pawlyn C, Bright MD, Buros AF, et al. Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle con- trol. Blood Cancer J 2017;7:e549.

[47] Ghamlouch H, Boyle EM, Blaney P, et al. Insights into high-risk multiple myeloma from an analysis of the role of PHF19 in cancer. J Exp Clin Cancer Res 2021; 40:380.

[48] Mason MJ, Schinke C, Eng CLP, et al. Multiple myeloma DREAM Challenge re- veals epigenetic regulator PHF19 as marker of aggressive disease. Leukemia 2020;34:1866–74.

[49] Qiang YW, Ye S, Huang Y, et al. MAFb protein confers intrinsic resistance to pro- teasome inhibitors in multiple myeloma. BMC Cancer 2018;18:724.

[50] Walker BA, Wardell CP, Murison A, et al. APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma. Nat Commun

2015;6:6997.

[51] Maura F, Rustad EH, Yellapantula V, et al. Role of AID in the temporal pattern of acquisition of driver mutations in multiple myeloma. Leukemia 2020;34:1476–80.

[52] Shou Y, Martelli ML, Gabrea A, et al. Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma. Proc Natl Acad Sci U S A 2000;97:228–33.

[53] Avet-Loiseau H, Gerson F, Magrangeas F, et al. Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors. Blood 2001;98:3082–6.

[54] Walker BA, Wardell CP, Brioli A, et al. Translocations at 8q24 juxtapose MYC with genes that harbor superenhancers resulting in overexpression and poor prognosis in myeloma patients. Blood Cancer J 2014;4:e191.

[55] Affer M, Chesi M, Chen WG, et al. Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma. Leukemia 2014;28:1725–35.

[56] Misund K, Keane N, Stein CK, et al. MYC dysregulation in the progression of multiple myeloma. Leukemia 2020;34:322–6

[57] Maura F, Petljak M, Lionetti M, et al. Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and mul- tiple myeloma cell lines. Leukemia 2018;32:1044–8.

[58] Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of mutational pro- cesses in human cancer. Nature 2013;500:415–21.

[59] Bolli N, Avet-Loiseau H, Wedge DC, et al. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nat Commun 2014;5:2997.

[60] Hoang PH, Cornish AJ, Dobbins SE, et al. Mutational processes contributing to the development of multiple myeloma. Blood Cancer J 2019;9:60.

[61] Rustad EH, Yellapantula V, Leongamornlert D, et al. Timing the initiation of mul- tiple myeloma. Nat Commun 2020;11:1917.

[62] Cowan G, Weston-Bell NJ, Bryant D, et al. Massive parallel IGHV gene sequencing reveals a germinal center pathway in origins of human multiple myeloma. Oncotarget 2015;6:13229–40.

[63] Rustad EH, Yellapantula VD, Glodzik D, et al. Revealing the impact of structural variants in multiple myeloma. Blood Cancer Discov 2020;1:258–73.

[64] Morgan GJ. Jumping translocations and high-risk myeloma. Blood 2014;123: 2442–3.

[65] Sawyer JR, Tian E, Heuck CJ, et al. Jumping translocations of 1q12 in multiple myeloma: a novel mechanism for deletion of 17p in cytogenetically defined high- risk disease. Blood 2014;123:2504–12.

[66] Hanamura I, Stewart JP, Huang Y, et al. Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prog- nosis and disease progression following tandem stem-cell transplantation. Blood 2006;108:1724–32.

[67] Sawyer JR, Tian E, Walker BA, et al. An acquired high-risk chromosome insta- bility phenotype in multiple myeloma: jumping 1q

syndrome. Blood Cancer J 2019;9:62.

[68] Hebraud B, Leleu X, Lauwers-Cances V, et al. Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients. Leukemia 2014;28:675–9.

[69] Hofman IJF, van Duin M, De Bruyne E, et al. RPL5 on 1p22.1 is recurrently deleted in multiple myeloma and its expression is linked to bortezomib response. Leukemia 2017;31:1706–14.

[70] Boyd KD, Ross FM, Walker BA, et al. Mapping of chromosome 1p deletions in myeloma identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as being genes in regions associated with adverse survival. Clin Cancer Res 2011;17:7776–84.

[71] Inoue J, Otsuki T, Hirasawa A, et al. Overexpression of PDZK1 within the 1q12-q22 amplicon is likely to be associated with drug-resistance phenotype in mul- tiple myeloma. Am J Pathol 2004;165:71–81.

[72] Mani M, Carrasco DE, Zhang Y, et al. BCL9 promotes tumor progression by conferring enhanced proliferative, metastatic, and angiogenic properties to can- cer cells. Cancer Res 2009;69:7577–86.

[73] Marchesini M, Ogoti Y, Fiorini E, et al. ILF2 Is a regulator of RNA splicing and DNA damage response in 1q21-amplified multiple myeloma. Cancer Cell 2017;32:88–100 e6.

[74] Teoh PJ, An O, Chung TH, et al. Aberrant hyperediting of the myeloma transcriptome by ADAR1 confers oncogenicity and is a marker of poor prognosis. Blood 2018;132:1304–17.

[75] Samo AA, Li J, Zhou M, et al. MCL1 gene co-expression module stratifies multiple myeloma and predicts response to proteasome inhibitor-based therapy. Genes Chromosomes Cancer 2018;57:420–9.

[76] Boyle EM, Blaney P, Stoeckle JH, et al. Multiomic Mapping of Acquired Chromosome 1 Copy-Number and Structural Variants to Identify Therapeutic Vulnerabilities in Multiple Myeloma. Clin Cancer Res 2023;29(19):3901–13.

[77] Owen RG, Davis SA, Randerson J, et al. p53 gene mutations in multiple myeloma. Mol Pathol 1997;50:18–20.

[78] Shah V, Johnson DC, Sherborne AL, et al. Subclonal TP53 copy number is asso- ciated with prognosis in multiple myeloma. Blood 2018;132:2465–9.

[79] Thakurta A, Ortiz M, Blecua P, et al. High subclonal fraction of 17p deletion is associated with poor prognosis in multiple myeloma. Blood 2019;133:1217–21.

[80] Martello M, Poletti A, Borsi E, et al. Clonal and subclonal TP53 molecular impair- ment is associated with prognosis and progression in multiple myeloma. Blood Cancer J 2022;12:15.

[81] Kunkel EJ, Butcher EC. Plasma-cell homing. Nat Rev Immunol 2003;3:822–9.

[82] Cyster JG. Homing of antibody secreting cells. Immunol Rev 2003;194:48–60.

[83] Danziger SA, McConnell M, Gockley J, et al. Bone marrow microenvironments that contribute to patient outcomes in newly diagnosed multiple myeloma: A cohort study of patients in the Total Therapy clinical trials. PLoS Med 2020;17: e1003323.

[84] Neri P, Ren L, Azab AK, et al. Integrin beta7-mediated regulation of multiple myeloma cell adhesion, migration, and invasion. Blood 2011;117:6202–13.

[85] Gupta VA, Matulis SM, Conage-Pough JE, et

al. Bone marrow microenvironment- derived signals induce Mcl-1 dependence in multiple myeloma. Blood 2017;129: 1969–79.

[86] de Jong MME, Kellermayer Z, Papazian N, et al. The multiple myeloma microenvironment is defined by an inflammatory stromal cell landscape. Nat Immunol 2021;22:769–80.

[87] Schinke C, Poos AM, Bauer M, et al. Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level. Blood Adv 2022;6:5873–83.

[88] Zavidij O, Haradhvala NJ, Mouhieddine TH, et al. Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma. Nat Cancer 2020;1:493–506.

[89] Friedrich MJ, Neri P, Kehl N, et al. The pre-existing T cell landscape determines the response to bispecific Tcell engagers in multiple myeloma patients. Cancer Cell 2023;41:711–725 e6.

[90] Moreau P, Attal M, Hulin C, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplanta- tion for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open- label, phase 3 study. Lancet 2019;394:29–38.

[91] Voorhees PM, Kaufman JL, Laubach J, et al. Daratumumab, lenalidomide, bor- tezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood 2020;136:936–45.

[92] Costa LJ, Chhabra S, Medvedova E, et al. Daratumumab, carfilzomib, lenalido- mide, and dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma. J Clin Oncol 2022;40:2901–12.

[93] Gay F, Musto P, Rota-Scalabrini D, et al. Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for pa- tients with newly diagnosed multiple myeloma (FORTE): a randomised, open- label, phase 2 trial. Lancet Oncol 2021;22:1705–20.

[94] Usmani SZ, Hoering A, Ailawadhi S, et al. Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk mul- tiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial. Lancet Haematol 2021;8:e45–54.

[95] Brown S, Sherratt D, Hinsley S, et al. MUKnine OPTIMUM protocol: a screening study to identify high-risk patients with multiple myeloma suitable for novel treatment approaches combined with a phase II study evaluating optimised combi- nation of biological therapy in newly diagnosed high-risk multiple myeloma and plasma cell leukaemia. BMJ Open 2021;11:e046225.

[96] Croft J, Ellis S, Sherborne AL, et al. Copy number evolution and its relationship with patient outcome-an analysis of 178 matched presentation-relapse tumor pairs from the Myeloma XI trial. Leukemia 2021;35:2043–53.

[97] Chavan SS, He J, Tytarenko R, et al. Bi-allelic inactivation is more prevalent at

relapse in multiple myeloma, identifying RB1 as an independent prognostic marker. Blood Cancer J 2017;7:e535.

[98] Bird S, Pawlyn C. IMiD resistance in multiple myeloma: current understanding of the underpinning biology and clinical impact. Blood 2023;142:131–40.

[99] Da Via MC, Dietrich O, Truger M, et al. Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma. Nat Med 2021;27:616–9.

[100] Swamydas M, Murphy EV, Ignatz-Hoover JJ, et al. Deciphering mechanisms of immune escape to inform immunotherapeutic strategies in multiple myeloma. J Hematol Oncol 2022;15:17.

15　复发难治性多发性骨髓瘤的新疗法涌现

[1] Kumar SK, Dispenzieri A, Lacy MQ, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 2014;28(5):1122 -8.

[2] Binder M, Nandakumar B, Rajkumar SV, et al.Mortality trendsin multiple myeloma after the introduction of novel therapies in the United States. Leukemia 2022;36(3):801 -8.

[3] Ravi P, Kumar SK, Cerhan JR, et al. Defining cure in multiple myeloma: a compar- ative study of outcomes of young individuals with myeloma and curable hemato- logic malignancies. Blood Cancer J 2018;8(3):26.

[4] Mateos M-V, Weisel K, De Stefano V, et al. LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma. Leukemia 2022;36(5):1371 -6.

[5] Gandhi UH, Cornell RF, Lakshman A, et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia 2019;33(9):2266 -75.

[6] Chari A, Vogl DT, Gavriatopoulou M, et al. Oral Selinexor -Dexamethasone for Triple-Class Refractory Multiple Myeloma. N Engl J Med 2019;381(8):727 -38.

[7] Lonial S, Lee HC, Badros A, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol 2020;21(2):207 -21.

[8] Dimopoulos M, Bringhen S, Anttila P, et al. Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed/refractory multiple myeloma. Blood 2021;137(9):1154 -65.

[9] Moreau P, Garfall AL, van de Donk NWCJ, et al. Teclistamab in Relapsed or Refractory Multiple Myeloma. N Engl J Med 2022;387(6):495 -505.

[10] Chari A, Minnema MC, Berdeja JG, et al. Talquetamab, a T-Cell -Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma. N Engl J Med 2022; 387(24):2232 -44.

[11] Lesokhin AM, Tomasson MH, Arnulf B, et al. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med 2023. https://doi.org/10.1038/s41591-023-02528-9.

[12] San-Miguel J, Dhakal B, Yong K, et al. Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma. N Engl J Med 2023;389(4):335 -47.

[13] Rodriguez-Otero P, Ailawadhi S, Arnulf B, et al. Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma. N Engl J Med 2023;388(11): 1002 -14.

[14] Touzeau C, Dousset C, Le Gouill S, et al. The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma. Leukemia 2014;28(1):210 -2.

[15] Cleynen A, Samur M, Perrot A, et al. Variable BCL2/BCL2L1 ratio in multiple myeloma with t(11;14). Blood 2018;132(26):2778 -80.

[16] Fonseca R, Blood EA, Oken MM, et al. Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients. Blood 2002;99(10): 3735 -41.

[17] Kumar S, Kaufman JL, Gasparetto C, et al. Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma. Blood 2017;130(22): 2401 -9.

[18] Punnoose EA, Leverson JD, Peale F, et al. Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in MultipleMyeloma Models. Mol Cancer Ther 2016;15(5): 1132 -44.

[19] Moreau P, Chanan-Khan A, Roberts AW, et al. Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM. Blood 2017;130(22):2392 -400.

[20] Kumar SK, Harrison SJ, Cavo M, et al. Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial. Lan- cet Oncol 2020;21(12):1630 -42.

[21] Kumar S, Harrison SJ, Cavo M, et al. Final Overall Survival Results from BELLINI, a Phase 3 Study of Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma. Blood 2021;138:84.

[22] Bahlis NJ, Baz R, Harrison SJ, et al. Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14). J Clin Oncol 2021; 39(32):3602 -12.

[23] Kaufman JL, Quach H, Baz RC, et al. An Updated Safety and Efficacy Analysis of Venetoclax Plus Daratumumab and Dexamethasone in an Expansion Cohort of a Phase 1/2 Study of Patients with t(11;14) Relapsed/Refractory Multiple Myeloma. Blood 2022;140(Supplement 1):7261 -3.

[24] Costa LJ, Davies FE, Monohan GP, et al. Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma. Blood Advances 2021;5(19):3748 -59.

[25] Mateos M-V, Moreau P, Dimopoulos MA, et al. A phase III, randomized, multi-center, open-label study of venetoclax or pomalidomide in combination with dexamethasone in patients with t(11;14)-positive relapsed/refractory multiple myeloma. J Clin Oncol 2020;38(15_ suppl):TPS8554.

[26] Lopez-Girona A, Mendy D, Ito T, et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia 2012;26(11):2326 -35.

[27] Bjorklund CC, Lu L, Kang J, et al. Rate of CRL4CRBN substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4. Blood Cancer J 2015; 5(10):e354.

[28] Matyskiela ME, Zhang W, Man H-W, et al. A Cereblon Modulator (CC-220) with Improved Degradation of Ikaros and Aiolos. J Med Chem 2018;61(2):535 -42.

[29] Hansen JD, Correa M, Nagy MA, et al. Discovery of CRBN E3 Ligase Modulator CC-92480 for the Treatment of Relapsed and

Refractory Multiple Myeloma. J Med Chem 2020;63(13):6648 -76.

[30] Amatangelo M, Bjorklund CC, Kang J, et al. Iberdomide (CC-220) Has Synergis- tic Anti-Tumor and Immunostimulatory Activity Against Multiple Myeloma in Combination with Both Bortezomib and Dexamethasone, or in Combination with Daratumumab in Vitro. Blood 2018;132(Supplement 1):1935.

[31] Bjorklund CC, Kang J, Amatangelo M, et al. Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- andpomalidomide-resistantmultiplemyelomacells with dysregulated CRBN.Leukemia 2020;34(4): 1197 -201.

[32] Wong L, Narla RK, Leisten J, et al. CC-92480, a Novel Cereblon E3 Ligase Modulator, Is Synergistic with Dexamethasone, Bortezomib, and Daratumumab in Multiple Myeloma. Blood 2019;134:1815.

[33] Lonial S, Popat R, Hulin C, et al. Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase1/2 trial. Lancet Haematol 2022; 9(11):e822 -32.

[34] Lonial S, Richardson PG, Popat R, et al. OAB-013: Iberdomide (IBER) in combination with dexamethasone (DEX) and daratumumab (DARA),bortezomib (BORT), or carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM). Clin Lymphoma, Myeloma & Leukemia 2021;21:S9.

[35] Lonial S, Quach H, Dimopoulos MA, et al. EXCALIBER-RRMM: A phase 3, two- stage study of iberdomide, daratumumab, and dexamethasone (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in patients (pts) with relapsed/refractory multiple myeloma (RRMM). J Clin Oncol 2023;41(16_suppl): TPS8069.

[36] Richardson PG, Vangsted AJ, Ramasamy K, et al. First-in-human phase I study of the novel CELMoD agent CC-92480 combined with dexamethasone (DEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM). J Clin Oncol 2020; 38(15_ suppl):8500.

[37] Wong L, Lamba M, Jimnez Nuez MD, et al. Dose- and Schedule-Dependent Immunomodulatory Effects of the Novel Celmod Agent CC-92480 in Patients with Relapsed/Refractory Multiple Myeloma. Blood2020;136(Supplement 1):47 -8.

[38] Richardson PG, Trudel S, Quach H, et al. Mezigdomide (CC-92480), a Potent, Novel Cereblon E3 Ligase Modulator (CELMoD), Combined with Dexamethasone (DEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma(RRMM): Pre- liminary Results from the Dose-Expansion Phase of the CC-92480-MM-001 Trial. Blood 2022;140(Supplement 1):1366 -8.

[39] Richardson P, Sandhu I, Oriol A, et al. OAB-053: Mezigdomide (MEZI;CC-92480) in combination with dexamethasone (DEX) and bortezomib (BORT) or carfilzomib (CFZ) in patients (pts) with relapsed/ refractory multiple myeloma (RRMM). Clin Lymphoma, Myeloma & Leukemia 2022;22:S33.

[40] Amatangelo M, Berenson JR, Cerchione C, et al. A phase 3, two-stage, randomized

study of mezigdomide, carfilzomib, and dexamethasone (MeziKd) versus carfilzomib and dexamethasone (Kd) in relapsed/refractory multiple myeloma (RRMM): SUCCESSOR-2. J Clin Oncol 2023;41(16_suppl):TPS8070.

[41] Bruins WSC, Rentenaar R, Collins S, et al. Modakafusp Alfa (TAK-573), a Novel CD38-Targeting Attenuated Interferon-Alpha Immunocytokine, Kills MM Cells Via NK Cell Activation. Blood 2022;140(Supplement 1):4236 -7.

[42] Vogl DT, Kaufman JL, Holstein SA, et al. TAK-573, an Anti-CD38/Attenuated Ifna Fusion Protein, Has Clinical Activity and Modulates the Ifna Receptor (IFNAR) Pathway in Patients with Relapsed/Refractory Multiple Myeloma. Blood 2020;136(Supplement 1):37 -8.

[43] Pogue SL, Taura T, Bi M, et al. Targeting Attenuated Interferon-alpha to Myeloma Cells with a CD38 Antibody Induces Potent Tumor Regression with Reduced Off-Target Activity. PLoS One 2016;11(9):e0162472.

[44] Vogl DT, Atrash S, Holstein SA, et al. Final Results from the First-in-Human Phase 1/2 Study of Modakafusp Alfa, an Immune-Targeting Attenuated Cytokine, in Patients(Pts) with Relapsed/Refractory Multiple Myeloma (RRMM). Blood 2022;140(Supplement 1):1357 -9.

16　多发性骨髓瘤免疫活性小鼠模型：治疗意义

[1] Kuehl WM, Bergsagel PL. Molecular pathogenesis of multiple myeloma and its premalignant precursor. J Clin Invest 2012;122(10):3456–63.

[2] Huang J, Chan SC, Lok V, et al. The epidemiological landscape of multiple myeloma: a global cancer registry estimate of disease burden, risk factors, and temporal trends. Lancet Haematol 2022;9(9):e670–7.

[3] Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 2014;15(12):e538–48.

[4] Bolli N, Martinelli G, Cerchione C. The molecular pathogenesis of multiple myeloma. Hematol Rep 2020;12(3):9054.

[5] Misund K, Keane N, Stein CK, et al. MYC dysregulation in the progression of mul- tiple myeloma. Leukemia 2020;34(1):322–6.

[6] Keats JJ, Fonseca R, Chesi M, et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 2007;12(2): 131–44.

[7] Maura F, Coffey DG, Stein CK, et al. The Vk*MYC Mouse Model recapitulates hu- man multiple myeloma evolution and genomic diversity. bioRxiv preprint 2023. https://doi.org/10.1101/2023.07.25.550482.

[8] Maura F, Petljak M, Lionetti M, et al. Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and mul- tiple myeloma cell lines. Leukemia 2018;32(4):1044–8.

[9] Hideshima T, Mitsiades C, Tonon G, et al. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer 2007;7(8):585–98.

[10] O'Connor BP, Raman VS, Erickson LD, et al. BCMA is essential for the survival of long-lived bone marrow plasma cells. J Exp Med 2004;199(1):91–8.

[11] Sklavenitis-Pistofidis R, Haradhvala NJ, Getz G, et al. Inflammatory stromal cells in the myeloma microenvironment. Nat Immunol 2021;22(6):677–8.

[12] de Jong MME, Kellermayer Z, Papazian N, et al. The multiple myeloma microenvironment is defined by an inflammatory stromal cell landscape. Nat Immunol 2021;22(6):769–80.

[13] Zhu YX, Braggio E, Shi CX, et al. Cereblon expression is required for the antimye- loma activity of lenalidomide and pomalidomide. Blood 2011;118(18):4771–9.

[14] Oliver AM, Martin F, Kearney JF. Mouse CD38 is down-regulated on germinal cen- ter B cells and mature plasma cells. J Immunol 1997;158(3):1108–15.

[15] Raje N, Berdeja J, Lin Y, et al. Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma. N Engl J Med 2019;380(18):1726–37.

[16] Carpenter RO, Evbuomwan MO, Pittaluga S, et al. B-cell maturation antigen is a promising target for adoptive T-cell therapy

of multiple myeloma. Clin Cancer Res 2013;19(8):2048–60.

[17] Seckinger A, Delgado JA, Moser S, et al. Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment. Cancer Cell 2017;31(3):396–410.

[18] Radl J, Hollander CF. Homogeneous immunoglobulins in sera of mice during aging. J Immunol 1974;112(6):2271–3.

[19] van den Akker TW, de Glopper-van der Veer E, Radl J, et al. The influence of ge- netic factors associated with the immunoglobulin heavy chain locus on the devel- opment of benign monoclonal gammapathy in ageing IgH-congenic mice. Immunology 1988;65(1):31–5.

[20] Asosingh K, Radl J, Van Riet I, et al. The 5TMM series: a useful in vivo mouse model of human multiple myeloma. Hematol J 2000;1(5):351–6.

[21] Maes K, Boeckx B, Vlummens P, et al. The genetic landscape of 5T models for multiple myeloma. Sci Rep 2018;8(1):15030.

[22] Vanderkerken K, De Raeve H, Goes E, et al. Organ involvement and phenotypic adhesion profile of 5T2 and 5T33 myeloma cells in the C57BL/KaLwRij mouse. Br J Cancer 1997;76(4):451–60.

[23] Amend SR, Wilson WC, Chu L, et al. Whole Genome Sequence of Multiple Myeloma-Prone C57BL/KaLwRij Mouse Strain Suggests the Origin of Disease Involves Multiple Cell Types. PLoS One 2015;10(5):e0127828.

[24] Noll JE, Hewett DR, Williams SA, et al. SAMSN1 is a tumor suppressor gene in multiple myeloma. Neoplasia 2014;16(7):572–85.

[25] Friend NL, Hewett DR, Panagopoulos V, et al. Characterization of the role of Samsn1 loss in multiple myeloma development. FASEB Bioadv 2020;2(9):554–72.

[26] Oyajobi BO, Franchin G, Williams PJ, et al. Dual effects of macrophage inflammatory protein-1alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease. Blood 2003;102(1):311–9.

[27] Van Valckenborgh E, Schouppe E, Movahedi K, et al. Multiple myeloma induces the immunosuppressive capacity of distinct myeloid-derived suppressor cell subpopulations in the bone marrow. Leukemia 2012;26(11):2424–8.

[28] Menu E, De Leenheer E, De Raeve H, et al. Role of CCR1 and CCR5 in homing and growth of multiple myeloma and in the development of osteolytic lesions: a study in the 5TMM model. Clin Exp Metastasis 2006;23(5–6):291–300.

[29] Hewett DR, Vandyke K, Lawrence DM, et al. DNA Barcoding Reveals Habitual Clonal Dominance of Myeloma Plasma Cells in the Bone Marrow Microenviron- ment. Neoplasia 2017;19(12):972–81.

[30] Khoo WH, Ledergor G, Weiner A, et al. A niche-dependent myeloid transcriptome signature defines dormant myeloma cells. Blood 2019;134(1):30–43.

[31] Merwin RM, Algire GH. Induction of plasma-cell neoplasms and fibrosarcomas in BALB/c mice carrying diffusion chambers. Proc Soc Exp Biol Med 1959;101(3): 437–9.

[32] Kishimoto T. The biology of interleukin-6. Blood 1989;74(1):1–10.

[33] Potter M. Neoplastic development in plasma

cells. Immunol Rev 2003;194: 177–95.

[34] Dechow T, Steidle S, Gotze KS, et al. GP130 activation induces myeloma and col- laborates with MYC. J Clin Invest 2014;124(12):5263–74.

[35] Zhang S, Ramsay ES, Mock BA. Cdkn2a, the cyclin-dependent kinase inhibitor encoding p16INK4a and p19ARF, is a candidate for the plasmacytoma susceptibility locus, Pctr1. Proc Natl Acad Sci U S A 1998;95(5):2429–34.

[36] Shen-Ong GL, Keath EJ, Piccoli SP, et al. Novel myc oncogene RNA from abor- tive immunoglobulin-gene recombination in mouse plasmacytomas. Cell 1982; 31(2 Pt 1):443–52.

[37] Kobayashi H, Potter M, Dunn TB. Bone lesions produced by transplanted plasma-cell tumors in BALB/c mice. J Natl Cancer Inst 1962;28:649–77.

[38] Hofgaard PO, Jodal HC, Bommert K, et al. A novel mouse model for multiple myeloma (MOPC315.BM) that allows noninvasive spatiotemporal detection of os- teolytic disease. PLoS One 2012;7(12):e51892.

[39] Cheung WC, Kim JS, Linden M, et al. Novel targeted deregulation of c-Myc cooperates with Bcl-X(L) to cause plasma cell neoplasms in mice. J Clin Invest 2004;113(12):1763–73.

[40] Carrasco DR, Sukhdeo K, Protopopova M, et al. The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis. Cancer Cell 2007;11(4):349–60.

[41] Chesi M, Robbiani DF, Sebag M, et al. AID-dependent activation of a MYC trans- gene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies. Cancer Cell 2008;13(2):167–80.

[42] Chesi M, Matthews GM, Garbitt VM, et al. Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy. Blood 2012;120(2):376–85.

[43] Chesi M, Mirza NN, Garbitt VM, et al. IAP antagonists induce anti-tumor immunity in multiple myeloma. Nat Med 2016;22(12):1411–20.

[44] Meermeier EW, Welsh SJ, Sharik ME, et al. Tumor burden limits bispecific anti- body efficacy through T cell exhaustion averted by concurrent cytotoxic therapy. Blood Cancer Discovery 2021;2(4):354–69, bloodcandisc. BCD-21-0038-E.2021.

[45] Calcinotto A, Brevi A, Chesi M, et al. Microbiota-driven interleukin-17-producing cells and eosinophils synergize to accelerate multiple myeloma progression. Nat Commun 2018;9(1):4832.

[46] Nakamura K, Kassem S, Cleynen A, et al. Dysregulated IL-18 Is a Key Driver of Immunosuppression and a Possible Therapeutic Target in the Multiple Myeloma Microenvironment. Cancer Cell 2018;33(4):634–648 e635.

[47] Minnie SA, Kuns RD, Gartlan KH, et al. Myeloma escape after stem cell transplantation is a consequence of T-cell exhaustion and is prevented by TIGIT blockade. Blood 2018;132(16):1675–88.

[48] Guillerey C, Harjunpaa H, Carrie N, et al. TIGIT immune checkpoint blockade restores CD8(+) T-cell immunity against multiple myeloma. Blood 2018;132(16): 1689–94.

[49] Chesi M, Stein CK, Garbitt VM, et al.

Monosomic loss of MIR15A/MIR16-1 is a driver of multiple myeloma proliferation and disease progression. Blood Cancer Discov 2020;1(1):68–81.

[50] Wen Z, Rajagopalan A, Flietner ED, et al. Expression of NrasQ61R and MYC transgene in germinal center B cells induces a highly malignant multiple myeloma in mice. Blood 2021;137(1):61–74.

[51] Morito N, Yoh K, Maeda A, et al. A novel transgenic mouse model of the human multiple myeloma chromosomal translocation t(14;16)(q32;q23). Cancer Res 2011;71(2):339–48.

[52] Winkler W, Farre Diaz C, Blanc E, et al. Mouse models of human multiple myeloma subgroups. Proc Natl Acad Sci U S A 2023;120(10). e2219439120.

[53] Larrayoz M, Garcia-Barchino MJ, Celay J, et al. Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma. Nat Med 2023;29(3):632–45.

[54] Watanabe H, Numata K, Ito T, et al. Innate immune response in Th1- and Th2- dominant mouse strains. Shock 2004;22(5):460–6.

[55] Hartmann W, Blankenhaus B, Brunn ML, et al. Elucidating different pattern of immunoregulation in BALB/c and C57BL/6 mice and their F1 progeny. Sci Rep 2021;11(1):1536.